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When a drug is allowed to enter the market, a long period of research has come to an end 
which is bound to strict rules to ensure a positive benefit/risk balance of the drug. Not 
only do drugs have many benefits, they also carry risks that can cause hospitalization, 
disablement, or even death of patients.(1-4) In their development phase, drugs are tested in 
small groups of relatively healthy people, often for a short period of time.(5) While after 
marketing approval, drugs are often used long term, by an older population that is 
frequently using other medication related to pre-existing diseases.(6,7) Also, pre-marketing 
clinical trials are primarily aimed at establishing the efficacy of drugs and not their safety. 
This means that only the most common side effects are known at market entry, causing 
the benefit-risk profile of a drug to be incomplete. Consequently the safety of a drug 
needs to be monitored after market approval. This protective activity is called 
pharmacovigilance. The World Health Organisation defines pharmacovigilance as follows:  
 
‘[…] the science and activities relating to the detection, assessment, understanding and 
prevention of adverse effects or any other possible drug-related problems.’(8)  
 
The European Medicines Agency, the Dutch Medicines Agency, and the Dutch Health Care 
Inspectorate are the responsible authorities at European and Dutch level respectively.  
Safety-related regulatory action 
An important component of pharmacovigilance is risk communication of serious safety 
issues of drugs after market approval. Healthcare professionals need to be informed when 
serious safety issues emerge, to ensure safe and effective use of medicinal products.(9) In 
the European Union this is done mainly by sending paper-based warning letters to 
healthcare professionals, so called Direct Healthcare Professional Communications 
(DHPCs). A DHPC is sent by the responsible marketing authorisation holder at the 
instigation of the European Medicines Agency and/or the national authority. The content 
of a DHPC must conform to a fixed template and can be issued in case of:(10) 
 
 suspension, withdrawal or revocation of a drug;  
 an important modification of the product information;  
 limited availability;  
 a change in the benefit/risk balance;  
 new recommendations for treating or preventing adverse reactions; 
 on-going assessment of an important potential risk, with insufficient existing 
data to take regulatory action. 







Figure 1. DHPCs issued in the Netherlands (1999-2012).  
The DHPCs were issued by the pharmaceutical company at the instigation of the European Medicines Agency 
(EMA) and/or the Dutch Medicines Evaluation Board (MEB). 
Scope of the problem 
Between January 1999 and January 2013 289 DHPCs were issued for 190 different active 
substances(11) encompassing 14,8% of the total number of unique active substances that 
were available on the Dutch market (Figure 1).(12) 
The DHPCs were issued for a wide range of drugs and safety issues. The three most 
frequent Anatomical Therapeutic Chemical drug classes were: anti-neoplastic and 
immunomodulating agents (22%), anti-infectives for systemic use (15%), and alimentary 
tract and metabolism (14%). For the DHPCs that were issued from 1999 to 2009 the safety 
issues mainly concerned cardiac disorders (15%), injury, poisoning and procedural 
complications (13%), and general disorders and administration site conditions (10%).(11) 
Relatively few DHPCs concerned a withdrawal of the drug from the market,(11,13) but these 
cases often received a great deal of media attention. For example, the cases of rofecoxib 
(Vioxx®) in 2004 and rosiglitazone (Avandia®) in 2010 were extensively discussed in lay and 
professional media. DHPCs were issued during the whole lifecycle of drugs with 26% being 
issued 10 years or more after registration (Figure 2). The median time between 
registration and the first DHPC was 5 years (ranging from 0 to 48 years). The number of 
warning letters that is issued increases by 2.4 DHPCs per year.  
The effectiveness of drug safety warnings is questioned.(14,16) In some cases repeated 
warnings were still not sufficiently complied with, resulting in the drug being taken off the 































Figure 2. Time from registration to first DHPC (1999-2012) 
 
For example, in the United States five consecutive DHPCs (1995-2000) were issued to warn 
healthcare professionals about cardiovascular problems related to the use of cisapride 
(Prepulsid®). Prescribing of cisapride with contra-indicated medications continued, 
eventually leading to its market withdrawal in 2000.(17,18) 
Also unintended effects can occur due to safety warnings.(19) In 1995, the United 
Kingdom venous thromboembolism DHPC for third generation oral contraception 
generated a pill scare. It caused many women to cease use of oral contraceptives all 
together, resulting in an increasing number of conceptions and abortions.(20-22) The 
selective serotonin reuptake inhibitor (SSRI) warnings that were issued between 2003 and 
2006 recommended to reduce prescribing of SSRIs to the adolescent population only, due 
to a risk of suicidality and suicidal thoughts.(23,24) Unintended decreases in adult SSRI 
prescriptions were observed, possibly associated with an increased number of suicides.(25-
27)  
The opinion about the impact of safety warnings is largely based on these and similar 
high profile safety cases. Little is known about the impact of DHPCs that were less 
extensively discussed in the media as well as the experiences and preferences of 
healthcare professionals regarding the DHPCs, especially in the Dutch setting. Such 
knowledge is vital to enable optimization of current risk communication methods. 
Effective risk communication is at the heart of successful risk management.(28) Moreover, 
in July 2012, new pharmacovigilance legislation is implemented which made evaluation of 
the effectiveness of risk minimization measures mandatory.(29,30) A point of reference 
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changes that are based on the preferences of healthcare professionals will increase their 
chance of success. And, above all, patient safety can be improved. 
Communicating risk effectively  
Over the last decades, people have become more concerned about risks,(31) leading to 
increased risk communication efforts. Risk communication can have different aims; to 
share information, change beliefs, or change behaviour. Changing specific behaviour such 
as drug prescribing is not always intended, sometimes the aim is merely to inform or 
educate. To date, it is no longer sufficient to present the public with quantitative risk 
estimates,(32) which only aims to share information, regardless of whether the message is 
understood.(19) Risk communication can be considered adequate when the information is 
useful to its audience(19) and this involves more than just presenting the numbers. The goal 
of a warning depends on each specific situation and should be linked to the desired 
outcome of the risk communication.(19) 
The effectiveness of a warning depends on a combination of the characteristics of 
the target audience, the characteristics of the source of the message, as well as the 
content of the message.(33) Concerning the target audience, it is important to understand 
how they perceive risk.(34,35) In general, people have sophisticated ideas about risks.(36) 
Risks are not only judged analytically, feelings are involved in the decision process as 
well.(37-39) Slovic and colleagues called the dependency on these feelings ‘the Affect 
Heuristic’.(38) Psychological, social and cultural aspects can influence risk perception and 
people give meaning to a message in a socio-cultural context.(36-40) According to Slovic, this 
means that ‘the concept ‘risk’ means different things to different people’.(41) 
Not all risk perception factors play a role in each situation and the degree to which 
they contribute varies as well.(35) This implies that in risk communication there is ‘no one 
size fits all’. Every single situation needs to be assessed individually, underlining the 
complexity of successful risk communication. With regard to the way that risks of 
medicines are perceived by healthcare professionals, it can be expected that trust plays an 
important role. The source of the information is primarily important in relation to its 
credibility. When trust and credibility of the source of the information are questioned, the 
message will not be heard, believed and acted upon.(31,34,42) Credibility is even more 
relevant when the receivers of the message are not highly knowledgeable of the issue at 
hand. This plays a clear role when considering risk communication about new drug safety 
issues. Pharmaceutical companies are often distrusted because of their commercial 








With regard to characteristics of the content of the message, the seriousness of the risk 
described and its consequences for the people involved are relevant. One may expect  
healthcare professionals to be more open to change their behaviour in case of safety 
issues with a high impact on patient outcome such as (irreversible) disablement or 
mortality. Another aspect that could influence the effectiveness of risk communication is 
the perceived benefit of the drug. It can be expected that higher risks will be accepted for 
drugs with greater benefits.(44)  
In  addition, it is clear that the channel that is used may also affect the response of 
the target audience.(19) Of course, in urgent risk communication not all methods may be 
equally useful or practically feasible. Nevertheless, in contrast to paper-based DHPCs 
various fast communication methods using IT solutions are available; e.g. internet, e-mail, 
social media, twitter, etcetera. Empirical evidence for preferences of the busy healthcare 
professional with respect to communication channels is however lacking. 
Although much progress has been made in understanding what is effective risk 
communication, little is known about this in the area of communicating risks of medicines 
to healthcare professionals. With better understanding of how risk perception factors play 
a role in communicating serious safety issues of medicines, regulators can improve current 
methods, (partially) predict responses to particular cases and develop new risk 
communication strategies.(41,45) By doing so, it can be possible to achieve changes in 
attitudes as well behaviour as intended by the message.(34)  
 
In this thesis we present the results of the Communicating Risk Effectively (CORE) study. 
The CORE study is designed to contribute to better risk communication of regulatory 
bodies by providing empirical evidence of the effectiveness of DHPCs, and the relevance of 
characteristics of their content, target population, and the information channel.  
 
The aims of the CORE study are: 
 To provide an overview of the impact of DHPCs and to explore determinants that 
influence the impact of DHPCs.  
 To explore what the experiences and preferences of Dutch healthcare professionals 
are with regard to DHPCs.  
 To determine the added value of a new risk communication method, that is based 
on the preferences of healthcare professionals. 
Outline of this thesis 
This thesis covers two parts. The first part consists of three studies that give an overview 
of the impact of safety-related regulatory actions.  







 In chapter 2 we reviewed the literature regarding the impact of safety-related 
regulatory action.  
 Chapter 3 gives an overview of the short-term and long-term impact of a large 
group of DHPCs on drug use.  
 In chapter 4 we assessed which determinants influence the impact of DHPCs on 
drug use. 
 
The second part of this thesis consists of two studies that focus on the optimization of the 
impact of DHPCs.  
 In chapter 5 we present the results of a survey that was conducted to identify the 
experiences and opinions of Dutch healthcare professionals regarding DHPCs.  
 Based on the results discussed in chapter 5, an intervention study is performed to 
determine the added value of a safety warning that is e-mailed to Dutch 
healthcare professionals. These results are shown in chapter 6. 
 
Finally, in chapter 7 the main findings as well as the implications of the CORE project are 
summarized and discussed. In addition, recommendations for further research and 
improvements of current risk communication are given.1 
                                                            
This chapter was partly based on: 
Mol, P.G.M.; Straus, S.M.J.M.; Piening, S.; De Vries, J.T.N.; De Graeff, P.A.; and Haaijer-Ruskamp, F.M. A decade of 
safety-related regulatory action in the Netherlands: A retrospective analysis of Direct Healthcare Professional 










1  Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions 
as cause of admission to hospital: Prospective analysis of 18 820 patients. Br Med J 2004 
07;329(7456):15-19.  
2  Leendertse AJ, Egberts ACG, Stoker LJ, Van Den Bemt PMLA. Frequency of and risk factors for 
preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008 
09;168(17):1890-1896.  
3  Van der Hooft CS, Dieleman JP, Siemes C, Aarnoudse ALHJ, Verhamme KMC, Strieker BHCH, et 
al. Adverse drug reaction-related hospitalisations: A population-based cohort study. 
Pharmacoepidemiol Drug Saf 2008 17(4):365-371.  
4  Schneeweiss S, Hasford J, Gottler M, Hoffmann A, Riethling A-, Avorn J. Admissions caused by 
adverse drug events to internal medicine and emergency departments in hospitals: A 
longitudinal population-based study. Eur J Clin Pharmacol 2002 58(4):285-291.  
5  Stricker BC, Psaty BM. Detection, verification, and quantification of adverse drug reactions. Br 
Med J 2004 07;329(7456):44-47.  
6  Wieringa NF, De Graeff PA, Van Der Werf GT, Vos R. Cardiovascular drugs: Discrepancies in 
demographics between pre- and post-registration use. Eur J Clin Pharmacol 1999 55(7):537-
544.  
7  Martin K, Bégaud B, Latry P, Miremont-Salamé G, Fourrier A, Moore N. Differences between 
clinical trials and postmarketing use. Br J Clin Pharmacol 2004 57(1):86-92.  
8  World Health Organisation. The importance of pharmacovigilance. Safety monitoring of 
medicinal products. 2002; Available at: 
http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf. Accessed 3 January, 2013.  
9  European Commission. Volume 9A of the rules governing medicinal products in the European 
Union. Guidelines on Pharmacovigilance for medicinal products for human use. 2008; Available 
at: http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf. Accessed 3 
January, 2013.  
10  European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module 
XV - Safety communication. 2012; Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC
500130396.pdf. Accessed 3 January, 2013.  
11  Mol PGM, Straus SMJM, Piening S, De Vries JTN, De Graeff PA, Haaijer-Ruskamp FM. A decade 
of safety-related regulatory action in the Netherlands: A retrospective analysis of direct 
healthcare professional communications from 1999 to 2009. Drug Saf 2010 33(6):463-474.  
12  Medicines Evaluation Board. Annual report 2011. 2012; Available at: http://www.cbg-
meb.nl/NR/rdonlyres/35387CF6-5850-4A1A-B8FD-
0909DAA34A93/0/CBGjaarverslag201120120522.pdf. Accessed 3 January, 2013.  
13  Arnardottir AH, Haaijer-Ruskamp FM, Straus SMJ, Eichler H-, de Graeff PA, Mol PGM. 
Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol 2011 
72(3):490-499.  
14  Goldman SA. Communication of medical product risk: How effective is effective enough? Drug 
Saf 2004 2004 27(8):519-534.  
15  Woosley RL. Drug labeling revisions - Guaranteed to fail? J Am Med Assoc 2000 
12;284(23):3047-3049.  







16  Yu DT, Seger DL, Lasser KE, Karson AS, Fiskio JM, Seger AC, et al. Impact of implementing alerts 
about medication black-box warnings in electronic health records. Pharmacoepidemiol Drug 
Saf 2011 20(2):192-202.  
17  Weatherby LB, Walker AM, Fife D, Vervaet P, Klausner MA. Contraindicated medications 
dispensed with cisapride: Temporal trends in relation to the sending of 'Dear Doctor' letters. 
Pharmacoepidemiol Drug Saf 2001 10(3):211-218.  
18  Guo JJ, Curkendall S, Jones JK, Fife D, Goehring E, She D. Impact of cisapride label changes on 
codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003 12(4):295-
301.  
19  Fischhoff B, Brewer NT, Downs JS. Communicating risks and benefits. An evidence-based user's 
guide. 2011; Available at: 
http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM268069.pdf.  
20  Child TJ, Mackenzie IZ, Rees M. Terminations of pregnancy, not unplanned deliveries, 
increased as result of pill scare [2]. Br Med J 1996 313(7063):1005.  
21  Skjeldestad FE. Increased number of induced abortions in norway after media coverage of 
adverse vascular events from the use of third-generation oral contraceptives. Contraception 
1997 55(1):11-14.  
22  Wood R, Botting B, Dunnell K. Trends in conceptions before and after the 1995 pill scare. Popul 
Trends 1997 (89):5-12.  
23  European Medicines Agency. European Medicines Agency finalises review of antidepressants 
in children and adolescents. 2005; Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SSRI_31/WC
500013082.pdf. Accessed 3 January, 2013.  
24  U.S. Food and Drug Administration. Historical information on antidepressant use in children, 
adolescents, and adults. 2010; Available at: 
http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096293.htm. Accessed 3 
January, 2013.  
25  Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, et al. Early evidence on the 
effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and 
adolescents. Am J Psychiatry 2007 164(9):1356-1363.  
26  Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on 
antidepressant use in a national sample. Arch Gen Psychiatry 2008 65(1):94-101.  
27  Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ. Spillover effects on 
treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidally 
with SSRIs. Am J Psychiatry 2007 164(8):1198-1205.  
28  Bahri P, Harrison-Woolrych M. Focusing on risk communication about medicines: Why now? 
Drug Saf 2012 35(11):971-975.  
29  The European Parliament and The European Council. DIRECTIVE 2010/84/EU. 2010; Available 
at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF. 
Accessed 3 January, 2013.  
30  The European Parliament and The European Council. REGULATION (EU) No 1235/2010. 2010; 
Available at: http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF. Accessed 3 
January, 2013.  
31  Slovic P. Perceived risk, trust, and democracy. Risk Anal 1993 13(6):675-682.  
32  Fischhoff B. Risk Perception and Communication Unplugged - 20 Years of Process. Risk Analysis 







33  Breakwell GM. Risk communication: Factors affecting impact. Br Med Bull 2000 56(1):110-120.  
34  Walaski P. Risk and Crisis Communications : Methods and Messages. Hoboken, NJ, USA: John 
Wiley & Sons, Inc.; 2011.  
35  Lundgren, R.E. & McMakin, A.H. Risk Communication. A handbook for communicating 
environmental, safety, and health risks. Third edition. ed. Columbus, Ohio, USA.: Battelle 
Press; 2004.  
36  Kasperson RE, Renn O, Slovic P, Brown HS, Emel J, Goble R, et al. The social amplification of 
risk: A conceptual framework. Risk Anal 1988 8(2):177-187.  
37  Slovic P, Finucane ML, Peters E, MacGregor DG. Risk as Analysis and Risk as Feelings: Some 
Thoughts about Affect, Reason, Risk, and Rationality. Risk Anal 2004 24(2):311-322.  
38  Slovic P, Peters E, Finucane ML, MacGregor DG. Affect, risk, and decision making. Health 
Psychol 2005 24(4 SUPPL.):S35; S40.  
39  Ropeik D, Slovic P. Risk communication: a neglected tool in protecting public health. Risk in 
Perspective 2003 11(2).  
40  Renn O. Three decades of risk research: accomplishments and new challenges. Journal of Risk 
Research 1998 1(1):49-71.  
41  Slovic P. Perception of risk. Science 1987;236(4799):280-5.  
42  McComas KA. Defining moments in risk communication research: 1996-2005. J Health 
Commun 2006 11(1):75-91.  
43  Lofstedt RE. The impact of the Cox-2 inhibitor issue on perceptions of the pharmaceutical 
industry: Content analysis and communication implications. J Health Commun 2007 12(5):471-
491.  
44  Slovic P. The Perception of risk. 2011th ed. London: Earthscan; 2000.  
45  Bahri P. Public pharmacovigilance communication: A process calling for evidence-based, 






















Impact of safety-related regulatory action on clinical practice.  






Sigrid Piening1  
Flora M. Haaijer-Ruskamp1  
Jonie T.N. de Vries1  
Menno E. van der Elst2 
Pieter A. de Graeff1,2  
Sabine M.J.M. Straus2,3  












Drug Safety 2012 35:5 (373-385) 
 
 
1 Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, the 
Netherlands 
2 Dutch Medicines Evaluation Board, The Hague, the Netherlands 









Background: After market approval, new serious safety issues are regularly identified for 
drugs that lead to regulatory action to inform healthcare professionals. However, the 
effectiveness of these safety-related regulatory actions is under question. We currently 
lack a comprehensive overview of the effects of these drug safety warnings on clinical 
practice to resolve the debate about their effectiveness. The aim of this systematic review 
is to provide an overview of studies that assessed the impact of safety warnings.  
Methods:  A systematic search was performed for articles assessing the impact of Direct 
Healthcare Professional Communications or ‘Dear Doctor’ letters, Black Box Warnings and 
Public Health Advisories on clinical behaviour published between January 1996 and 
January 2010. The following variables were extracted: publication year, country, name of 
the drug, safety issue, specific safety warning (Direct Healthcare Professional 
Communication/Black Box Warning/Public Health Advisory), effect (intended/unintended) 
of the safety warning, outcome measure and study design. Papers were checked for 
several quality aspects. Study data were summarized using descriptive analyses.  
Results: A total of 50 articles were identified. Two articles assessed two different drugs 
and were therefore counted twice (N=52). Thirty-three articles described the impact of 
safety warnings issued for three drugs and drug groups, i.e. third-generation oral 
contraceptives, cisapride and selective serotonin reuptake inhibitors. The remaining 19 
articles described a broad variety of 14 drugs and drug groups. Twenty-five studies applied 
an interrupted time series design, 23 a controlled or uncontrolled before/after design, and 
four articles applied both. None of the articles could rule out the influence of confounding 
factors. The intended effects were reported in 18 (72%) of the 25 before/after analyses, 
whereas only 11 (41%) of the 27 interrupted time series analyses reported an impact. Only 
two (8%) of the before/after analyses against 11 (41%) of the interrupted time series 
analyses reported mixed impacts. When unintended effects were assessed in case of 
selective serotonin reuptake inhibitors and third-generation oral contraceptives, these 
were almost always present: in 19 of 22 and 4 of 5 articles, respectively. Our review shows 
that safety-related regulatory action can have some impact on clinical practice but firm 
conclusions are difficult to draw. Evidence is primarily based on three drugs and drug 
groups. Almost half of the studies had inadequate before/after designs and the 
heterogeneity in analyses and outcome measures hampered the  
reporting of overall effect sizes. Studies with adequate interrupted time series design 
reported a more mixed impact of safety warnings than before/after studies. Furthermore, 
this review shows the relevance of considering not only the intended but also the 
unintended effects of safety warnings.  







Conclusions: There is a clear need for further research with appropriate study designs and 
statistical analyses, with more attention to confounding factors such as media coverage, 









Knowledge of the full benefit-risk profile of a drug at the time of market approval is 
incomplete. Pre-registration trials are limited in establishing the full safety profile of new 
drugs due to, for example, small sample size, short duration, and a homogeneous study 
population.(1,2) In approximately 10% of all marketed drugs, safety-related regulatory 
action is required for new and serious safety issues(3-5) leading to hospitalization, disability 
or even death.(6,7) With these safety warnings, healthcare professionals and patients are 
informed of these safety issues or even of the possible withdrawal of the drug from the 
market.  
Regulatory authorities and the pharmaceutical industry employ several safety 
warnings to inform healthcare professionals of serious safety issues of drugs.(8) The 
summary of product characteristics can be updated with new safety information. Public 
Health Advisories (US only) permit the notification of patients and physicians of a serious 
safety issue to improve selection of medication. A Black Box Warning (US only) highlights a 
drug’s potential safety issues in a framed box on the label and the patient package inserts. 
A Direct Healthcare Professional Communication (DHPC; in the EU) and Dear Healthcare 
Professional letter (in the US) or ‘Dear Doctor’ letter (further referred to as a DHPC) is a 
paper-based personalized mailing to healthcare professionals. Finally, a drug can be 
withdrawn from the market due to a safety issue when the benefits of a drug no longer 
outweigh its risks.  
The effectiveness of safety warnings has been criticized.(9,10) Previous research 
concluded that safety warnings can be effective, albeit not always and not always 
sufficiently.(10) Additionally, safety warnings have resulted not only in intended, but also in 
unintended effects. The safety warnings for selective serotonin reuptake inhibitors 
resulted in intended reduced prescription in the population at risk after the identification 
of an increased risk of suicidality and suicidal thoughts in children and adolescents.(11) 
Unfortunately, some unintended effects were also reported. The prescription of selective 
serotonin reuptake inhibitors decreased in adults as well,(12-14) possibly associated with a 
temporal increase in suicidality in the general population,(12) although these results have 
been contradicted.(15) 
The experience with selective serotonin reuptake inhibitors indicates that several 
inventories of effectiveness of safety warnings have been performed, but with various 
results. The overall effect of safety warnings is unclear. Since the monitoring of the 
outcome of risk minimization measures will become mandatory in the near future, such an 
overview is required.(16,17) To that end, we performed a systematic review of the effects  







– both intended and unintended – of safety warnings on clinical practice. In this review, 
we specifically targeted DHPCs, Black Box Warnings and Public Health Advisories when 
referring to safety warnings. 
Methods 
Search strategy 
A systematic search for articles published between January 1996 and January 2010 
evaluating the impact of DHPCs, Black Box Warnings and Public Health Advisories safety-
related regulatory actions was performed in three steps. First, index terms and free text 
words were identified from an initial set of papers retrieved by random search. Based on 
the terms used in these articles, we systematically searched the online literature 
databases MEDLINE and EMBASE for relevant papers without any language restrictions 
(Table 1).  
 
Table 1. Search strategy 






 ((drug information* OR drug 
information) OR (drug labelling* 
OR drug labelling) OR (drug 
surveillance program* OR drug 
surveillance program) OR (drug 
monitoring* OR drug monitoring) 




OR dear doctor 
OR warning*)  
 
 
((clinical study* OR 
clinical study) OR 
(time series 
analysis* OR time 






Step 2: DHPC 
search 
 































Underlined terms were adjusted according to specific drug/safety issue for which the DHPC was issued, or the 
author. 
DHPC = Direct Healthcare Professional Communication. 
 
A second search in MEDLINE and EMBASE was performed based on drugs with a DHPC in 
the Netherlands. We added this step because the initial analyses indicated that we were 
missing relevant publications. As a third step, the included papers’ references were 
checked (snowballing) and a first author search was performed to search for additional 







Two reviewers (SP/JV and PM) independently evaluated all the papers identified for 
eligibility. A first selection was based on titles and abstracts and a second and final 
selection was based on examination of each full paper. Any disagreements were resolved 
during consensus meetings with a third reviewer (SS/ME). 
Inclusion and exclusion criteria 
Only randomized trials, quasi experiments (interrupted time series and controlled or 
uncontrolled before/after studies) evaluating the impact of DHPCs, Black Box Warnings 
and/or Public Health Advisories on clinical practice were included. In randomized trials the 
impact of an intervention is assessed by comparing an intervention group to a randomly 
assigned control group. Both groups are exposed to the same biases and therefore 
considered alike, permitting the assessment of the causal effect of an intervention. 
Before/after studies are used to measure the impact of safety warnings at three or fewer 
time points both before and after the intervention. Interrupted time series designs have 
data collected at multiple instances (preferably >20 data points) before and after an 
intervention, with the advantage that they can detect whether an intervention has an 
effect significantly greater than underlying secular trends.(18)  
Cross-sectional articles evaluating only the situation after a safety warning were 
excluded since no comparative impact could be estimated. For example, articles only 
evaluating a safety warning in cases of a withdrawal of a drug were excluded, since clinical 
behaviour will change by definition and the article would therefore cause bias. Opinion 
articles, surveys, reviews, duplicates in different languages and publications of non-
original data were excluded to avoid publication bias.(19)  
Data extraction 
Five reviewers (SP, JV, ME, FT and PM working in varying pairs) systematically extracted 
the following variables: publication year, country, drug name, safety issue, effect 
(intended/unintended), study design, safety warning type (DHPC/Black Box 
Warning/Public Health Advisory) and outcome measure. The Cochrane Effective Practice 
and Organisation of Care Review Group (EPOC) quality criteria for interrupted time series 
studies score list was used to check the quality aspects of the studies.(20) The same quality 
aspects were scored for before/after papers, except for items that were only applicable to 
interrupted time series design studies. Again, any disagreements were resolved by 
consensus or, if necessary, by a third reviewer.  
The main goal of a safety warning, i.e. to minimize occurrence of the issue, was 
defined as its intended effect – for instance, to prevent prescription to specific patient 
groups (e.g. selective serotonin reuptake inhibitors to adolescents/children), to prevent 







co-prescription in case of a drug-drug interaction (e.g. cisapride and macrolides increasing 
the risk of QT prolongation), or to promote baseline/follow-up laboratory tests (e.g. liver 
function testing with troglitazone use).  
Unintended effects were defined as unforeseen or unintended, for instance, an 
increase in suicides after the issuance of warnings restricting the use of selective serotonin 
reuptake inhibitors in children and adolescents.  
The effect of a safety warning was scored on the authors’ reports, i.e. a safety warning 
had an effect, no effect or mixed effects. Mixed effects were defined as an effect for one 
outcome measure but no effect for another. 
Data analysis 
Data were summarized according to the following variables: drug group, assessed impact, 
study design, safety warnings type and outcome measure, using descriptive analyses. The 
quality of the included studies was scored by adding up each quality aspect that was met. 
The studies were counted in different ways for each variable:  
 
 Drug group: if an article assessed a safety warning for more than one drug, the 
article was assigned to all relevant drugs and drug groups. In that case the study 
was counted more than once.  
 Assessed impact: the impact of a safety warning was split into intended and 
unintended impacts.  
 Study design: if one study assessed several outcome measures with different 
study designs, the result of each individual outcome measure was attributed to 
the related study design. In such cases a study design was counted more than 
once.  
 Type of safety warning: in papers assessing more than one safety warning, the 
effect of each safety warning was assessed separately. If more than one safety 
warning was evaluated, but only one overall effect was presented, the overall 
effect was attributed to each individual safety warning. 
 Outcome measure: if one study assessed several outcome measures, the impact 
of a safety warning was counted for each individual outcome measure. 
Consequently, when an impact was observed on drug use but not on a more 
specific outcome measure such as conducted laboratory tests, the effect of that 








A total of 4086 papers were identified using the first search strategy, of which 215 papers 
were selected for full-text examination resulting in the inclusion of 34 papers for detailed 
analysis (Figure 1).  
 
 
Figure 1. Search results 
a Two reviewers independently evaluated the papers, with a third reviewer adjudicating in a consensus meeting 
when there was disagreement regarding the eligibility of a study. b Two of 50 papers evaluated safety-related 
regulatory action for two different drugs and drug groups (Wilkinson et al.,
[21]
 Starner et al.
[22]
). 
DHPC = Direct Healthcare Professional Communication 
 
The second step, based on the safety issues mentioned in 160 DHPCs issued in the 
Netherlands, yielded a further five eligible papers. Snowballing yielded another eleven 
papers. In total 50 papers were included. In two papers(21,22) two different drugs and drug 
groups were assessed, therefore each paper was counted twice in further analyses 
(n=52).The main results of the data extraction are shown in Table 2 and the key variables 
of the individual studies are shown in the Appendix table. 
Drug Group 
Three different drugs and drug groups, i.e. third-generation oral contraceptives (increased 
risk of thrombosis, published 1996-1999;(23-31) cisapride (risk of serious cardiac 
arrhythmias, published 2000-2005);(21,32-39) and selective serotonin reuptake inhibitors 
(risk of suicide in adolescents and children, published 2005-2009)(11-15,40-49) accounted for 
33 articles in our review (Table 2). The remaining 19 papers described a broad variety of 
14 different drugs and drug groups.(7,21,22,50-64) 







Table 2. Study characteristics 
Key study characteristics Number of studies 
(N=52) [N; %] 
References 
Country   
     USA 26 (50) 7,13,14,21,22,32-35,40-44,49,50-58
  
     EU 19 (37) 11,15,23-31,36-38,45,59-62  
     Other 7 (13) 12,39,46-48,63,64  
Drug or drug group  
 
     SSRI 15 (29) 11-15,40-49 
     Third gen. O.C. 9 (17) 23-31 
     Cisapride 9 (17) 21,32-38,56
  
     Terfenadine 3 (6) 50-52
  
     Troglitazone 3 (6) 7,21,53 
     Tramadol 2 (4) 54,58 
     Other 11 (21) 22,54,56,57,59-64 
Assessed impact  
 
     Intended effect 40 (77) 7,11,21,22,32-35,40,41,43,44,50-58
  
     Unintended effect 4 (8) 23,27,30,42 
     Both intended & 
unintended effect 
8 (15) 12-15,29,45,46,49 
Study design  
 
     ITS 25 (48) 13,14,21,30,32,34,35,39-
43,45,47,48,52,54,56,57,59,61,63,64 
     BA 23 (44) 7,11,12,15,23-27,29,31,33,36-38,44,46,50,53,55,58 





     DHPC 65 (67) 7,11,12,15,21,23-40,42,45,47,48,50-57,58-64 
     BBW 15 (15) 12,14,22,40-42,44,47,50,51,55-57
  





     Drug use (volume) 35 (45) 11-14,21,22,24-26,28-31,36,39,41,45-49,56,57,59,63,64
  
     CI use/DDI 17 (22) 22,32-38,50-52,54,57,58 
     Laboratory testing 4 (5) 7,53,55,56
  
     Spont. ADE reporting 2 (3) 60,61
  
     Care 7 (9) 13,15,41,43,46,49,59 
     Other 12 (16) 12,15,23,25,27-29,42,44-46,59
  
a The numbers of evaluated safety warnings and outcome measures are larger than the number of included 
studies as several studies evaluated more than one safety warnings and/or outcome measure. 
USA = United States of America; EU = European Union; SSRI = Selective serotonin reuptake inhibitors; Third gen. 
O.C. = Third generation oral contraceptives; ITS = Interrupted Time Series; BA = Before/After study or ITS with 
less than 3 data points before or after an intervention; DHPC = Direct Healthcare Professional Communication; 
BBW = Black Box Warning; PHA = Public Health Advisory; CI/DDI = Contraindicated use/Drug-Drug Interaction; 
ADE = Adverse Drug event. 
Assessed Impact 
An intended effect was observed in 9 of 14 articles(11-15,40,41,43-49) in which the intended 
effect of safety warnings for selective serotonin reuptake inhibitors was assessed (Figure 
2). These intended effects primarily concerned (large) decreases of the volume of drug use 









Figure 2. Study design and intended effects per drug and drug group. 
1 ‘Other’ includes: antipsychotics, infliximab, isotretinoin, nimesulide, pemoline, pioglitazone, rosiglitazone, 
statins, telithromycin, ticlopidine. Panel (a) reports the effects of all included studies (N=52); panel (b) of ITS 
studies only (N=27); and (c) BA studies alone (N=25). Two papers evaluated safety-related regulatory action for 
two drugs and drug groups (Wilkinson et al.,
[21]
 Starner et al.
[22]
) and four papers used both ITS and BA analyses 
for different outcome measures (Libby et al.,
[49]
 Farmer et al.,
[28]
 Starner et al.[x2]
[22]
) and are therefore 
represented twice. Four articles assessed only unintended effects of safety warnings and are therefore not 
reflected in this figure (Forrester et al.,
[42]
 Child et al., 
[23]
 Williams et al.,
[30]
 Wood et al.
[27]
).  
BA= before/after study or ITS with less than three data points before or after an intervention; ITS=Interrupted 
Time Series; SSRIs= selective serotonin reuptake inhibitors; Third-gen. O.C.= third-generation oral 
contraceptives. 
 
effects of a safety warning issued for third-generation oral contraceptives were assessed 
in six articles.(24-26,28,29,31) In four of these six articles(24,26,29,31) strong reductions in the use 
of third-generation oral contraceptives were reported and/or a shift in use towards 
second-generation oral contraceptives. The remaining two articles(25,28) reported mixed 
impact; a reduction in drug use was observed but no changes in venous thromboembolism 
cases and discontinuation rates/switches were reported. In the case of cisapride, 7 of 17 
assessed DHPCs(21,32,35,38,39) presented intended effects, and 9(32-37) showed no intended 
effects (reduced drug use volume or contraindicated drug use). One DHPC showed mixed 
results. While no effect was observed for overall use of the DHPC, an effect was observed 
for new users of cisapride.(21) The early US DHPCs (1995 and 1996) and the Italian 1998 
DHPC lacked impact, whereas subsequent US DHPCs (1998 onwards) and the Dutch and 
New Zealand DHPCs did achieve their intended effects (Appendix table).  
Articles published on safety warnings issued for the remaining drugs and drug groups 
reported effects as intended to a varying degree. The three papers assessing terfenadine 
safety warnings(50-52) reported intended effects on contraindicated drug use, except for 
contraindicated concomitant use of ketaconazole, which did not decrease.(50) Two of three 
troglitazone papers reported intended increases in laboratory testing after the safety 
warnings.(53,65) In the remaining publications a decrease in filled prescriptions was 







observed only for new drug users and not for all drug users, explained by a higher 
sensitivity to detect changes in prescriptions for new users.(21) The warning for tramadol 
failed to achieve the intended decrease in contraindicated drug use.(54,58)  
Unintended effects were evaluated for safety warnings issued for selective serotonin 
reuptake inhibitors and third-generation oral contraceptives. In the 12 publications 
addressing possible unintended effects, of which four only assessed unintended and no 
intended effects,(23,27,30,42) nearly all warnings for selective serotonin reuptake inhibitors 
(19 of 22 warnings)(12-14,42,45,46) and all four warnings for third-generation oral 
contraceptives(23,27,29,30) showed unintended effects. 
Study Design 
No randomized controlled trials, or controlled before/after studies were identified that 
assessed the intended or unintended impact of safety warnings. Of those studies 
evaluating the intended effects, 23 papers applied an interrupted time series design and 
21 a before/after design (Table 2). Four papers applied both interrupted time series and 
before/after designs for different outcome measures.(22,28,49) These articles are counted 
twice with respect to our study design analysis, leading to a total of 25 before/after and 27 
interrupted time series analyses.  
Overall, intended effects were reported in 29 (56%) of 52 analyses (Figure 2). While 
only 11 (41%) of 27 interrupted time series analyses reported an impact, such intended 
effects were reported in 18 (72%) of 25 before/after analyses. Eleven (41%) interrupted 
time series and two (8%) before/after analyses reported mixed impact.  
All six papers assessing the intended effects of safety warnings on third-generation oral 
contraceptives had a before/after design (Figure 2), one paper also included an 
interrupted time series analysis where no impact of the warning on venous 
thromboembolism cases was reported (Appendix table).(28) Seventeen interrupted time 
series and 13 before/after designs were used in the remaining studies. The nine 
interrupted time series analyses for safety warnings on selective serotonin reuptake 
inhibitors, mainly reported effects (four articles)(13,45,48,49) and mixed effects (four 
articles).(14,40,41,47) The five interrupted time series analyses assessing cisapride warnings 
primarily reported mixed effects (three articles)(21,32,35) for the different warnings that 
were evaluated.  
Unintended effects of the evaluated safety warnings were reported in five of six 
analyses for both interrupted time series and before/after analyses.  
Regarding the quality assessment of the papers, interrupted time series papers 
scored on average 6.7 out of 8 quality aspects, ranging from 3 to 7 of 8 (Appendix table). 







to 5 of 6. All papers used a reliable outcome measure. However, none of the papers could 
rule out the influence of confounding factors such as media attention. Of the 29 analyses 
applying the stronger interrupted time series design, 21 used appropriate statistics. 
The Type of Safety Warning 
Ninety-seven safety warnings were assessed in the 52 articles, ranging from 1 to 8 
warnings per paper and 1 to 13 warnings per drug or drug group (Appendix table). 
Twenty-one papers evaluated more than one safety warning.(12,14,15,21,22,32,34,35,40-
42,47,50,51,53,55,56,59,62,63,65) The DHPC was the most frequently evaluated warning (65 of 97 
warnings), with similar numbers of Black Box Warnings (15) and Public Health Advisories 
(16) evaluated (Table 2).  
Intended effects were evaluated in 91 cases: 52 (57%) showed an impact, 24 (26%) 
did not and 15 (16%) had mixed effects (Figure 3).  
 
 
Figure 3. Safety warnings and intended effects (N=86). 
Two papers evaluated warnings for two drugs and drug groups (Wilkinson et al.,
[21]
 Starner et al.
[22]
) and four 
papers used both ITS and BA analyses for different outcome measures (Libby et al.,
[49]
 Farmer et al.,
[28]
 Starner et 
al.[x2]
[22]
), and are therefore represented twice. The number of evaluated warnings is larger than the number of 
included studies, as several studies evaluated more than one safety warning (see Appendix table).  
BA= before/after study or ITS with less than three data points before or after an intervention; BBW= Black Box 
Warning; DHPC= Direct Healthcare Professional Communication; ITS=Interrupted Time Series; PHA= Public 
Health Advisory; SRRAs= Safety-Related Regulatory Action. 
 







In our study, DHPCs, Black Box Warnings and Public Health Advisories had similar patterns 
of impact as intended by the warnings, showing an effect in 56%, 57% and 61%, 
respectively, with no effect in 27%, 21% and 31%, respectively, or a mixed effect in 17%, 
21% and 8%, respectively.  
Effects were reported for nearly all (86%) safety warnings evaluating unintended 
effects but assessment was limited to selective serotonin reuptake inhibitors and third-
generation oral contraceptives (Appendix table). Only DHPCs were issued for third-
generation oral contraceptives, while selective serotonin reuptake inhibitors received 
DHPCs, Black Box Warnings and Public Health Advisories. No variation in impact was 
observed across the different safety warnings. 
Outcome Measures 
The 52 articles in our study assessed the impact of safety warnings for 77 outcome 
measures. The majority (28) of articles assessed the intended impact of warnings on 
clinical behaviour by evaluating overall drug use volume (Appendix table).(11,12,14,15,21,22,24-
26,28,29,31,36,39-41,45-47,49,56,57,59) In some articles more specific drug use measures were 
assessed: drug-drug interaction/contraindicated use (16 articles),(22,32-38,50-52,54,57,58,62) drug 
use in defined populations (adults, children, etc.) (16 articles),(11,12,14,15,25,28,29,31,40,41,44-49) 
new users of a drug (1 article),(21) refusal of antidepressant prescription (1 article),(44) or 
discontinuation rates/switches (1 article).(25) Nine studies assessed care-related outcomes 
such as the type of healthcare professional (e.g. general practitioner, psychiatrist), 
diagnosing patterns (5 articles),(13,41,43,49,59) and adherence to performing warning-dictated 
laboratory tests (4 articles).(53,55,56,65) These papers specifically intended to evaluate the 
non-drug treatment recommendations of a warning. Additionally, in five papers clinical 
outcome measures were assessed, e.g. venous thromboembolism cases (1 article),(28) 
mortality (1 article),(59) hospital admissions (1 article)(59) and spontaneous adverse drug 
event reports (2 articles).(60,61)  
In eight studies the use of multiple outcome measures led to mixed intended effects 
(Appendix table).(21,25,28,41,50,56,57,59) For six of these eight articles, impact was observed on 
the volume of drug use in general but not for more specific outcome measures such as 
drug use outcomes, e.g. only new users of troglitazone,(21,25,57) healthcare outcomes such 
as laboratory tests because of hepatoxicity risks,(56,59) and clinical outcomes such as 
venous thromboembolism cases in third generation oral contraceptives.(28,59) The 
remaining two articles only reported the impact of safety warnings on one of two 
contraindicated concomitantly used drugs,(50) and the impact of two of the three assessed 







The outcome measures for the unintended effects of safety warnings were matched with 
the specific message of a warning (Appendix table). All three publications assessing 
spillover effects (decreased drug use by the non-targeted adult population) of the 
selective serotonin reuptake inhibitor warnings reported effects.(12-14)  
The outcome measures related to suicide and suicidal thoughts (self-poisoning, 
suicide rates and hospital admissions) showed more varied results. Two articles reported 
increases in self-poisoning cases;(42,45) but of three articles assessing suicide rates,(12,15,46) 
one(15) reported no increase. The latter study also found no increase in hospital admissions 
for self-harm.(15) Lastly, impact was found on health services use, as shown by a decrease 
in the rate of physician visits after the safety warning.(46)  
Both articles assessing abortions after a safety warning for third-generation oral 
contraceptives reported increases in the number of abortions.(23,29) In addition, an increase 
in conceptions was observed.(27) Moreover, a decrease in third-generation oral 
contraceptive use was observed in Ireland, although this was not in line with 
recommendations by national authorities.(30)  
Discussion 
This systematic review provides the first overview of articles published on the effect of 
safety warnings. We identified 52 studies that assessed the impact of safety warnings on 
clinical practice. Intended effects were found in the majority of cases but varied between 
drugs and drug groups. Unintended effects were also reported. No firm conclusions on 
effect size can be drawn due to a number of factors, including the small number of drug 
groups evaluated, deficiencies in the study design and inconsistency in outcome 
measures.  
The available studies mainly assessed three drug groups: selective serotonin 
reuptake inhibitors, third-generation oral contraceptives and cisapride. The focus on these 
drug groups is in line with the extensive media attention that two of these safety related 
issues received. The studies included indicated that the so-called ‘pill scare’ had a very 
large impact, specifically in the UK(23-28) after the UK Committee of Safety of Medicine 
advised discontinuation of third-generation oral contraceptive use. Consequently, the 
warnings resulted in a similar impact in adjacent countries that had taken a less rigorous 
approach.(30) A BBC broadcast(66) in the UK about self-harm and suicide related to the 
selective serotonin reuptake inhibitor paroxetine caused further media attention in 
several countries, which was followed by an extensive reassessment of the benefits and 
risks associated with the product group and a number of successive regulatory actions, 
especially in the US.(67) The debate about cisapride seems to have been triggered by the 







potential preventability of prescribing concomitant contraindicated drugs, but did not 
generate as much public interest.  
Data related to selective serotonin reuptake inhibitors and third-generation oral 
contraceptives also shows that the observed impact was not always as intended, which 
highlights the relevance of taking not only the intended but also the unintended effects 
into account. Of eight selective serotonin reuptake inhibitor papers evaluating the 
unintended effects of the warnings, six identified unintended effects such as increases in 
suicide rates and unintended spillover effects, in particular decreased use of 
antidepressants in adults. Unintended effects of the warnings were also found for third-
generation oral contraceptives: increases in conceptions and abortion rates were 
observed. The concerns surrounding this specific safety issue caused many women to 
switch to other oral contraceptives or to cease using oral contraceptives all together.  
How to present risk to the general public was extensively discussed as a result of the 
‘pill scare’. The risk of venous thromboembolism with third generation oral contraceptive 
use was presented as doubling. This implied a large increase in risk, although the absolute 
risk of venous thromboembolism was still smaller than that of venous thromboembolism 
during pregnancy. Afterwards, restrictions on third-generation oral contraceptive use 
were withdrawn in the UK and the wording of the warning was adjusted.(68)  
Almost half of the studies applied a before/after design, which coupled with 
heterogeneity in the analyses and outcome measures hampered reporting of overall effect 
sizes of safety warnings. Inclusion of before/after studies could be considered a limitation 
due to their inherent methodological flaws.(69) For example, with a before/after study 
design it is not possible to control for seasonal changes in drug use. However, it is 
suggested that using a before/after design could be valid where a comparable control 
group is used to assess any differences between the groups that could be attributed to the 
intervention.(70) Notwithstanding that, all papers with before/after design were included in 
the systematic review to provide a comprehensive overview of what had been evaluated 
to date. Interrupted time series design is the best available study design to evaluate the 
impact of policy changes where it is almost impossible to employ a control group, and it is 
regarded as the ‘strongest’ quasi-experimental study design.(71) When considering the 
interrupted time series studies alone, the most apparent intended effects of safety 
warnings were observed in the case of terfenadine through a decrease in contraindicated 
drug use. In cases of the selective serotonin reuptake inhibitors and cisapride, the majority 
of interrupted time series studies reported mixed effects, mainly regarding the volume of 
drug use.  
The interpretation of results is further complicated because of the assessment of 







tests/spontaneous adverse drug event reports), different interventions (DHPCs/Black Box 
Warnings/Public Health Advisories), and the heterogeneity of analyses. However, since 
the warnings can have different intentions, assessing specific outcome measures 
regarding the safety issue in question is a more accurate method to detect the intended 
impact of a warning. For example, where a DHPC is issued to address an increased 
hepatoxicity risk, with a recommendation for testing the liver function of patients, 
assessing the impact on laboratory tests could be more appropriate than simply assessing 
drug use.  
In addition, the majority of the papers included did not assess every safety warning 
that was issued for the drugs and drug groups. Sometimes, warnings were preceded by or 
coincided with other warnings regarding the same safety issue, and which were not 
analysed in the study. This was the case in the study by Gibbons et al.(12) in which several 
warnings issued between October 2003 and December 2006 were evaluated, although 
three other warnings issued within that period (between September and December 2005), 
were not assessed. These other warnings may have strengthened the safety message, the 
impact of which was assessed, and therefore have biased the results. Similarly, several 
articles reported an overall effect only, and lacked assessment of the effect by individual 
warnings. Therefore, our data do not allow the drawing of conclusions about which safety 
warning strategy is more effective, especially since two-thirds of the warnings evaluated 
concerned DHPCs.  
A limitation of the outcome in all studies was that none of the papers could rule out 
the influence of confounding factors such as media attention, which could have 
strengthened the effect of the safety warnings. For example, in the case of the increased 
risk of suicide and suicidal thoughts in selective serotonin reuptake inhibitor use, the 
media hype that occurred could have been an influential factor on the effect of the safety 
warnings on drug use.(14,40,45)  
The strength of this research was that it was extensive and comprehensive. Various 
search methods were used to minimize selection bias; searches were performed without 
any language restrictions and only the first or most relevant paper published on the same 
dataset was included.(19) Furthermore, we evaluated different safety warnings; papers 
assessing the effects of Black Box Warnings and Public Health Advisories, which were also 
commonly used to communicate safety problems of drugs in the US, were included as well 
as DHPCs. 
Conclusions 
Our review highlights the gap in the current knowledge on effectiveness of safety 
warnings and also shows the relevance of taking not only the intended effects but also the 







unintended affects into account. There is a clear need for more research to understand 
the impact of safety warnings, using appropriate study designs and statistical analyses. 
Both the intended and the anticipated unintended effects of safety warnings should be 
assessed. Not only should the impact on drug use be evaluated, but also the impact on 
outcome measures that specifically evaluate the intention of the warning. Moreover, all 
individual warnings issued for the drug in question should be assessed instead of only a 
selection. The impact should be reported per warning instead of an overall effect. The 
interrupted time series study is the preferred study design as it allows for greater 
reliability in assessing the impact of safety warnings in comparison to before/after 
designs. When conducting a study with one drug or a limited selection of drugs, 
confounding factors should be better described and included in the analysis, which is 
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The effect of Direct Healthcare Professional Communications (DHPCs) informing health-
care professionals of serious drug safety issues has been questioned. The aim of this study 
was to evaluate the impact of DHPCs on drug use. Nationwide dispensing data for the 
period 2000–2008 for new users of 46 drugs with one or more DHPCs were assessed. 
Impact on short-term volume of use was evaluated with regression models, and the 
presence of long-term changes in use was evaluated with interrupted time series analyses 
incorporating pre-existing trends. The short-term prescription level was lower post-DHPC 
in 28 (48.3%) of 58 cases. Twenty (34.5%) DHPCs resulted in long-term changes in use. 
A long-term mean reduction in use was observed in 26.7% of cases (95% confidence 
interval, −15.2 to −38.2%). Long-term changes in use were not significantly related to pre-
existing trends in use. Although short- and long-term decreases in use were observed after 
only half and a third of DHPCs, respectively, the decrease was substantial.  








At market entry, the safety profile of a new drug is not fully known because of inherent 
shortcomings of preregistration clinical trials, such as small sample sizes, focus on efficacy, 
and inclusion of relatively healthy patient groups.(1,2) For ~10% of all drugs, new and 
serious safety issues are identified after market approval, necessitating safety-related 
regulatory action.(3-5) These safety issues can emerge not only shortly after market entry 
but also at a later stage in the drug’s life cycle.(3-5) Occasionally, the benefits of a drug no 
longer outweigh its risks, leading to its withdrawal from the market. For example, 
rimonabant, an anti-obesity drug, was withdrawn in 2009 because of safety concerns at an 
early stage of its life cycle (<3 years after market approval). Similarly, rosiglitazone, a drug 
used to treat diabetes, was withdrawn in 2010 because of safety concerns at a more 
mature stage (>10 years after market approval).(6,7) On-going post-registration benefit–risk 
evaluation and, when indicated, safety-related regulatory action are required to safeguard 
a positive balance of benefits over risks of individual drugs. To this end, risk-management 
plans became mandatory in the European Union in 2005.(8)  
Prescribing trends of drugs presumably show an initial increase in prescription rates, 
after which they level out, and at a later stage in the life cycle they decrease.(9) One would 
expect safety-related regulatory action to have dissimilar impact, depending on when in 
the drug’s life cycle it is taken. However, such information is currently not available.  
Communication of important new safety issues in the European Union is currently 
primarily performed by sending paper-based warning letters to health-care professionals; 
these are called Direct Healthcare Professional Communications (DHPCs or ‘Dear Doctor 
letters’). DHPCs in the European Union are defined as information aimed at ensuring safe 
and effective use of medicinal products.(10) In recent years, the effectiveness of these 
warning letters has been questioned.(11-13) The impact of safety-related regulatory action 
was evaluated mainly for third generation oral contraceptives, cisapride, and selective 
serotonin reuptake inhibitors.(14-19) The small number of drug groups, often weak study 
designs, and differences in outcome measures hamper drawing conclusions on effect sizes 
of safety-related regulatory action. Information about the impact of DHPCs is particularly 
relevant because evaluating the outcome of risk minimization will become mandatory in 
the near future and a point of reference is needed.(20,21)  
The aim of this study was to evaluate the impact of DHPCs on drug use in the 









In this longitudinal study, all drugs for which a DHPC was issued between January 2001 
and January 2008 in the Netherlands were included. We excluded drugs that were not 
dispensed in ambulatory care, drugs that had insufficient dispensing data (≤10 
prescriptions/month pre- and post-DHPC), and drugs for which a market withdrawal was 
announced in the DHPC. New drug use (defined as number of new prescriptions per drug 
and no dispensing to the patient in the previous 6 months) was selected as main outcome 
measure to assess the impact of DHPCs. The following drug and DHPC characteristics were 
retrieved: International Non-proprietary Names, ATC classification, registration date, date 
of DHPC, time from registration to DHPC, and safety issue (including System Organ Class). 
Data  
Monthly dispensing data for the period 2000–2008 were obtained from the Dutch 
Foundation for Pharmaceutical Statistics database. This database comprises drug 
dispensing data of about 90% (15 million) of the Dutch population.(22) DHPCs were 
collected from the Dutch Healthcare Inspectorate paper archive and the website of the 
Dutch Medicines Evaluation Board.(23) The drug and DHPC characteristics were retrieved 
from the DHPCs, the Database Human Medicines of the Dutch Medicines Evaluation 
Board,(24) the World Health Organization ATC classification system,(25) and the Medical 
Dictionary for Regulatory Activities. 
Analyses  
The DHPC was used as the unit of analysis. We first evaluated the impact of DHPCs on 
short-term volume of drug use using regression models. Second, we determined whether 
a DHPC led to a long-term change in use with interrupted time series analyses. Short-term 
changes in use were defined as a significant increase, no change, or a significant decrease 
in prescription rates. Two aspects of change were identified: changes in average use (i.e., 
level) and trends in use (i.e., slopes) before and after the DHPC. Per DHPC, we computed 
trend regression models for the periods 12 months before and 12 months after the DHPC. 
A pooled (two-sample) t-test was used to determine whether the intercept estimates for 
the pre- and post- DHPC period were significantly different from each other. To consider 
all possible combinations in trend before and after the DHPC, we tested whether the 
estimates of the slope coefficient (for the pre- and post-DHPC period) were significantly 
different from zero, negative, or positive. For that purpose, we performed standard t-
tests. P values of ≤0.05 were considered statistically significant. We used an interrupted 







time series design based on the autoregressive integrated moving average modelling 
approach(26,27) to analyse the size and significance of long-term changes in use during the 
total study period associated with the DHPC for each drug included. Long-term changes 
indicate a change in the level of use from the time of the DHPC until the end of our 
observational period. Safety-related regulatory action in the form of a DHPC is included in 
the model as an intervention that may interrupt the normal course of the use of a drug. 
We expected a DHPC to have a sudden (rather than gradual) effect on drug use; therefore, 
we modelled the intervention as an abrupt change at the time of the DHPC that will have a 
permanent effect on drug use. The DHPC was included as a dummy variable taking the 
value 0 in the pre-intervention period and the value 1 at the time of intervention and 
thereafter. Because a DHPC could have been surrounded by premonition (e.g., scientific 
articles, communication circulated by healthcare professionals) or issued at the end of a 
month, we also allowed for a lead (i.e., the month before the issuance month) or delayed 
effect (i.e., 1 or 2 months after the DHPC) of the DHPC on the prescription series. We 
determined an appropriate time series regression model that accounts for any 
(systematic) variation that is independent of the intervention. Plots of the raw data and 
the (partial) autocorrelation function were used to identify non-stationarity. In addition, 
unit root tests were applied. If non-stationarity was present, we transformed the series by 
taking first differences to yield a stationary series. On the basis of the partial 
autocorrelation function, we determined the order of the autoregressive and moving 
average components. Both seasonal fluctuations and trends were taken into account. The 
model with the best fit and adequate diagnostic statistics was chosen according to Akaike 
and Schwarz information criteria.(28,29) Residuals were computed for diagnostic checks. To 
assess the impact of the intervention, the intervention term was inserted into the 
previously determined time series model. Changes in the level of prescribing (drug use) 
related to the intervention were considered statistically significant when p≤0.05. The 
analyses were performed separately for each drug. When two DHPCs were issued close in 
time, they were treated as a single intervention and analysed together. In such a case, the 
date of issuance of the first DHPC was taken as the time point of intervention. To make 
the size of the impact comparable across drugs, we calculated standardized effect sizes by 
dividing the effect size by the median drug use in the 12 months before the intervention. 
Chi-square tests were used to assess associations between pre-existing trends and long-
term changes in use. 
Results 
A total of 120 DHPCs were issued in the Netherlands during the study period. Sixty-one 







hospital settings, 18 DHPCs were issued for drugs with fewer than (median) 10 drug users 
per month over the entire study period, and five DHPCs were issued for drugs that were 
withdrawn from the market. As a result, 59 DHPCs were included for 46 drug groups 
covering 11 of 14 Anatomical Therapeutic Chemical (ATC) groups (level 1) (Table 1). The 
impact of two DHPCs, both issued for nelfinavir 1 month apart, could not be evaluated 
separately and were therefore analysed as one, leading to a total of 58 DHPCs to be 
analysed for 46 drugs. DHPCs were issued after a mean of 9.67 (SD 8.3) years after 
registration (‘time from registration to DHPC’). In the 12-month (baseline) period 
preceding the DHPC, the median number of users of the included drugs ranged from 7 
(sirolimus) to 53,596 (salbutamol) (Table 1). 
Short-term changes in volume of use 
Half (29) of all DHPCs were issued for drugs without any significant change in pre-existent 
trends (slope) in use, 13 were issued for drugs whose use was decreasing, and 16 for drugs 
whose use was increasing in the 12-month period before the DHPC was issued (Table 2). 
The short-term level of prescribing was lower after the DHPC for half (28) of the drugs and 
evenly distributed across the unchanged (14) or higher (16) categories for the other half of 
the drugs. Three clusters in short-term changes in use exist. The first cluster consists of 11 
of 13 drugs with decreasing use before the DHPC that continued to decrease or levelled 
off after the DHPC, but at a lower level than before the DHPC. A second cluster consists of 
21 of 29 drugs with unchanged slope coefficients before and after the DHPC and with no 
changes in levels of use. The third cluster consists of eight drugs for which  pre-existent 
increasing use levels off after the DHPC but at a higher level than before the DHPC. 
Long-term changes in volume of use 
Forty-six interrupted time series models were developed to evaluate any long-term 
change in number of prescriptions after (58) individual DHPCs were issued for the 46 drugs 
(descriptions of individual models are available upon request). Twenty (34.5%) DHPCs 
resulted in a long-term  change in drug use (Table 1). For these 20 DHPCs, the mean use 
decreased by 26.7% (95% confidence interval, −15.21 to −38.19%). A long-term increase in 
use (+15.4%; 95% confidence interval, 3.74 to 27.06%) was observed after the DHPC for 
lopinavir/ritonavir (Figure 1). 
Long-term changes in volume of use in relation to pre-existing trends in use 
Significant long-term changes were seen in 8 of 13 (62%) drugs with a pre-existing 
decreasing trend in use (cisapride1, itraconazole, piroxicam, rosiglitazone2, didanosine, 
leflunomide, desogestrel + ethinylestradiol (EE), and gestodene + EE), in 8 of 29 (28%)  












date Safety issue (SOC) 
Median  









DHPCs with significant long-term changes in use 
cisapride 
(A03FA02) 
Jul-88 Sep-02 Electrocardiogram QT prolonged 
(Investigations) 
4148.5 -0.433 0.000 108 
rosiglitazone 
(A10BG02) 
Jul-00 Jan-06 Macular oedema (Eye) 1488 -0.327 0.000 108 
  Mar-07 Fracture (Musculoskeletal) 964 -0.637 0.000 108 
pioglitazone 
(A10BG03) 
Oct-00 Apr-07 Fracture (Musculoskeletal) 1012 -0.320 0.005 84 
desogestrel and 
EE (G03AA09) 
May-81 Sep-01 Venous thrombosis (Vascular) 10605 -0.153 0.001 108 
gestodene and 
EE (G03AA10) 
May-89 Sep-01 Venous thrombosis (Vascular) 5719.5 -0.208 0.000 108 
itraconazole 
(J02AC02) 




Mar-01 Sep-06 Circumstance or information capable 
of leading to medication error (Injury) 
94.5 0.154 0.011 89 
didanosine 
(J05AF02) 
Aug-00 Mar-05 Drug effect decreased (General) 40.5 -0.438 0.002 108 
leflunomide 
(L04AA13) 
Sep-99 Mar-01 Hepatitis (Hepatobiliary) 432 -0.315 0.000 108 
piroxicam 
(M01AC01) 
Jun-87 Aug-07 Gastrointestinal disorder 
(Gastrointestinal) 
2920.5 -0.494 0.000 108 
celecoxib 
(M01AH01) 
May-00 Dec-04 Cardiovascular disorder (Cardiac)  11851.5 -0.570 0.000 72 
etoricoxib 
(M01AH05) 




Sep-04 Nov-07 Drug rash with eosinophilia and 
systemic symptoms: DRESS (Blood) 
344.5 -0.674 0.000 41 
vigabatrine 
(N03AG04) 
Sep-90 Sep-02 Visual field defect (Nervous) 40 -0.186 0.007 108 
lamotrigine 
(N03AX09) 
Jan-96 Jun-06 Maternal drugs affecting foetus 
(Injury) 
746 -0.155 0.001 108 
pergolide 
(N04BC02) 
Jul-91 Apr-05 Cardiac valve disease (Cardiac) 142 -0.245 0.008 108 
olanzapine 
(N05AH03) 
Sep-96 Mar-04 Death (General) 2193 -0.171 0.009 70 
paroxetine 
(N06AB05) 
Jun-91 Mar-06 Maternal drugs affecting foetus 
(Injury) 
10613 -0.145 0.044 67 
bupropion 
(N06AX12) 
Dec-99 May-01 Convulsion 4399.5 -0.406 0.000 108 
DHPCs without significant long-term changes in use 
cisapride 
(A03FA02) 
Jul-88 Sep-04 Electrocardiogram QT prolonged 
(Investigations) 
408.5 0.155 0.880 108 
sibutramine 
(A08AA10) 
Apr-01 Jul-02 Cardiovascular disorder (Cardiac) 567.5 0.001 0.998 92 
repaglinide 
(A10BX02) 













date Safety issue (SOC) 
Median  











Nov-88 Nov-01 Aplasia pure red cell (Blood) 417 0.078 0.563 108 
epoetine alfa 
(B03XA01) 
Nov-88 Jul-02 Aplasia pure red cell (Blood) 495.5 0.201 0.076 108 
epoetine alfa 
(B03XA01) 
Nov-88 Dec-02 Aplasia pure red cell (Blood) 551.5 -0.114 0.256 108 
rosuvastatine 
(C10AA07) 
Nov-02 Jun-04 Rhabdomyolysis (Musculoskeletal) 5968.5 0.122 0.312 70 
gemfibrozil 
(C10AB04) 
Jul-90 May-03 Hypoglycaemia (Endocrine) 595 0.029 0.747 108 
tacrolimus 
(D11AX14) 
Apr-96 Apr-06 Lymphoma (Blood) 1550.5 -0.199 0.147 108 
pimecrolimus 
(D11AX15) 




Jul-76 Dec-03 Breast cancer (Neoplasms) 2951 0.104 0.375 108 
tamsulosine 
(G04CA02) 
Apr-95 Aug-06 Floppy iris syndrome (Nervous) 6142 0.016 0.749 108 
somatropin 
(H01AC01) 
Nov-91 Jun-07 Circumstance or information capable 
of leading to medication error (Injury) 




Sep-66 Dec-06 Eye disorder (Eye) 11643.5 -0.091 0.225 108 
nelfinavir 
(J05AE04) 
Jan-98 Jun-07 & 
Jul-07a  
Therapeutic product contamination 
(Injury) 




Mar-01 Aug-07 Incorrect dose administered (Injury) 109.5 0.036 0.476 89 
stavudine 
(J05AF04) 
May-96 Sep-01 Muscular weakness (Nervous) 73.5 -0.045 0.580 108 
tenofovir 
(J05AF07) 
Feb-02 Jul-03 Drug effect decreased (General) 97.5 0.206 0.324 74 
tenofovir 
(J05AF07) 
Feb-02 Oct-03 Drug effect decreased (General) 97.5 -0.284 0.176 74 
tenofovir 
(J05AF07) 
Feb-02 Mar-05 Drug effect decreased (General) 137 -0.010 0.947 74 
tenofovir 
(J05AF07) 
Feb-02 Mar-06 Renal disorder (Renal) 167.5 0.163 0.183 74 
nevirapine 
(J05AG01) 








Nov-01 Dec-06 Cardiac failure (Cardiac) 53.5 -0.197 0.175 60 
Hydroxycarba-
mide (L01XX05) 
Nov-72 Dec-05 Cutaneous vasculitis (Skin) 133 0.047 0.212 108 
letrozol 
(L02BG04) 
Jan-97 Dec-05 Maternal drugs affecting foetus 
(Injury) 
240.5 0.139 0.089 108 












date Safety issue (SOC) 
Median  












Feb-96 Nov-07 Maternal drugs affecting foetus 
(Injury) 
274 -0.028 0.602 108 
sirolimus 
(L04AA10) 
Mar-01 Feb-03 Bronchial anastomosis complication 
(Respiratory) 
6.5 0.717 0.084 94 
etanercept 
(L04AB01) 
Feb-00 Feb-03 Infection (Infections) 28 -0.041 0.961 108 
celecoxib 
(M01AH01) 
May-00 Feb-05 Cardiovascular disorder (Cardiac) 11851.5 0.037 0.582 72 
botuline a toxin 
(M03AX01) 
Dec-93 Jun-07 Muscular weakness (Nervous) 25 -0.030 0.883 108 
lamotrigine 
(N03AX09) 
Jan-96 Oct-05 Drug effect decreased (General) 688 0.075 0.152 108 
topiramate 
(N03AX11) 
Jun-99 Oct-01 Oculomucocutaneous syndrome (Eye) 142 -0.048 0.868 108 
levetiracetam 
(N03AX14) 
Sep-00 Nov-07 Incorrect dose administered (Injury) 701 0.055 0.087 86 
paroxetine 
(N06AB05) 
Jun-91 Jan-06 Maternal drugs affecting foetus 
(Injury) 
10451 0.041 0.658 108 
venlafaxine 
(N06AX16) 
Dec-97 Sep-03 Suicidal ideation (Psychiatric) 4222.5 0.105 0.128 108 
galantamine 
(N06DA04) 
Jul-03 Oct-05 Death (General) 232 -0.075 0.559 61 
salbutamol 
(R03AC02) 
Dec-73 May-07 Myocardial ischaemia (Cardiac) 53595.5 -0.114 0.105 108 
a The two DHPCs issued for nelfinavir were issued close in time and were therefore treated as a single 
intervention and analysed together. The first DHPC was taken as the time point of intervention.  
ATC= Anatomical Therapeutic Chemical; DHPC= Direct Healthcare Professional Communication; DRESS= Drug 
Rash Eosinophilia Systemic Symptoms; EE= ethinylestradiol; INN= International Proprietary Name; MedRA= 
Medical Dictionary for Regulatory Activities; Rx= Medical prescription; SOC: System Organ Class. System Organ 
Class according to MedRA: Investigations: Investigations; Eye: Eye disorders; Musculoskeletal: Muscoloskeletal 
and connective tissue disorders; Vascular: Vascular disorders; Cardiac: Cardiac disorders; Injury: Injury, poisoning 
and procedural complications; General: General disorders and administration site conditions; Hepatobiliary: 
Hepatobiliary disorders; Gastrointestinal: Gastrointestinal disorders; Blood: Blood and lymphatic system 
disorders; Nervous: Nervous system disorders; Endocrine: Endocrine disorders; Neoplasms: Neoplasms benign, 
malignant and unspecified (including cysts and polyps); Renal: Renal and urinary disorders; Skin: Skin and 
subcutaneous tissue disorders; Respiratory: Respiratory, thoracic and mediastinal disorders; Infections: 
Infections and infestations; Psychiatric: Psychiatric disorders 
 
drugs with a stable (no significant increase or decrease) pre-existing trend (etoricoxib, 
rosiglitazone1, bupropion, lamotrigine2, pergolide, pioglitazone, vigabatrin, and lopinavir + 
ritonavir), and in 4 of 16 (25%) drugs with a pre-existing increasing trend (celecoxib1, 
paroxetine2, strontium ranelate, and olanzapine) (Table 2; drugs with more than one 
DHPC are indicated here by superscript numbers). However, no significant association was 
found between pre-existing trends in use and significant long-term changes (χ2=5.46; 







Table 2. Short-term changes in drug use pre and post DHPC (N=58).  
Changes in trend
*










































































































Drugs with more than one DHPC are indicated by their superscript numbers. a Short-term changes in trend 12 
months pre and post-DHPC, are indicated by ‘decrease (-)’ or, ‘increase (+)’ (p<0.05), or by ‘unchanged (0)’ 
(p≥0.05). b Short-term changes in mean level 12 months post-DHPC compared to 12 months pre-DHPC, are 
indicated by ‘lower’ or ‘higher’ (p<0.05) or unchanged (p≥0.05). Example: cisapride
1
 situated in the upper left 
cell, indicates that before the first DHPC of cisapride its short-term use was decreasing (changes in trend pre-
DHPC) and continued to decrease after (post-DHPC) the DHPC. In addition, the level of use was lower after the 
DHPC.  
DHPC: Direct Healthcare Professional Communication; EE: Ethinylestradiol; HRT: Hormone Replacement Therapy. 
 
Almost all (18 of 20) DHPCs leading to long-term changes in drug use had a lower level of 
use in the short term (12 months), whereas the DHPC for lopinavir/ritonavir (reporting a 
switch from capsule to tablet formulation) showed both a long-term increase in use and a 
higher use in the short term. The impact of the DHPC for olanzapine is characterized by a 
short-term flattening off of use (increasing slope pre-DHPC and no significant (from null) 
change in slope post-DHPC), resulting in no significant short-term change in the level of 
use, but a significant long-term decrease in use post-DHPC (data available upon request). 









Figure 1. Standardized effect sizes of Direct Healthcare Professional Communications (DHPC) 
leading to significant long-term changes in volume of new drug use. 
Drugs with more than one DHPC are indicated by their number  
 
Discussion 
This study is the first to systematically assess the effect of safety-related regulatory action 
on changes in volume of drug use in ambulatory care over a an extended period. In the 
short term, almost half of all drugs with a DHPC showed a decrease in use in the year after 
the DHPC was issued as compared with the year before. Long-term changes in use were 
observed for a third of the drugs with a DHPC, resulting in a mean decrease of 26.7% in 
drug use, ranging from −10 to −67%. Changes in use were not clearly related to pre-
existent trends in use. 
This study shows that DHPCs can lead to a considerable decrease in use of a minority 
of drugs. The results support earlier reported variation in the effect of safety-related 
regulatory action. Large reductions in use of coxibs in favour of non-steroidal anti-
inflammatory drugs were reported earlier in Germany,(30) and large reductions in use of 
glitazones have been reported in the United States.(31) Similar to our study, smaller or no 
decreases in drug use have been reported as well. A decrease of only 20% in overall 








isotretinoin did not decrease significantly after a DHPC informing health-care professionals 
about risk of psychiatric problems.(33)  
Several factors might explain the observed decreases in the use of drugs after a 
DHPC. For example, the observed decreases in use of the coxibs, pergolide, anti-HIV drugs, 
and bupropion may be explained by the availability of alternative drugs with a more 
favourable benefit–risk profile (Table 3).  
Moreover, in the Netherlands, bupropion is also indicated to assist patients in their 
wish to give up smoking and could therefore be considered a luxury drug, with limited 
medical need and a low acceptance of drug risks. The severity of the reported adverse 
drug events, e.g., strontium ranelate (Drug Rash with Eosinophilia Systemic Symptoms 
(DRESS), the coxibs (cardiovascular risk), glitazones (fracture risk), pergolide (cardiac valve 
disease), cisapride (QT prolongation), olanzapine (death), and vigabatrin (visual field 
defects), may explain the significant impact of the related DHPCs on drug use. The second 
DHPCs for both lamotrigine and paroxetine warned of potential teratogenic effects, which 
may be considered severe. However, these affect only a distinct subpopulation of women 
of childbearing age. The observed 15% (lamotrigine) and 16% (paroxetine) decreases in 
use may thus have been attenuated by evaluating the impact of the DHPCs on overall use, 
instead of use by this specific group of women alone.  
Remarkably, the first DHPC for lopinavir/ritonavir led to increased use, over both the 
long and the short term. This may be explained by the message of the DHPC, which 
announced a switch from a capsule to a tablet formulation, which was intended to 
prevent a safety issue and thus not expected to cause a decrease in prescription rates. 
Moreover, prescribing of lopinavir/ritonavir is highly valued by many specialists because of 
the effectiveness of this combination in lowering patients’ viral load.(34)  
Of note, two-thirds of the DHPCs did not result in long-term changes in drug use. 
Factors that may explain the absence of long-term changes in our study are a lack of 
available alternative drugs, as in the case of etanercept, gemfibrozil, hydroxycarbamide, 
and imatinib (Table 3). The high medical need for these drugs in specific populations could 
overrule concerns prescribers may have with the reported safety issues in the DHPC. A 
number of DHPCs reported safety issues that were either already known or not 
unexpected from the underlying mechanism of action; for example, the second DHPCs for 
celecoxib and cisapride, hormone replacement therapy (breast cancer risk was widely 
published before the DHPC was issued),(35) sibutramine (potential cardiovascular risk was 
already known at the time of approval), and pimecrolimus and tacrolimus (immune-
modulating agents and risk of lymphomas). In these cases, physicians may have realized 
the risk associated with these drugs earlier and adapted their prescribing behaviour   







Table 3. Potential explanations for (lack of) impact of DHPCs on volume of drug use. 
DHPCs with long term changes (decrease in Rx) in use 
Alternative treatment available 
bupropion, celecoxib
1
, didanosine, etoricoxib, itraconazole, pergolide, 
stavudine. 
Limited medical need Bupropion. 















Confirmation of existing 
doubts/accelerating effect on 




, combinations of desogestrel and gestodene with ethinylestradiol, 
piroxicam. 
DHPC with long term change (increase in Rx) in use 
High medical need lopinavir/ritanovir
1
. 
DHPCs without long term changes in use 
No alternative treatment 
available/high medical need 






, etanercept, HRT, lamotrigine
1
, mycophenolate mofetil, 
nevirapine, pimecrolimus, rosuvastatin, sibutramine, tacrolimus, tamsulosine. 
Rare ADE tamsulosine, hydroxycarbamide. 










, pimecrolimus, sirolimus, stavudine, 
tacrolimus, tenofovir
1, 2, 3, 4
, topiramate. 
Off label use 
botuline a toxin, galantamine hydrobromide, letrozole, salbutamol, 
triamcinolon acetonide, venlafaxine. 




, repaglinide, somatropin. 
Several explanations for (absence of) impact of a DHPC for a drug are possible. Drugs with more than one DHPC 
are indicated by their superscript numbers. 
ADE= Adverse drug event; DHPC= Direct Healthcare Professional Communication; HRT= Hormone Replacement 
Therapy; Rx= Medical prescription.  
 
accordingly. Some adverse drug events may be rare and considered acceptable risks in the 
specific populations these drugs are used in, as in the case of tamsulosin (floppy-iris 
syndrome in the elderly patient) and hydroxycarbamide (cutaneous vasculitis in patients 
with cancer). Prescription of drugs such as epoetin alfa, imatinib mesilate, and 
levetiracetam is usually initiated by specialists and subsequently continued in ambulatory 
care. Specialists make more use of resources such as laboratory tests in comparison to 
general practitioners, facilitating continued use of drugs with a safety warning.(36) DHPCs 







such a case, the drug in question is often prescribed only to a small group of patients 
outside of the regular indication. This could explain the lack of long-term impact of DHPCs 
for botulin toxin, galantamine, and letrozole. The DHPCs for levetiracetam, 
lopinavir/ritonavir2, nelfinavir1,2, repaglinide, and somatropin were issued to prevent 
medication errors (including drug–drug interactions). For example, in the DHPC for 
somatropin, defective calculators were called back that were distributed to prescribers to 
facilitate dose calculation of the growth hormone.  
Half of all included drugs had a decrease in use in the year after the DHPC was 
issued. For 8 of 13 drugs with a declining use in the year preceding the DHPC, a long-term 
change in use was observed. This indicates an accelerating effect of the DHPC on already 
decreasing use of drugs that might be at the end of their life cycle. Although we could not 
confirm that older drugs more often showed declining use, at the mature stage of a 
product’s life cycle several alternative agents have usually become available. It is likely 
that the DHPC confirmed already existing doubts of prescribers about the safety of some 
of these drugs (cisapride, combinations of desogestrel and gestodene with EE, piroxicam), 
which made them stop prescribing the drugs to new patients. In the cases of cisapride-
related cardiac arrhythmias and venous thrombosis related to combinations of 
desogestrel and gestodene with EE, the safety issues had already been described in the 
literature,(37,38) whereas the DHPC followed some time afterward.(23) A similar pattern was 
observed for piroxicam; its use had decreased before the DHPC was issued because of 
gastrointestinal complications. Nevertheless, we cannot conclude that a pre-existent 
declining use is an established factor in predicting the effectiveness of a DHPC because we 
did not observe a statistically significant association.  
Further research is needed to determine the impact of the different factors discussed 
on the effect of DHPCs on use of individual drugs. Such knowledge can help optimize the 
impact of DHPCs. 
Strengths and limitations 
Our study expands the limited evidence that currently exists in literature on the impact of 
DHPCs. Our study includes DHPCs issued over a period of 8 years and a wide range of 
safety issues representing all main therapeutic classes (ATC) prescribed in ambulatory 
care. Because the same method was used to assess the impact of DHPCs issued for a wide 
range of drugs, our results enable the comparison of effects of the different DHPCs. Our 
study could serve as a starting point for future research aimed at evaluating the impact of 
safety-related regulatory action.  
In our study, we focused on the volume of new drug use as an outcome measure, 
instead of overall drug use. We assumed new drug use to be more sensitive to changes in 







prescribing and therefore more responsive to the impact of safety-related regulatory 
action. The impact of DHPCs can also be analysed using outcome measures that are 
directly attuned to the safety issue, for example, occurrence of the adverse event itself(39) 
or how often health-care professionals perform recommended laboratory tests to identify 
early potential drug toxicity.(40) These effects remain to be explored further in new studies.  
We combined trend regression analysis for short-term evaluation of usage patterns 
with time series analyses to assess long-term changes in use. Time series analyses account 
for potential biases in the effect estimate of the intervention, such as secular trends, 
cyclical effects, random fluctuations, and correlation of adjacent error terms. This affords 
greater reliability of the measurement than before–after comparisons or linear 
regression.(41) Although suitable in the short-term, linear regression models cannot 
appropriately account for possible dependencies among observations over time. The 
combination of the two strategies allows for a clearer understanding of the impact of a 
DHPC.  
A limitation of our study is that we did not have information on possible concomitant 
interventions that may have occurred at the same time. However, long-term changes 
affecting all DHPCs are unlikely given the heterogeneity in the drugs under study and the 
diverse timing of issuance of the DHPCs. In addition, our study has no control group, 
because legal requirements specify that DHPCs be sent to all relevant Dutch healthcare 
professionals. However, interrupted time series analysis is the most appropriate method 
for studying intervention effects when it is not feasible to define a comparison group.(42) 
Moreover, we evaluated the impact of DHPCs only in the Netherlands. Healthcare 
professionals in other countries may respond differently to DHPCs. Similar analyses 
conducted in other countries would be an interesting route for further research. 
Conclusion and recommendation 
In conclusion, once safety issues for drugs are identified that warrant strong regulatory 
action, i.e., DHPCs, these result in substantial long-term reductions in use of only a third of 
issued DHPCs, independent of pre-existing trends in use. The reason for less impact could 
be due to factors such as the type of adverse drug event, availability of alternative agents, 
and the type of prescriber. Further research is needed to determine the influence of these 
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Serious safety issues relating to drugs are communicated to healthcare professionals via 
Direct Healthcare Professional Communications (DHPCs). We explored which 
characteristics determined the impact of DHPCs issued in the Netherlands for ambulatory 
care drugs (2001-2008). 
With multiple linear regression we examined impact on the relative change in new drug 
use post-DHPC of: time to DHPC, trend in use, degree of innovation, specialist drug, 
first/repeated DHPC, DHPC template, and type of safety issue.  
DHPCs have less impact on use of specialist drugs than non-specialist drugs (p<0.05). The 
DHPCs’ impact increased after availability of a template emphasizing the main problem 
(p<0.05), and for safety issues with a risk of death and/or disability (both p<0.05) (adjusted 
R²=0.392). 
Risk communication can be effective, specifically in case of well-structured information, 
and very serious safety issues. Effectiveness may improve by tailoring DHPCs and adding 
other communication channels, for example for drugs that are increasingly being used.  








Due to the well-known limitations of pre-approval clinical trials, the safety profile of a drug 
is only partly known at the time of market entry.(1) Market approval does not signal the 
end of drug development, but the start of continuous evaluation of both benefits and risks 
during the entire lifecycle of a drug. Throughout this lifecycle serious safety issues may 
emerge,(2-4) which can cause hospitalization, disability, or even death of patients.(5,6) 
Healthcare professionals need to be informed of these safety issues as soon as possible in 
order to minimize the risk of preventable adverse drug events. In the European Union (EU), 
these risks are communicated through paper-based warning letters, so-called Direct 
Healthcare Professional Communications (DHPCs) or ‘Dear Doctor Letters’. Over the last 
decade, risk minimization interventions such as DHPCs have been issued in increasing 
numbers(2,7) to ensure continued safe and effective use of medicinal products.(8) 
However, the limited evidence so-far indicates that DHPCs are not always effective in 
changing behaviour of physicians.(9,10) Most studies that have assessed the impact of drug 
safety warnings, focused on one drug or on a limited number of warnings only, and often 
had methodological limitations.(9) When looking at a large number (58) of different drug 
safety issues, we showed that DHPCs lowered drug use in half of the cases in the short 
term, and in a third of the cases in the long term.(11)  
With the new EU pharmacovigilance legislation, which came into force in July 2012, 
evaluation of the impact of risk minimization measures has become mandatory.(12,13) 
Currently, it is unknown which determinants might influence the impact of DHPCs. A better 
understanding of the influence of these determinants can facilitate optimization of future 
risk communication and evaluation of risk minimization measures. In this study we explore 
the impact of drug and DHPC related characteristics on the effect of DHPCs on drug use.  
Methods  
Data collection  
Data was collected for all drugs for which a DHPC was issued in the Netherlands between 
January 2001 and January 2008. Monthly dispensing data for the period 2000-2008 were 
obtained from the Dutch Foundation for Pharmaceutical Statistics (SFK). The SFK database 
contains drug dispensing data of more than 95% of Dutch community pharmacies, serving 
approximately 15.3 million people.(14) The DHPCs were collected from the website of the 
Dutch Medicines Evaluation Board (MEB),(15) and the Dutch Healthcare Inspectorate (IGZ) 
paper archive. We excluded DHPCs for drugs that were not dispensed in ambulatory care, 







prescribed the same drug within the previous six months; pre- and post-DHPC), and drugs 
for which a market withdrawal was announced in the DHPC. 
The drug and DHPC characteristics were retrieved from the DHPCs, the human 
medicines database of the MEB,(16) the World Health Organization ATC classification 
system, and the Medical Dictionary for Regulatory Activities (MedDRA®, version 13).ii1 We 
recorded the International Non-proprietary Names (INN), Anatomical Therapeutic 
Chemical (ATC) classification, registration date, date of DHPC, and safety issue (including 
System Organ Class). 
Data measurement 
Outcome measure  
The outcome measure for this study was the relative change in new drug use after a DHPC 
was issued. We defined new drug use as the number of new prescriptions of a drug for 
which no prescriptions were dispensed to the patient in the previous six months. We 
chose new drug use as our outcome measure since we assumed it to be more sensitive to 
changes in prescribing than overall drug use. The relative change was calculated as the 
absolute change in drug use divided by the median drug use in the 12 months before the 
DHPC. Changes in the absolute number of new drug use were determined through 
interrupted time series analyses based on separate autoregressive integrated moving 
average (ARIMA) models for each individual drug. Observed changes indicated a change in 
the level of new use from the time of the DHPC until the end of the observation period. 
The calculation of the outcome measure and in- and exclusion criteria were described in 
more detail elsewhere.(11)  
Determinants  
Characteristics of the drugs and the DHPC were assessed to explain differences in the 
outcome. We included four drug related characteristics: (1) The time to DHPC, defined as 
the elapsed time in months from drug approval (registration date) to the publication of 
the DHPC. (2) Trends in use before the DHPC, based on trend analyses(11) to identify 
changes in the number of new users in the 12 months before the publication of the DHPC. 
(3) The degree of therapeutic innovation was determined by using the score of 
                                                            
1
 The MedDRA terminology is the international medical terminology developed under the auspices of the 
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use. MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers 
and Associations. 







therapeutic innovation as reported by Motola et al. for drugs that were centrally approved 
in Europe.(17) Using this score, drugs can be classified as important, moderate, modest, or 
as solely pharmacological/technological innovations, taking into account the seriousness 
of the disease, the availability of alternative drugs and whether drug effects have been 
shown on relevant clinical endpoints and observed effect size. For the drugs that were 
approved via the decentralized system, that is at the national level, two investigators (PM 
and PdG) independently evaluated the degree of therapeutic innovation using the ‘Motola 
algorithm’. In case of disagreement consensus was reached by discussion. (4) Specialist 
drugs, i.e. the drug required an initial prescription from a medical specialist as indicated in 
the Summary of Product Characteristics (SmPC).  
The following three DHPC related characteristics were included: (1) First or repeated 
DHPC, a dichotomous variable indicating whether the DHPC was the first safety-related 
regulatory action or whether another DHPC had been sent previously. This included 
identical as well as different safety issues. (2) DHPC template, a dichotomous variable 
indicating whether the DHPC was issued after a DHPC template was published in Volume 
9A of ‘The rules governing medicinal products in the European Union’ in January 2007. (3) 
The type of serious safety issue, which was classified according to the World Health 
Organisation listing of serious adverse events or reactions, as resulting into: death, 
(prolongation of) hospitalization, and persistent or significant disability/incapacity.(18) We 
added a category ‘other’ for cases that could not be classified into any of the 
aforementioned categories, e.g. product contamination. Two pharmacovigilance experts 
(medical doctors) independently categorized the adverse drug reactions. Any 
disagreement was resolved by a third expert (PM).  
Statistical Analyses 
We performed a multiple linear regression analysis to examine the impact of drug and 
DHPC characteristics on the observed relative change in new drug use following a DHPC. 
As the assumption of homoscedasticity, one of the key assumptions in linear regression,(19) 
was not fulfilled, a weighted least squares procedure was applied. The size of the weight 
was inversely related to the uncertainty of the information contained in the associated 
data point. The point estimates of relative changes in new drug use weighed less when the 
observed absolute changes in effect sizes were found to have higher standard errors in the 
ARIMA model. The independent variables were entered block wise, with the variables 
describing the drug characteristics entering in the first block. The second block included 
the DHPC characteristics. The degree of therapeutic innovation was treated as a 
continuous, independent variable in the analysis. The explained variance of the model was 







the contribution of each block to the variance explained was computed (∆ R²). Raw 
coefficients (B) with 95% confidence intervals (CIs), standardized beta coefficients (β), and 
P values were calculated. Statistical analyses were performed with SPSS 18 (SPSS Inc., 
Chicago, Illinois). 
Results 
We identified 59 DHPCs for 46 drugs that fulfilled all in- and exclusion criteria. Two DHPCs 
that were issued within two consecutive months for nelfinavir were analysed as one. This 
resulted in 58 evaluable drug & DHPC pairs for which the relative changes in new drug use 
following the DHPC were calculated (Table 1). The median number of new drug users per 
month in the year before the DHPC ranged from 7 (sirolimus) to 53,596 (salbutamol) 
(Appendix table). 
The mean relative change in new drug use among all DHPCs analysed was -9% (SD: 
±2.4%) and ranged from -67.4% for strontium ranelate to +71.7% for sirolimus (Appendix 
table). The median time from approval to DHPC was 82.5 months (6.9 years, IQR: 3.4 – 
13.6) and 80% of the DHPCs were issued for drugs that had been licensed for more than 
three years. Almost a quarter of the drugs showed a decrease in new drug use prior to the 
DHPC. Similar numbers of DHPCs were issued for all drugs independent of their degree of 
innovation (important, moderate and solely pharmacological/technological) with a few 
drugs classified as modestly innovative. More than half (59%) of the DHPCs were sent for 
specialist drugs. The majority (71%) of the 58 DHPCs concerned a first DHPC. DHPCs were 
evenly divided over the seriousness categories.  
When the first block with the drug characteristics was entered in the model to test if these 
characteristics explained any differences in the impact of the DHPC on drug use, we found 
that DHPCs sent for specialist drugs were associated with a more positive change in use 
than the change in use of non-specialist drugs (Table 2; Model 1, p=0.046). Within the 
group of drugs for which the DHPC leads to a decrease in use, the positive β value 
indicated that the negative usage effect was (partially) offset for specialist drugs. 
Conversely, for the cases where a DHPC increased drug use, the increase was stronger for 
specialist drugs than for non-specialist drugs.  This effect remained significant after 
entering the DHPC characteristics in the model (Table 2; Model 2, p=0.008). In the second 
model, we also found that DHPCs for drugs with a decreasing pre-DHPC trend were 
associated with a change towards lower drug use; this effect was marginally significant 
(Table 2; Model 2, p=0.055). DHPCs issued after a template was made available 
contributed to a change towards lower drug use (Table 2; Model 2, p<0.05). Both safety 
issues with a risk of death and disability were significantly associated with changes issues 
with a risk of death and disability were significantly associated with changes towards   







Table 1. Descriptive statistics for outcome and independent variables  
Variable Drug & DHPC paira  
Sample 58 
Outcome measure (Relative change in new drug use)  
Mean (SD) -0.09 (0.24) 
Range -0.674 to 0.717 
Independent variables  
Drug characteristics:  
  Time to DHPC since registration  
      Median, year (IQR)  6.9 (3.4 - 13.6) 
      ≤ 3, year (%) 12 (20.7) 
      >3-10, year (%) 23 (39.7) 
      >10, year (%) 23 (39.7) 
  Trends in use (before DHPC was issued), No. (%)  
     increasing use 16 (27.6) 
     no change in use  29 (50,0) 
     decreasing use 13 (22.4) 
  Degree of therapeutic innovation, No. (%)   
     important  23 (39.7) 
     moderate 12 (20.7) 
     modest 4 (6.9) 
     mere pharmacological/ technological 19 (32.8) 
  Specialist drug, No. (%)  
     no 24 (41.4) 
     yes 34 (58.6) 
DHPC characteristics:  
  First/repeated DHPC, No. (%)  
     first  41 (70.7) 
     repeated  17 (29.3) 
  DHPC template, No. (%)  
     no 47 (81.0) 
     yes 11 (19.0) 
  Type of serious safety issue, No. (%)  
     death  10 (17.2) 
     (prolonged) hospital admission 17 (29.3) 
     (temporary/persistent) disability or incapacity/teratogenicity 18 (31.0) 
     other 13 (22.4) 
a Unless otherwise indicated, data are reported as numbers (percentages) of drug & DHPC pairs. Percentages 
might not add up to 100% due to rounding. 
SD= standard deviation, IQR=interquartile range, y=years 
 
lower drug use (Table 2; Model 2, p<0.05 for both), whereas no significant impact was 
observed for safety issues regarding the risk of hospitalization (Table 2; Model 2, p=0.867).  
The block of DHPC characteristics contributed significantly to the model, explaining 
an additional 32% of variance (F-change=5.906, ∆R²=0.315, p≤0.001). The drug and DHPC  
 
  
Table 2. Results of the weighted regression analysisa 
 Blocks entered in the analysis Model 1 (block 1 entered) Model 2 (both blocks entered) 
   B [95% CI] β P value B [95% CI] β P value 
 (constant)  -0.214 [-0.386; -0.042]  0.016 -0.043 [-0.212; 0.126]  0.608 
 








g Time to DHPC (months) 3.05*10
-4
 [-0.000; 0.001] 0.149 0.257 1.67*10
-4
 [-0.000; 0.001] 0.082 0.478 
Trend in use (before DHPC)        
  increasing ref ref  ref ref  
  no change 0.036 [-0.097; 0.169] 0.084 0.593 0.011 [-0.106; 0.128] 0.025 0.854 
  decreasing -0.080 [-0.242; 0.082] -0.160 0.324 -0.135 [-0.273; -0.003] -0.270 0.055 
Degree of therapeutic innovation 
b
 -0.002 [-0.057; 0.052] -0.013 0.934 0.004 [-0.044; 0.053] 0.025 0.860 
Specialist drug       
  No  ref ref  ref ref  










 First/repeated DHPC       
  First     ref ref  
  Repeated     -0.092 [-0.213; 0.029] -0.187 0.133 
DHPC template       
  No    ref ref  
  Yes    -0.157 [-0.266; -0.049] -0.308 0.005 
Type of serious safety issue       
  Death    -0.265 [-0.415; -0.114] -0.450 0.001 
  Hospital admission    -0.012 [-0.152; 0.129] -0.025 0.867 
  Disability/Incapacity/Teratogenicity    -0.155 [-0.288; -0.023] -0.348 0.023 
  Other    ref ref  
 R² (adjusted R²)  0.184 (0.106)   0.499 (0.392)  
 ∆R²     0.315  
 F change      5.906 0.000 
a A negative regression coefficient is associated with a lower use post DHPC (i.e., a larger decrease or a smaller increase as a result of the DHPC). b Treated as 











characteristics together explained 39% (adj. R²=0.392) of the overall variation in change of 
new drug use. 
Discussion 
This study gives a first impression of the determinants that increase the impact of DHPCs 
on drug use. We found that declining drug use prior to the DHPC, specialist drugs, the type 
of serious safety issue, and DHPCs that were issued after the DHPC template was made 
available were associated with changes in drug use. We discuss the comments from the 
viewpoint of the most common situation that a DHPC leads to a decrease in the number of 
new users.  
The marginally significant effect found for already declining use pre DHPC confirms 
our earlier assumption that DHPCs have an accelerating effect on the decline in use of 
drugs that are at the end of their lifecycle, when several substitute drugs have become 
available.(11)   
As hypothesized earlier,(11) we observed that DHPCs issued for drugs that require a 
specialist to initiate prescribing have less impact compared to those sent for drugs that 
can also be prescribed by a GP. Drugs are given this requirement in the SmPC, because of 
the expected complexity in prescribing them. The specialist drugs in our sample were 
mainly prescribed for the human immunodeficiency virus (HIV), epilepsy and cancer. 
Specialists often have additional resources at their disposal to monitor their patients, 
which facilitates continued use of a drug post DHPC.(20) Also, specialists might tend to use  
more risky treatment options in view of the patient population they treat (e.g. more 
complex patients, patients that previously failed on other therapies). Another explanation 
could be that the perception of their own expertise limits their willingness to accept 
recommendations from others, as was observed during implementation of treatment 
guidelines.(21)  Towards the end of our study period the European guidelines were 
amended to include a fixed DHPC template.(8) When we analysed the content of the 
DHPCs in our sample, we observed an increase in uniformity of the structure and layout of 
the DHPCs. The results of our analysis confirm that DHPCs that were issued after the DHPC 
template was made available had more impact compared to DHPCs issued before the 
availability of the template, suggesting that the DHPC template has contributed to the 
understandability and uptake of the safety information, which would be in line with earlier 
findings that explicit wording contributes to improved uptake of DHPC 
recommendations.(22) The increased impact of more recent DHPCs also reflects a generally 
increased risk awareness due to intensified media accessibility and rapid information 







rosiglitazone) and more proactive pharmacovigilance in the last decade may have further 
contributed to the awareness of prescribers regarding drug safety warnings.(24)  
Communicating on serious safety issues potentially causing death or disability led to 
significantly lower drug use. Even though all DHPCs are issued for serious safety issues, it 
is to be expected that these particularly serious safety issues will affect the prescribing 
behaviour of physicians more.(11)  
The impact of DHPCs is not influenced by the age of the drug, indicating that DHPCs 
affect the use of older and younger drugs in the same way. This is consistent with our 
earlier finding that important safety issues requiring DHPCs are identified throughout the 
entire lifecycle of drugs,(2) which would indicate that the age of the drug does not need to 
be considered when tailoring the communicating drug safety issues.  
More innovative drugs did not show greater impact of a DHPC on drug use than less 
innovative drugs. Therapeutically innovative drugs can provide physicians with treatment 
options for complex patients who do not respond well to less innovative drugs. Physicians 
could be of the opinion that the innovativeness of the drug outweighs the risk of 
occurrence of the safety issue. However, our level of analysis does not allow us to 
elaborate how this translates to behaviour of individual physicians. This aspect could be 
explored in a focus group setting or by conducting individual interviews with prescribers.  
Our results show that a repeated safety warning is not necessarily more effective in 
changing drug use than a single DHPC. This is consistent with findings of several prior 
studies that reported no changes in the assessed outcome after repeated safety warnings 
were issued.(25-28) The repeated DHPCs in our sample concerned both identical as well as 
different safety issues. Possibly, repeated DHPCs that were issued for the same safety 
issue are more effective than repeated DHPCs that were issued for different safety issues 
with the same drug. However, due to the limited sample size, we were not able to 
incorporate this aspect into our model.  
Strengths and limitations 
To our knowledge, this study is the first to systematically evaluate determinants of the 
impact of DHPCs on new drug use. We included a large number of DHPCs in our analyses, 
covering a wide variety of drugs and safety issues. With the results of this study it will be 
possible to anticipate and possibly enhance the impact of future DHPCs on drug use, by 
tailoring risk communication about safety issues of drugs more specifically. On a case by 
case basis it can be decided to add other communication channels in addition to the DHPC 
to obtain the desired outcome: minimisation of the risk. Communication tools additional 
to the DHPC should be considered for specialist drugs, in case of safety issues leading to 
hospitalization, and for drugs of which the use is on the rise or at a stable plateau before 







the DHPC is issued. For example, an additional  e-mail could prove to be a useful and easy 
tool to rapidly inform healthcare professionals of safety issues. Professional associations 
and specialist learned societies should be involved in drafting DHPCs for specialist drugs, 
for a more motivating outreach to reduce prescribing if that is the desired outcome. 
Repetition of the message for example by professional associations to their members, 
either by e-mail or in their news bulletins could also improve the impact of the 
communication. While in case of the most severe safety issues that can lead to disability 
and/or death of the patient, one clear and strong DHPC might be sufficient. To make the 
DHPC stand out more to healthcare professionals, they should all be sent with an extra 
symbol such as a picture of an orange hand printed on the envelope, as is currently done 
in the Netherlands in cases that require immediate action from the healthcare 
professional. A different colour, .e.g. yellow could be used to distinguish DHPCs to merely 
alert healthcare professionals of a drug safety issue from cases where immediate action is 
required.  
We included a set of seven factors in our full model, however, the range of 
determinants is limited due to the sample size and its corresponding power. Our full 
model explained 39% of the overall variation in DHPC effect size and can be considered as 
a first exploration of determinants that influence the impact of DHPCs. Other factors, 
which we did not include in our model might also attribute to variations in the impact of 
DHPCs, for example media attention, the incidence of safety issues, safety issues related 
to off-label use, and availability of an alternative treatment. It is suggested that media 
attention can play an important role in the impact of DHPCs.(29) To probe this, we 
performed an explorative lay- and professional literature search for a selection of the 
DHPCs in our study population. This search resulted in too little information to include 
presence of media attention in our model. Likewise, the incidence of the safety issue could 
not be included, since this aspect was not mentioned in the majority of the DHPCs. Too 
few DHPCs concerned safety issues related to off label use, which led to insufficient 
variation within the variable for incorporation into our model. Alternative treatment was 
available for almost all drugs and was indirectly covered in the innovation variable. We did 
not find associations for older versus newer drugs and degree of innovation with DHPC 
impact. Therefore, it seems unlikely that availability of an alternative treatment is a major 
determinant. The limited sample size could be addressed by repeating this study in a few 
years, when more DHPCs will be issued.  
In addition, our study was limited to the Dutch setting, and extrapolation of these findings 
to hospital drugs is not possible. An EU wide study would allow for a comparison of the 







This will provide much needed information regarding locally tailored risk communicating 
strategies. 
It should be noted that a decrease in use is not always the desired impact of a DHPC. 
The results of this study can thus only be used to anticipate the impact of DHPCs on new 
drug use, not for other outcomes that might be more attuned to the recommendation in 
the DHPC, such as necessity for liver function tests performed in case of risk of 
hepatotoxicity. This means that any additional action should be carefully considered. 
Nevertheless, we think that new drug use is the most appropriate outcome measure to 
explore the role of determinants of impact of DHPCs, since it is the single outcome 
measure that can reliably be assessed for such a large group of drugs. Also, new use is a 
more sensitive measure than overall use, since changes in prescribing behaviour can more 
likely be expected in new users. Further research could be aimed at clusters of drugs with 
the same recommendation in the DHPC, e.g. all drugs which require laboratory testing, or 
all drugs with restrictions regarding concomitant use of contraindicated drugs. This may 
provide insight into how the impact of DHPCs on more specific outcomes can best be 
anticipated. 
Conclusion and recommendation 
This study provides a first exploration of determinants that influence the impact of DHPCs 
on drug use. The results show that declining use prior to the DHPC, specialist drugs, DHPCs 
issued after availability of a template, and the type of serious safety issue are associated 
with changes in new drug use. These results can be used as a first step in tailoring risk 
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Appendix table 1. Characteristics of DHPCs with and without long term impact on drug use. 
DHPCs with significant long-term changes in use 
Drug Characteristics DHPC Characteristics Drug use  DHPC impact  



























Jul-88 S 4 Sep-
02 
repeat Electrocardiogram QT prolonged 
(Investigations) 





Jul-00 GP 1 Jan-
06 





Jul-00 GP 1 Mar-
07 





Oct-00 GP 1 Apr-
07 

























Oct-90 GP 3 May-
01 










first Circumstance or information 
capable of leading to medication 
error (Injury) 





Aug-00 S 4 Mar-
05 





Sep-99 S 1 Mar-
01 





Jun-87 GP 1 Aug-
07 
first Gastrointestinal disorder 
(Gastrointestinal) 








Appendix table 1. Continued 
DHPCs with significant long-term changes in use 
Drug Characteristics DHPC Characteristics Drug use  DHPC impact  



































Jul-02 GP 1 Feb-
05 
first Cardiovascular disorder (Cardiac) H 12375.5 0 -1898.57 
(666.33) 
-0.153 






first Drug rash with eosinophilia and 
systemic symptoms: DRESS 
(Blood) 


















repeat Maternal drugs affecting foetus 
(Injury) 





Jul-91 S 3 Apr-
05 


















repeat Maternal drugs affecting foetus 
(Injury) 











D 4399.5 0 -1785.26 
(440.44) 
-0.406 
DHPCs without significant long-term changes in use 
cisapride2  
(A03FA02) 
Jul-88 S 4 Sep-
04 
repeat Electrocardiogram QT prolonged 
(Investigations) 
























Appendix table 1. Continued 
DHPCs without significant long-term changes in use 
Drug Characteristics DHPC Characteristics Drug use  DHPC impact 































first Aplasia pure red cell (Blood) H 417 ↑ 32.42 
(55.88) 
0.078 




S 4 Jul-02 repeat Aplasia pure red cell (Blood) H 495.5 ↑ 99.64 
(55.66) 
0.201 






















Jul-90 GP 3 May-
03 
























Jul-76 GP 4 Dec-
03 


















first Circumstance or information 
capable of leading to medication 
error (Injury) 










first Eye disorder (Eye) O 11643.5 0 -1055.56 
(863.04) 
-0.091 





07 &  
Jul-
07*  
first Therapeutic product 
contamination (Injury) 








Appendix table 1. Continued 
DHPCs without significant long-term changes in use 
Drug Characteristics DHPC Characteristics Drug use  DHPC impact 































repeat Incorrect dose administered 
(Injury) 




















































repeat Skin reaction (Skin) F 86.5 0 3.03 
(7.30) 
0.035 






first Urinary bladder adenoma (Renal) O 37.5 ↑ 7.06 
(7.02) 
0.188 
























first Maternal drugs affecting foetus 
(Injury) 










first Maternal drugs affecting foetus 
(Injury) 









first Bronchial anastomosis 
complication (Respiratory) 
















Appendix table 1. Continued 
DHPCs without significant long-term changes in use 
Drug Characteristics DHPC Characteristics Drug use  DHPC impact 






























GP 1 Feb-05 repea
t 
Cardiovascular disorder (Cardiac) H 11851.5 0 441.44 
(798.52) 
0.037 


















S 3 Oct-01 first Oculomucocutaneous syndrome 
(Eye) 







S 3 Nov-07 first Incorrect dose administered 
(Injury) 







GP 2 Jan-06 first Maternal drugs affecting foetus 
(Injury) 





















GP 4 May-07 first Myocardial ischaemia (Cardiac) H 53595.5 0 -6126.38 
(3744.96) 
-0.114 
* The two DHPCs issued for nelfinavir were issued close in time and were therefore treated as a single intervention and analysed together. The first DHPC was taken as the time  
point of intervention.  
Legend: DHPC: Direct Healthcare Professional Communication; INN: International Proprietary Name: drugs with more than one DHPC in our study period are indicated by their 
superscript numbers; ATC: Anatomical Therapeutic Chemical; Appr. Date: Approval date; Initial prescriber: S = medical specialist, GP = general practitioner; Innovativeness: 4 = 
important, 3 = moderate, 2 = modest, 1 = mere pharmacological/technological; SOC: System Organ Class; Type of serious safety issue = F = Death (fatal), H = Hospitalization, D = 
Disability/Incapacity, O = other; Rx: Medical prescription. Median Rx before = median number of Rx in the 12 months pre DHPC; Trend = Trend in use pre DHPC: ↑ = increasing, 0 = 
unchanged, ↓ = decreasing; Absolute change in new drug use = Change in absolute number of new drug use as determined through interrupted time series analyses; SE: standard  















Towards optimisation of the impact of safety-related 
regulatory action:  
















Healthcare professionals’ self-reported experiences and 
preferences  
related to Direct Healthcare Professional Communications.  







Flora M. Haaijer-Ruskamp1 
Pieter A. de Graeff1,2 
Sabine M.J.M. Straus2,3 












Drug Safety 2012 35:11 (1061-1072) 
 
 
1 Department of Clinical Pharmacology, University of Groningen, University Medical Center, 
Groningen, the Netherlands 
2 Dutch Medicines Evaluation Board, The Hague, the Netherlands 








Background: In Europe, Direct Healthcare Professional Communications (DHPCs) are 
important tools to inform healthcare professionals of serious, new drug safety issues. 
However, this tool has not always been successful in effectively communicating the 
desired actions to healthcare professionals.  
Objective: The aim of this study was to explore healthcare professionals’ experiences and 
their preferences for improvement of risk communication, comparing views of general 
practitioners (GPs), internists, community pharmacists and hospital pharmacists.  
Methods: A questionnaire was developed and pilot tested to assess experiences and 
preferences of Dutch healthcare professionals with DHPCs. The questionnaire and two 
reminders were sent to a random sample of 3488 GPs, internists and community and 
hospital pharmacists in the Netherlands. Descriptive statistics were used to describe 
demographic characteristics of the respondents. Chi squares, ANOVAs and the Wilcoxon 
signed rank test were used, when appropriate, to compare healthcare professional 
groups.  
Results: The overall response rate was 34% (N=1141, ranging from 24% for internists to 
46% for community pharmacists). Healthcare professionals trusted safety information 
more when provided by the Dutch Medicines Evaluation Board (MEB) than by the 
pharmaceutical industry. This was more the case for GPs than for the other healthcare 
professionals. Respondents preferred safety information to be issued by the MEB, the 
Dutch Pharmacovigilance Center or their own professional associations. The preferred 
alternative channels of drug safety information were e-mail, medical journals and 
electronic prescribing systems. 
Conclusions: Safety information of drugs does not always reach healthcare professionals 
through DHPCs. To improve current risk communication of drug safety issues, alternative 
and/or additional methods of risk communication should be developed using electronic 
methods and medical journals. Moreover, (additional) risk communication coming from an 
independent source such as the MEB should be considered. Special effort is needed to 
reach GPs.  








At the time of market entry, the safety profile of a drug is incomplete due to inherent and 
known shortcomings of pre-marketing clinical trials.(1) Recent studies have shown that 10–
14% of medicinal products require a Direct Healthcare Professional Communication (DHPC 
in the EU; Dear Healthcare Professional letter in the US) or ‘Dear Doctor’ letter (hereafter 
referred to as a DHPC) to inform healthcare professionals of newly identified risks within 
the first 3 years of market approval.(2,3)  
Effective risk communication is essential to prevent or minimize harm. Evaluation of 
communication about cisapride and selective serotonin re-uptake inhibitors (SSRI) has 
shown that it is not always possible to achieve desired actions by healthcare professionals 
through risk communication. After safety warnings were issued announcing that the use 
of certain medications in combination with cisapride could cause severe cardiovascular 
problems, prescribing of cisapride with contraindicated medication continued, leading to 
its market withdrawal.(4,5) Although the SSRI warnings were only aimed at reducing new 
prescriptions in adolescents, unintended decreases in SSRI prescribing in adults were also 
observed.(6-8)  
Currently, the paper-based DHPC is a major tool in risk communication of drug safety 
issues. In the EU, DHPCs are sent to pre-specified target groups of healthcare professionals 
by the pharmaceutical industry as commissioned by the European Medicines Agency and 
national authorities.(9)  
Since effectiveness of risk communication depends largely on trust in the source of 
the information,(10) it is important to evaluate how different sources are perceived by 
healthcare professionals. In addition, evaluation of the effectiveness of risk minimization 
measures will become mandatory in the EU with the new pharmacovigilance legislation 
that came into force in July 2012.(11,12)  
To optimize current risk communication methods and to improve implementation of 
any necessary actions into clinical practice, it is important to have good insight into the 
preferences of healthcare professionals. A tailor-made approach that incorporates 
preferences of different healthcare professional groups may facilitate the uptake of the 
risk information as well as implementation of the desired actions.(13) To date, little 
information is available on preferences of different healthcare professional groups. The 
aim of this study was to explore healthcare professionals’ experiences and their 
preferences for risk communication of safety issues of medicines, comparing the views of 








Questionnaire Development  
An explorative literature search did not result in any validated questionnaires that could 
be used in our study. Hence, a questionnaire with open ended and closed questions was 
developed using the ‘knowledge, attitudes, behaviour’ framework introduced by Cabana 
et al.(14)  
The attitude of healthcare professionals towards risk information was assessed with 
a number of statements (Table I). All attitude-related statements were rated on a 5-point 
Likert scale ranging from (1) strongly disagree to (5) strongly agree.  
 
Table 1. Questionnaire overviewa  
Section/Question Answer categories 
Attitude 
1. I think information about drug safety is important. 1: Strongly disagree – 5: strongly agree. 
2. It takes too much time to remain up to date on new 
drug safety issues. 
1: Strongly disagree – 5: strongly agree. 
3. I think the MEB is knowledgeable about drugs. 1: Strongly disagree – 5: strongly agree. 
4. I think information from the MEB is trustworthy. 1: Strongly disagree – 5: strongly agree. 
5. I think the pharmaceutical industry is knowledgeable 
about drugs. 
1: Strongly disagree – 5: strongly agree. 
6. I think information from the pharmaceutical industry is 
trustworthy. 
1: Strongly disagree – 5: strongly agree. 
Knowledge  
7. Have you ever seen a DHPC? Yes. 
No, I have heard of DHPCs, but I have never 
seen one. 
No, I have never heard of DHPCs. 
8. Do you read the DHPCs you receive? No, I do not read any letters from the 
pharmaceutical industry, either in an orange 
hand envelope
b
 or not.   
Yes, if they contain safety information that is 
important to me. 
Yes, only if they are sent in an orange hand 
envelope. 
Yes, only when the envelope indicates it 
contains important, non-commercial 
information. 
Yes, I read all letters from the pharmaceutical 
industry. 
9. Do you visit the MEB website for specific information on 
drug safety issues? 
Never, I never heard of the MEB. 
Never, I did not know the MEB had a website. 
Never, I did know the MEB has a website. 












Table 1. Continued  
Section/Question Answer categories 
10. Are you aware of the safety issues of the following 
drugs for which information was sent in 2007/ 2008? 
(rimonabant; moxifloxacine; clopidogrel; etoricoxib) 
Yes. 
No 
11. If yes; how did you receive this information? (DHPC; 
Website MEB; Media; Specialist journal; electronic 
mailing/internet; other, namely.) 
Yes. 
No - Several answers possible.  
Behavior 
12. Can you estimate in which percentage of the received 
DHPCs you undertook action (e.g. adjusting therapy, 
inform colleagues, discuss with patient)? 
Visual analogue scale ranging from 0% to 100%. 
Preferences for alternative methods 
13. What do you think of the current method (DHPC) with 
which you are informed of new drug safety issues? 
1: Very poor – 10: very good. 
14. How useful do you consider repetition is of the safety 
information (e.g. repetition of the letter or e-mail)?  
1: not at all useful – 10: very useful. 
15. How useful do you consider receiving safety 
information is through several methods at the same 
time (e.g. both postal and by e-mail)?  
1: not at all useful – 10: very useful. 
16. Which of the following information channels do you 
think are suitable for fast information about new drug 
safety issues? (e-mail; text message; twitter; electronic 
newsletter; medical journals; RSS feed; computerized 
prescription system) 
1: Not all useful – 10: very useful. Separately 
rated for each channel. 
17. Which of the following senders do you think are suitable 
for fast information about new drug safety issues? 
(physician/pharmacist; professional association; Lareb; 
pharmacotherapy meetings; media; drug compendium)  
1: Not at all useful – 10: very useful. 
Separately rated for each sender. 
18 Are you willing to provide the MEB with your e-mail 
address and/or mobile phone number to receive specific 
information about drug safety issues? 
Yes, but only my e-mail address 
Yes, but only my mobile phone number 
Yes, both my e-mail address and my mobile 
phone number 
No 
a Eighteen of the 25 questions posed in the survey are represented. Seven questions are not included here as 
they did not provide directly relevant information or they produced responses that demonstrated the so-called 
‘halo effect’. b Orange hand envelope: safety issues requiring immediate action (e.g. in case of contaminated 
batches of drugs) are sent in envelopes with an orange hand printed on them, to attract extra attention of the 
healthcare professional. 
DHPC = Direct Healthcare Professional Communication; Lareb = Netherlands Pharmacovigilance Center;  
MEB = Dutch Medicines Evaluation Board; RSS = Really Simple Syndication. 
 
The healthcare professionals were then asked various knowledge-related questions, and 
were presented with four specific drugs with safety issues (rimonabant and depression, 
moxifloxacin and skin reactions and hepatoxicity, clopidogrel and interaction with proton 
pump inhibitors, etoricoxib and hypertension).(15) These four drugs were chosen because 
DHPCs regarding these issues were sent to all groups of healthcare professionals included 







The respondents were asked if they were aware of these safety issues and, if so, what 
their source of information was (DHPC, Dutch Medicines Evaluation Board [MEB] website, 
lay media, medical journal, electronic mailing/internet and/or other).  
With regard to the behaviour component of the questionnaire, respondents were 
asked in what percentage of DHPCs was action taken. Respondents rated this question 
using a visual analogue scale ranging from 0% to 100%.  
Preferences for improved risk communication were assessed on a 10-point Likert 
scale ranging either from (1) very poor to (10) very good or from (1) not at all useful to 
(10) very useful. The respondents’ preferences for alternative channels (e-mail, text 
message, twitter, electronic newsletters, medical journals, RSS31 feeds and computerized 
prescription system) and sources (physician/pharmacist, professional association, 
Netherlands Pharmacovigilance Centre, MEB, pharmacotherapy meetings, media, drug 
compendium) of risk communication were explored using a 10-point Likert scale ranging 
from (1) not at all useful to (10) very useful. The most appropriate answering scale was 
chosen for each individual question.  
The following demographic aspects were collected: specific profession, sex, period of 
registration as a healthcare professional, full-time or part-time employment.  
Face validity of the questionnaire was evaluated by five professionals (two 
physicians, two pharmacists, one regulator), after which changes were made to the layout, 
wording and predefined answers. The questionnaire was then sent to a random sample of 
50 healthcare professionals to test its feasibility. Further changes were made to improve 
the clarity of the questionnaire. The pilot test data were not included in the final data 
analysis. 
Study Population 
Healthcare professionals living in the Netherlands were surveyed. GPs and internists 
(doctors of internal medicine) were included since they prescribe a wide range of drugs 
and therefore have a high likelihood of dealing with risk communications of drug safety 
issues. Hospital and community pharmacists were included because of their central role in 
drug dispensing and information. Respondents were excluded if they were no longer 
actively working as a physician or pharmacist (n=11).  
Addresses of the healthcare professionals were obtained from the Dutch Internist 
Association (NIV) and the Dutch Pharmacist Association (KNMP). Most (~90%) of the Dutch 
internists and pharmacists are members of their professional association, partly because 
accreditation of training is arranged within these associations. The Netherlands Institute 
                                                            
1
 RSS (Really Simple Syndication) feeds make it possible to see when websites have added new information, such 
as, for example, news headlines and press releases. RSS feeds make checking separate websites unnecessary. 







for Health Services Research (NIVEL) provided a random sample of Dutch GPs. A sample 
size calculator(16) was used to determine the number of respondents that would be 
needed to obtain the appropriate sample size to result in 80% power to detect a 10% 
difference in healthcare professionals’ ratings of individual questions.  
We adjusted the sample size based on the response rates observed in the feasibility 
study, where response ranged from 20% to 80% for internists and community 
pharmacists, respectively (Table 2).  
 
Table 2. Demographic characteristics of the respondents 
Characteristic Total 







[N (%)]  
Hospital 
pharmacist 




 1,141 (34%) 233 (33%) 410 (24%) 323 (46%) 175 (45%) 
Initial mailing 686 (60%) 112 (48%) 269 (66%) 184 (57%) 121 (69%) 
Reminder 1 358 (31%) 67 (27%) 137 (33%) 101 (31%) 53 (30%) 
Reminder 2 97 (9%) 54 (23%) 4 (1%) 38 (12%) 1 (1%) 
Pilot (N=50) 22 (44%) 6 (40%) 3 (20%) 8 (80%) 5 (50%) 
Healthcare professional characteristics 
Female (4 missing) 465 (40%) 97 (42%) 141 (34%) 146 (45%) 81 (47%) 
Years of professional accreditation (2 missing) 
     Trainee 7 (1%) 1 (0%) 0 (0%) 5 (2%) 1 (1%) 
     1-5  207 (18%) 24 (10%) 87 (21%) 58 (18%) 38 (22%) 
     6-10  240 (21%) 47 (20%) 76 (19%) 68 (21%) 49 (28%) 
     11-15  173 (15%) 37 (16%) 49 (12%) 61 (19%) 26 (15%) 
     ≥16  512 (45%) 124 (53%) 197 (48%) 130 (40%) 61 (35%) 
Working part time (3 missing) 258 (22%) 78 (34%) 57 (14%) 72 (22%) 51 (29%) 
a Differences in percentages may exist due to rounding. 
GP= General Practitioner. 
 
This resulted in sending questionnaires to 3488 healthcare professionals (700 randomly 
selected GPs, 700 randomly selected community pharmacists, all 1696 Dutch internists 
and all 392 hospital pharmacists) in the Netherlands in December 2009.  
The anonymous questionnaire was sent with a cover letter and a prepaid return 
envelope. To maximize the response, a total of two reminders accompanied by the 







Data Entry and Analysis 
Data were entered by three data entry assistants using structured data entry forms. Data 
entry was checked by examining duplicate entries of 10% of all returned questionnaires 
for errors. The duplicate data entry resulted in less than 0.1% error in the entered 
variables. The majority of the data entry errors (83%) were related to questions 10  
and 11 (Table 1). All entries of these two questions were therefore compared with the 
original returned questionnaires and corrected when appropriate.  
Assuming that the respondents who returned the questionnaire only after a 
reminder were most comparable to non-responders, sensitivity analyses were performed 
to explore possible differences between initial and late responders, on the main questions 
of trust, knowledge and preferences. Descriptive statistics were used to describe 
demographic characteristics of the respondents. Chi squares, ANOVAs and the Wilcoxon 
signed rank test were used when appropriate to compare healthcare professional groups. 
Data were analysed using SPSS 16.0 software (SPSS, Inc., Chicago, Illinois, USA). 
Results 
The questionnaire and reminders were sent to 3488 healthcare professionals in the 
Netherlands in December 2009 and January 2010, resulting in an overall response rate of 
34% (N=1141; ranging from 24% for internists to 46% for community pharmacists; Table 
2). Most healthcare professionals who returned our questionnaire were male (60%), 
working full-time (78%) and registered as a healthcare professional for 15 years or fewer 
(55%). 
Attitude 
The majority (mean ± SD) of the healthcare professionals considered risk information of 
medicinal products to be important (4.67 ± 0.6), ranging from an average of 4.55 ± 0.5 
reported by the GPs to 4.77 ± 0.5 by the hospital pharmacists (p≤0.0001). Most healthcare 
professionals did not have an opinion, or had a neutral attitude about the statement ‘It 
takes too much time to remain up to date on new drug safety issues’ (2.56 ± 0.9). The GPs 
more often reported that remaining up to date took too much time (2.80 ± 1.0), while the 
community pharmacists indicated this the least often (2.39 ± 0.9; p≤0.001).  
The healthcare professionals considered both the MEB and the pharmaceutical 
industry knowledgeable about drugs (4.06 ± 0.7 and 3.91 ± 0.7, respectively), but trusted 
the risk information provided by the MEB more (4.13 ± 0.6 and 2.70 ± 0.8, respectively; 
p≤0.001; Figure 1). In particular, the GPs thought that information provided by the MEB 
was significantly more trustworthy than information provided by the pharmaceutical 
industry (p≤0.001). 








Figure 1. Trust and knowledge attributed to the Dutch MEB/ pharmaceutical industry 
GP= General Practitioner; MEB= Medicines Evaluation Board. 
Knowledge 
Sixteen percent of the healthcare professionals (ranging from 5% of the hospital 
pharmacists to 28% of the GPs; p≤0.001) were not familiar with DHPCs. The majority (58%) 
of the healthcare professionals indicated that they read only the DHPCs that contained 
information that was relevant to them, and 30% of the community pharmacists read all 
letters they received from the pharmaceutical industry (p≤0.001).  
Four specific drugs with safety issues were presented to the healthcare professionals 
(rimonabant, moxifloxacin, clopidogrel and etoricoxib). Most healthcare professionals 
indicated that they were aware of all four safety issues, ranging from 56% for the 
etoricoxib issue to 88% for the clopidogrel issue (Figure 2). The pharmacists were better 
informed than the physicians (p≤0.001) for all safety issues except etoricoxib. In the 
etoricoxib case, primary care healthcare professionals (GPs and community pharmacists) 
were more aware of the safety issue (67% and 71%, respectively) than the secondary care 
healthcare professionals (internists and hospital pharmacists; 40% and 51%, respectively; 
p≤0.001). Knowledge of the four safety issues was mostly obtained from professional 
journals (59%) and DHPCs (49%), while the MEB website was rarely indicated (5%) as the 
information source.  
Sixty-four per cent of the respondents indicated that they never visited the MEB 








Figure 2. Healthcare professionals’ knowledge of safety issues of four drugs. 
CP = Community pharmacist; GP= general practitioner; HP= hospital pharmacist; INT= internist; PPI= proton 
pomp inhibitor. 
 
healthcare professionals were not aware of the existence of the MEB. Only 6% of the 
respondents visited the website weekly and only 1% did so daily. Hospital and community  
pharmacists were more aware of the MEB and visited the MEB website more often than 
internists and GPs (p≤0.001), although 38% of the pharmacists visited the website only 
monthly or 6 monthly. 
Behaviour 
The healthcare professionals reported to have taken action (e.g. adjusting therapy, 
informing colleagues, discussion with patient) in response to 29% of the DHPCs, ranging 
from 23% of internists to 37% of community pharmacists (p≤0.001).  
Preferences for Improved Risk Communication 
Satisfaction with the current way of risk communication was rated as mean 6.9 (SD ±1.9) 
out of 10, ranging from 6.0 ± 2.1 on average by GPs to 7.6 ± 1.4 by community pharmacists 
(p≤0.001). Repetition of the risk communication as well as information coming from 
several sources simultaneously was rated as moderately useful (5.8 ± 2.4; and 6.3 ± 2.4, 
respectively). The open- ended question regarding which specific combination was 
preferred yielded responses from 494 healthcare professionals (multiple answers were 







given). Predominantly, a combination of the paper-based DHPC with an e-mail was 
suggested (n=184). Receiving risk information via e-mail only was indicated 91 times and 
via the paper-based DHPC only was indicated 41 times. The preferred alternative channels 
of risk information were e-mail, medical journals and electronic prescribing systems. The 
preferences for these three channels varied across the four healthcare professional groups 
(Table 3).  
RSS feeds, text messages and twitter were not favoured methods. According to the 
healthcare professionals, risk communication should preferably be issued by the MEB, the 
 
Table 3. Preferred alternative drug safety information channels and sources [mean (SD)]a 







Channel       
E-mail 7.16 (2.5) 7.24 (2.5) 8.07 (1.8) 8.09 (2.0) 7.59 (2.3) p≤0.001
b 
Text message 232 (1.9) 2.13 (1.7) 3.05 (2.4) 2.41 (2.3) 2.47 (2.1) p≤0.001
b
 
Twitter 1.72 (1.2) 1.65 (1.2) 2.13 (1.8) 1.68 (1.4) 1.81 (1.4) p≤0.001
 b
 
Electronic newsletter 5.66 (2.9) 5.99 (2.8) 6.53 (2.4) 6.37 (2.8) 6.14 (2.7) p≤0.001
 b
 
Medical journals 7.32 (2.2) 7.85 (1.7) 7.32 (2.0) 7.15 (2.2) 7.49 (2.0) p≤0.001
 b
 
RSS feeds 3.44 (2.4) 3.74 (2.7) 4.05 (2.7) 5.06 (3.0) 3.98 (2.8) p≤0.001 
Computerised 
prescription system 
7.83 (2.2) 6.52 (3.1) 7.45 (2.4) 7.03 (2.6) 7.14 (2.7) p≤0.001
 b
 
Source       
Physician (by pharmacists) NA NA 4.76 (2.5) 3.90 (2.4) 4.46 (2.5) p≤0.001
b
 
Pharmacist (by physicians) 8.14 (1.8) 6.90 (2.4) NA NA 7.35 (2.3) p≤0.001
b
 
Professional association 7.60 (1.9) 7.98 (1.7) 8.27 (1.4) 7.93 (1.9) 7.98 (1.7) p≤0.001 
Lareb 7.82 (1.8) 7.98 (1.8) 8.37 (1.2) 8.00 (1.8) 8.06 (1.7) p≤0.001
 b
 





7.63 (2.1) 4.94 (2.3) 6.06 (2.4) 4.55 (2.3) 5.76 (2.5) p≤0.001
b
 
Media 3.90 (2.2) 3.90 (2.3) 3.78 (2.3) 3.42 (2.2) 3.79 (2.2) p=0.101 
Drug Compendium 7.41 (2.1) 7.19 (22) 6.29 (2.6) 5.40 (2.8) 6.71 (2.5) p≤0.001
b
 
a All channels and sources were rated on a 10-point Likert scale ranging from (1) not at all useful, to (10) very 
useful. b Indicates significant (p≤0.05) differences in preference between the four healthcare provider groups in 
the ANOVA analysis.  
GP= general practitioner; Lareb= Dutch Pharmacovigilance Centre; MEB= Dutch Medicines Evaluation Board; 








Dutch Pharmacovigilance Center (Lareb) or their own professional association (Table 3). 
The media were rated as the least preferable source of risk communication.  
Sensitivity analyses showed significant differences between responders to the initial 
mailing and the two subsequent reminders in only two preference variables. In those two 
cases, the late responding physicians rated safety information coming from pharmacists 
higher than did physicians responding to the initial mailing (p=0.007). The late responding 
healthcare professionals also rated the pharmacotherapy meetings higher than did early 
responding healthcare professionals (p≤0.001). 
Discussion 
Although the responding healthcare professionals considered risk information on drug 
safety issues to be important, a substantial group was not familiar with the DHPC as a tool 
for risk information. Pharmacists appeared to be more aware of, and more responsive to, 
safety issues than physicians, particularly GPs. The majority of the healthcare 
professionals preferred to receive drug safety information from an independent source 
such as the MEB or their own professional association than from DHPCs. Moreover, most 
healthcare professionals preferred to receive the information through medical journals or 
electronically, for example, by e-mail or electronic (prescribing) systems.  
Fifteen percent of the respondents had never heard of or seen a DHPC. This 
percentage is similar to the results from an earlier study performed in the US, where 18% 
of the respondents indicated they had never seen a DHPC.(18) In contrast, other studies 
reported higher percentages of respondents with knowledge of drug safety warnings.(19-21)  
Awareness of the specific safety issues and reported action in response to a DHPC 
was higher among pharmacists. In addition, they visited the MEB website more frequently 
than physicians. This might be explained by the focus of pharmacists on pharmacotherapy 
and drug risks, while for physicians this aspect might have a lower priority. This is 
supported by the finding that the physicians rated ‘keeping up to date on risk information’ 
as time consuming more often than pharmacists.  
Awareness of the four safety cases ranged from moderate for the etoricoxib issue 
(55%) to high for the clopidogrel issue (85%). Pharmacists were better informed than 
physicians, except in the etoricoxib case, where the GPs and community pharmacists were 
more aware of the safety issue than hospital pharmacists and internists. Etoricoxib is 
mainly prescribed and dispensed in primary care, which could explain this finding. Only in 
the moxifloxacin case was the DHPC indicated as the main risk information source. In the 
other three cases, the information was mainly obtained from professional journals. This is 
in line with earlier research, which found that healthcare professionals mainly use sources 
of safety information other than the DHPC.(22,23)  







The respondents reported having taken action in relation to 29% of the DHPCs they 
received. This percentage is higher than that reported by Canadian healthcare 
professionals, which ranged from 2% adjusting their prescribing to 16% forwarding the 
DHPC to other healthcare professionals.(19) In other studies, higher percentages of action 
were reported by healthcare professionals, e.g. changes in prescribing behaviour of 80% 
related to an antidepressants black-box warning,(20) and 40% related to a long-acting beta 
agonists black-box warning.(21) It should be noted that not all DHPCs require immediate 
action from all healthcare professionals.  
The preference for receiving drug safety information from an independent 
organization is in line with findings of earlier studies. Physicians in the UK and the US 
prefer independent sources (e.g. medical journals and colleagues) over commercial (e.g. 
pharmaceutical companies) and third-party sources (e.g. general media).(22,23) The 
respondents in our study, especially the GPs, indicated they would have more trust in drug 
safety information coming from the MEB than from the pharmaceutical industry. Trust in 
both the sender and the information itself plays an essential role in successful risk 
communication.(24) It is suggested that inadequate risk communication may be caused by 
insufficient trust in the institutions that are responsible for risk management.(10)  
E-mail and electronic prescribing/dispensing systems, the preferred channels of 
respondents, could prove to be good channels of risk communication because of their 
user-friendliness. Such an e-mail would preferably consist of a short summary of the drug 
safety issue and the recommendations to the healthcare professional on how to manage 
the safety issue. A link to the DHPC and to background information on the drug safety 
issue could be incorporated in the e-mail. The header of the e-mail should clearly indicate 
the safety issue and the drug in question. Presently, the MEB already offers an e-mail 
service to voluntary subscribers. In our survey, 84% of the respondents indicated they 
were willing to provide the MEB with their e-mail address to receive such an e-mail. The 
physicians, especially the GPs, rated pharmacists quite highly as an alternative source of 
safety information. Information from professional associations was also a preferred 
alternative. A more active involvement of these groups as intermediaries in the risk 
communication process could be an important additional step to strengthen this process.  
One of the aims of DHPCs is to rapidly inform healthcare professionals when a safety 
issue is identified. However, it should be noted that incorporating warnings of safety 
issues into electronic prescribing/dispensing systems requires some time, which could 
cause unnecessary harm to patients. E-mail could prove to be more useful in rapidly 
informing healthcare professionals, and incorporating warnings in electronic 
prescribing/dispensing systems may additionally be applied. The respondents indicated 







feeds and text messaging, even though communication through these methods could be 
implemented relatively easily. Since these are relatively novel methods, it may be 
worthwhile to keep track of how the use of and preference for these methods develop.  
A substantial number of respondents indicated that they would prefer to receive the 
safety information via both the paper-based DHPC and an additional e-mail. However, 
repetition of the risk information as well as receiving information simultaneously from 
several sources was rated as only moderately useful. This apparent discrepancy indicates 
that a fine balance seems to exist between a preference for receiving the information 
through various methods and an overload of information. This is important to note, since 
such an overload could easily cause ‘warning fatigue’, resulting in healthcare professionals 
not taking notice of risk communications.  
The limited awareness that healthcare professionals had of the MEB and the MEB 
website seems to be comparable to familiarity with other national authorities. In the UK 
for example, approximately 20% of the healthcare professionals indicated they were 
aware of the Medicines and Healthcare products Regulatory Agency (MHRA).(23) In Canada, 
38% of the healthcare professionals were familiar with the drug safety advisories on the 
Health Canada website, but only 9% of the healthcare professionals visited this website to 
retrieve new drug safety information.(19) A focus group study performed in Canada 
indicated that the ‘reporting authority is perceived as a virtual and remote entity’.(25) 
Although it appears that healthcare professionals see a clear role for regulating authorities 
in communicating safety issues, their visibility amongst healthcare professionals should be 
improved. 
Strengths and Limitations 
This is one of the first studies assessing healthcare professionals’ opinions of DHPCs. A 
sizable group of 1141 healthcare professionals, both pharmacists and physicians, were 
included in our survey. We used a pre-tested questionnaire, preserving the anonymity of 
the respondents to reduce the possibility of socially desirable answers.  
Limitations to this study include a fairly low response rate, with only 34% of the 
healthcare professionals responding. This is comparable to other surveys amongst 
healthcare professionals, especially amongst physicians.(20,21,26) Still, the low response may 
have biased our results in that healthcare professionals who are unaware of, or not 
interested in, DHPCs could be underrepresented in our sample. This might mean that, in 
reality, even fewer healthcare professionals are aware of DHPCs and safety issues, which 
underlines the need for improvements in current risk communication. We were unable to 
analyse any characteristics of the non-responders due to the anonymous nature of the 
questionnaire. We can only report that our sample is representative for the Dutch setting 







in terms of sex,(27) and the percentage of GPs who work part-time.(28) We found no 
significant differences between early and late responders, except for two preference 
variables. It is possible that the non-responders have different preferences with regard to 
the pharmacists and pharmacotherapy meetings than the responders. We can conclude 
that, apart from these two variables, our results are, in all likelihood, not affected by non-
response bias. Due to the anonymous nature of the questionnaire, it is possible that 
healthcare professionals might have responded to both the initial mailing as well as the 
reminders. However, in the cover letters of the reminders, we explicitly stated that these 
mailings concerned reminders, which should be ignored if the questionnaire had already 
been returned. Since the reminders were sent within a month of the previous mailing, and 
because of the specific topic, we assume that the respondents would have remembered 
filling out the earlier questionnaire. This was underlined by the fact that some 
respondents actually notified us about this. It should be noted that ‘action in response to 
DHPCs’ was a self-reported measure. Respondents may have had difficulties remembering 
the number of DHPCs they received for which they actually took action, leading to possible 
recall bias. We cannot rule out that some healthcare professionals may perceive a DHPC 
as information from the pharmaceutical industry, despite our explanation in the 
questionnaire that a DHPC is issued on request from and in collaboration with the MEB. 
This might have influenced their responses to several questions, for example questions 8 
(reading the DHPCs) and 13 (satisfaction with the current communication method). 
Conclusions 
Healthcare professionals consider staying up to date on new drug safety issues important, 
although a fair proportion were not aware of the DHPC as a risk communication tool. 
Those who were aware rated this risk communication method as reasonable, but valued 
electronic methods as alternative or additional risk communication channels. In line with 
this, healthcare professionals indicated mainly other channels as the source for their 
knowledge of some recent drug safety issues. Our study also showed that healthcare 
professionals had greater trust in the MEB than in industry as a source of drug safety 
information and that they would prefer to be informed through independent 
organizations.  
Therefore, current risk communication of medicinal products should be improved, 
preferably by using electronic methods, including e-mail and electronic prescription 
systems, and/or medical journals. Moreover, (additional) safety information should come 
from an independent source such as the MEB to optimize credibility. The results of this 
study indicate that additional efforts are needed to ensure that the safety information 
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Background: The usefulness and the impact of Direct Healthcare Professional 
Communications (DHPCs, or ‘Dear Doctor letters’) in changing the clinical behaviour of 
physicians have been debated. Changes in the current risk communication methods 
should preferably be based on the preferences of the healthcare professionals, to 
optimize the uptake of the message.  
Objective: The aim of this study was to assess whether safety issues are communicated 
more effectively with an additional e-mail sent by the Dutch Medicines Evaluation Board 
(MEB) than with the DHPC only. 
Methods: A randomized controlled trial was conducted amongst ophthalmologists and 
hospital pharmacists in the Netherlands, who were the target group of a DHPC that was 
issued for pegaptanib, a drug that is administered intra-ocularly in patients with macular 
degeneration. The intervention group (N=110) received the pegaptanib DHPC, as well as 
the MEB e-mail. The control group (N=105) received the traditional paper-based DHPC 
only. Two weeks later, the study population received an invitation to fill out an online 
questionnaire. Questions were asked about the respondents’ knowledge and attitude 
regarding the pegaptanib issue, and any action they had consequently taken. Additional 
questions were asked about their satisfaction with the DHPC and the e-mail, and their 
preferred source of such information. 
Results: Forty respondents (18.6%) completed the questionnaire. Eighty-one percent of 
the respondents in the intervention group (N=21) and 47% of the control group (N=19) 
correctly indicated that a serious increase in intra-ocular pressure could be caused by 
pegaptanib injections (Fishers’ exact test, p=0.046). Nine respondents in the intervention 
group versus none of the control group respondents indicated that they had taken action 
in response to the pegaptanib safety issue (Fishers’ exact test, p=0.01). The majority of 
both the intervention group and the control group confirmed that they would like to 
receive an MEB e-mail with safety information about drugs in the future (90 and 95%, 
respectively).  
Conclusion: The results of this study indicate that an additional e-mail might strengthen 
the uptake of the safety information provided to healthcare professionals, who prefer to 
receive an e-mail from the MEB as a source of such information, as well as the DHPC. This 
study may serve as a starting point for new strategies to improve risk communication 
regarding safety issues associated with drugs and its impact on prescribing.  








The usefulness and the impact of Direct Healthcare Professional Communications (DHPCs, 
or ‘Dear Doctor letters’) in changing the clinical behaviour of physicians have been 
debated.(1-3) Currently, very little is known about the effect of communication efforts 
other than the DHPC to rapidly inform healthcare professionals about newly identified 
safety issues associated with drugs. Such information would provide a much needed 
knowledge base, in particular since evaluation of the impact of risk-minimization 
measures became mandatory in July 2012 in Europe, when the new European 
pharmacovigilance legislation(4,5) came into force. What is known, though, is that any 
change in the current risk communication methods should preferably be based on the 
preferences of the healthcare professionals, to optimize the uptake of the message.(6)  
Previous research has shown that healthcare professionals prefer to receive safety 
information electronically and from an independent, trustworthy source.(7-12) 
Strengthening the safety message by repetition through different means might be very 
effective in getting the information across, especially when the message is similar but not 
identical.(13) For this reason, the Dutch Medicines Evaluation Board (MEB) has offered, 
from October 2010 onwards, an additional e-mail newsletter, to which interested parties 
can subscribe. With this e-mail, healthcare professionals are informed of drug safety 
issues for which a DHPC is issued.  
Recently, the MEB planned to send such an e-mail in conjunction with a DHPC that 
was issued for pegaptanib (a drug that is administered intra-ocularly in patients with 
macular degeneration), as serious adverse drug reactions had occurred. The aim of this 
study was to assess whether safety issues are communicated more effectively with an 
additional e-mail than with a DHPC only, by studying the impact of this e-mail, in particular 
on the knowledge and action taken by the healthcare professionals, their attitude to this 
safety issue, and their satisfaction with this additional information. For this reason, a 
special questionnaire was developed.  
Methods 
Study Population 
The study population was chosen in agreement with the target population (as stated in 
the communication plan of the pegaptanib DHPC), consisting of ophthalmologists and 









Figure 1. Study flow chart 
DHPC= Direct Healthcare Professional Communication. 
 
The study population was not selected from a list of previous subscribers to the 
newsletter. The e-mail addresses of the hospital pharmacists (N=84) were obtained from 
the Dutch Pharmacist Association (KNMP). For the e-mail addresses of ophthalmologists 
(N=131), the websites of Dutch hospitals were reviewed. The healthcare professionals 
were randomly assigned to the control group (N=105) or the intervention group (N=110). 
In addition to the traditional paper-based DHPC, the intervention group received the e-
mail newsletter (Figure 2). The control group received the DHPC only. Two weeks later, 
both groups received an invitation by e-mail to fill in an online questionnaire (Questback 
EFS survey 9.0). The questionnaire could be accessed by clicking on a personalized link in 
the invitation e-mail. Reminders were sent 1 and 2 weeks after the original invitation, 
including the same personalized link. 
The Study Drug 
Pegaptanib was approved in January 2006 for the treatment of neovascular (wet) age-
related macular degeneration in adults.(14) It should only be administered by  








Figure 2. The e-mail that was sent to the intervention group 











SUBJECT: MEB warning – Risk information Macugen 
 
Dear Sir, Madam, 
 
The information below was written by the Medicines Evaluation Board, in relation to safety issues of the drug 
Macugen (pegaptanib). Simultaneously a letter (‘Dear Doctor letter’) was sent to you about this issue by the 
pharmaceutical company.  
You are receiving this e-mail in the framework of the CORE study (UMCG) which aims to improve the current risk 
communication of safety issues of medicines. 
 
Kind regards, 




Risk information Macugen 
 
The Medicines Evaluation Board draws your attention to the following: 
 
RISK OF SERIOUS INCREASE OF INTRAOCULAR PRESSURE WITH INJECTION OF EXCESS VOLUME OF MACUGEN 
 
Information from clinical trials and clinical practice has shown that there is a risk when administering pre-filled 
syringes with pegaptanib (Macugen). The prefilled syringes contain an excess volume. It is important that this 
excess volume is properly removed, and not injected the eye. Two cases were reported where this has not been 
done and where the anterior chamber had to be pierced to lower the pressure. 
 
This is written by Pfizer in a letter, a so-called Direct Healthcare Professional Communication (DHPC). The letter 
with this important risk information is sent to ophthalmologists and hospital pharmacists in consultation with the 
Board of the Medicines Evaluation Board (MEB) and the Health Care Inspectorate (IGZ). 
 
The product information for doctors and pharmacists (SmPC) is also added to this letter. 
Pegaptanib is prescribed for the treatment of patients with the wet type of age-related macular degeneration 
(AMD). This disease affects the central part of the retina (the macula) at the back of the eye and causes loss of 
vision when looking straight ahead. 
 
Identifying and analysing adverse events throughout the life cycle of a drug is called pharmacovigilance. This is a 
core task of the MEB. In case of urgent and/or important safety issues healthcare professionals are informed by 
means of a ‘Direct Healthcare Professional Communication’. Click here for an overview of DHPCs. 
 
This is the electronic newsletter of the Medicines Evaluation Board. You can respond to this newsletter via the 
button bottom right of the page or contact the Information and Communication Department of the MEB. 
 
 
CORE = Communicating Risk Effectively; UMCG = University Medical Center Groningen. 
  







ophthalmologists experienced in giving intravitreal injections.(15) Due to reports of a 
serious adverse drug reaction, consisting of increased intraocular pressure caused by 
administration of the excess volume of pegaptanib present in the pre-filled syringe, a 
DHPC was instigated at the EU level.(15) In the Netherlands, the DHPC was sent to all 
ophthalmologists and hospital pharmacists,(16) advising ophthalmologists to expel the 
excess volume of pegaptanib from the syringe before administration. The DHPC was 
accompanied by the amended Summary of Product Characteristics(17) and a visual 
representation of the correct administration method.(18)  
Questionnaire Development 
The main outcome measures of this intervention study were knowledge of the issue, the 
attitude towards the issue, and action taken to minimize the risk. Additionally, satisfaction 
with the risk communication was assessed. Since an explorative literature search did not 
result in any usable validated questionnaires, we developed a questionnaire (Table 1) 
using the ‘knowledge, attitudes, behaviour’ model of Cabana et al.,(19) representing 
possible barriers to physicians’ adherence to guidelines.  
 
Table 1. Questionnaire overview  
Section/Question
a
 Answer categories 
General 
1. Did you receive and read the letter (DHPC) about 
Macugen (pegaptanib)? 
1: Yes, I have received the letter and read it in 
detail. 
2: Yes, I have received the letter and skimmed 
through it. 
3: Yes, I have received the letter, but I have not 
read it. 
4: No, I have not received the letter. 
2. Did you receive and read the e-mail about Macugen 
(pegaptanib)? 
1: Yes, I have received the e-mail and read it in 
detail. 
2: Yes, I have received the e-mail and skimmed 
through it. 
3: Yes, I have received the e-mail, but I have not 
read it. 
4: No, I have not received the e-mail. 
Knowledge  
3. Does it take you too much time to keep up with new 
drug safety issues? 








Table 1. Continued 
Section/Question* Answer categories 
4. Can you specify which new safety issue was identified 
for Macugen (pegaptanib)?  
1: Yes, an increased risk of retinal detachment 
due to administration of Macugen (pegaptanib). 
2: Yes, an increased risk of an increased 
intraocular pressure due to administration of an 
excess volume of Macugen (pegaptanib). 
3: Yes, an increased risk of endophthalmitis, 
possibly leading to panophthalmia due to 
administration of Macugen (pegaptanib). 
4: I don’t know 
5. Were you aware of the Macugen (pegaptanib) safety 
issue of before the DHPC and/or e-mail were sent? 
(Several answers possible) 
1: No 
2: Yes, via scientific literature 
3: Yes, via my professional association 
4: Yes, via colleagues 
5: Yes, via the sales representative of the 
pharmaceutical company 
6: Yes, via an e-mail newsletter 
7: Yes, otherwise, namely… 
6. Can you specify which recommendation was made in 
connection with this safety issue? 
1: Yes, remove the excess volume from the 
syringe before administration of Macugen 
(pegaptanib). 
2: Yes, stop administration of Macugen 
(pegaptanib) at the first sign of the adverse 
event. 
3: Yes, stop administration of Macugen 
preventively and switch to alternative 
treatment. 
4: I don’t know 
Attitude 
7. Do you think information about drug safety by means 
of DHPCs is important for your work in daily practice? 
1: Very important – 5: not at all important. 
8. Do you agree with the message about this safety 
issue? 
1: Yes, completely – 5: No, not at all. 
9. If not, can you indicate why you do not agree with the 
message about this safety issue? 
Open question 
10. Are you of the opinion that one or more of your 
patients are at risk of the safety issue? 
1: Yes, all patients who received Macugen 
(pegaptanib) 
2: Yes, a specific group of patients who received 
Macugen (pegaptanib) 
3: No, because I did not administer/provide 
Macugen (pegaptanib) 
4: I don’t know 
Action taken 
11. Did you search for more information regarding the 
safety issue? 
Yes/No 
12. If so, did you visit the MEB website for more 
information regarding the safety issue? 
Yes/No 











Table 1. Continued 
Section/Question* Answer categories 
14. Did you discuss the safety issue with (some of) your 
patients? 
Yes/No 
15a. Did you advise one or more physicians to adjust 
treatment of one or more current patients? (hospital 
pharmacists only) 
Yes/No 
15b. Did you change the treatment of one or more of your 
current patients? (ophthalmologists only) 
Yes/No 
16a. If so, which adjustments have you advised? (hospital 
pharmacists only) 
Open question 
16b. If so, in which way have you adjusted treatment? 
(ophthalmologists only) 
Open question 
17. Did you take any other action in response to the 
safety issue? 
No/Yes, namely … 
Satisfaction with DHPC/e-mail 
18. Does the DHPC offer you specific support for your 
work in daily practice? 
Yes/No 
19. If not, do you have any suggestions for improvement? Open question 
20. Does the e-mail offer you specific support for your 
work in daily practice? 
Yes/No 
21. If not, do you have any suggestions for improvement? Open question 
22. How satisfied are you in general with the provision of 
information by letter (DHPC)? 
Visual analogue scale ranging from 1: very 
dissatisfied to 10: very satisfied. 
23. How satisfied are you with the provision of 
information by e-mail? 
Visual analogue scale ranging from 1 very 
dissatisfied to 10: very satisfied. 
24. Do you think the link in the e-mail that provides 
access to the DHPC on the MEB website is useful? 
1: Very useful – 5: not at all useful. 
25. In future, would you like to receive e-mails with 
similar information in addition to the letter (DHPC)? 
1: Yes, for all drugs. 
2: Yes, only for drugs that are relevant to my 
work in daily practice (for example not for 
specialized oncolytics). 
3: No. 
26. Would you rather receive safety information via a 
letter, e-mail, or both? 
1: Preferably via a letter (DHPC). 
2: Preferably via an e-mail 
3: Preferably via both. 
27. Would you rather receive such an e-mail from the 
pharmaceutical company, or the MEB? 
1: Preferably from the pharmaceutical 
company. 
2: Preferably from the MEB. 
3: Preferably from both. 
28. Would you rather receive the letter (DHPC) from the 
pharmaceutical company, or the MEB? 
1: Preferably from the pharmaceutical 
company. 
2: Preferably from the MEB. 
3: Preferably from both. 
29. Do you have any other suggestions for improvement 
of safety communication? 
Open question 
a Respondents were not presented all questions. For example: all questions regarding ‘action taken in response 
to the DHPC’ were automatically skipped in case a respondent indicated not to be aware of the safety issue and 
the recommendations that were given in the DHPC.  







To minimize the respondent burden, some questions were skipped automatically where 
appropriate (e.g. respondents who did not know what safety issue was identified were not 
asked if they took any consequent action). In addition, they were asked about their sex, 
age, whether they worked full time or part time, in a general or academic hospital, and 
how many years they had been professionally registered. 
Results 
Forty respondents (19%) completed the questionnaire (intervention group N=21; control 
group N=19; Table 2; Figure 1).  
 
Table 2. Demographic characteristics respondents (N=40) 
 Intervention 
group [N (%)] 
(N = 21) 
Control 
group [N (%)] 
(N = 19) 
Total [N (%)] 
 








 5 (5) 
 3 (3) 
 
9 (9) 
 5 (5) 
























































Years of professional accreditation 
< 5 years 
5-10 years 

















Mann Whitney U test; b χ
2
; c Fishers’ exact test. Differences in percentages may exist due to rounding. 
 
An additional 14 healthcare professionals notified us that they would not fill out the 
questionnaire, 11 of whom did not administer or provide pegaptanib. The remaining three 
gave no reasons or gave other reasons for not participating. The majority of the 
respondents were male (73%), ophthalmologists (65%), working full time (93%), in a 
general hospital (83%). The mean age was 52 years (range 36–64 years), and most (90%) 
had been professionally registered for more than 10 years.  
No significant differences were observed when comparing responders with non-
responders with regard to sex, occupation and hospital type (χ2, p=0.273; p=0.359; 
p=0.894, respectively). Respondents in the intervention group did not differ significantly 







from those in the control group (Table 2). Eighteen intervention group respondents (86%) 
and thirteen control group respondents (68%) indicated that they had received the DHPC 
(FET p=0.265). In both groups, one respondent had not read the DHPC. Twelve 
respondents (67%) in the intervention group and ten (77%) in the control group reported 
that they had skimmed through the DHPC. The remaining respondents had read the DHPC 
carefully. Ten intervention group respondents (48%) indicated that they had received the 
initial e-mail, and four of them had read it carefully. The remaining six reported skimming 
through the e-mail.  
Knowledge 
Eighty-one percent of the respondents in the intervention group correctly identified the 
pegaptanib issue, versus 47 percent in the control group (FET p=0.046; Figure 3a). Over 
two thirds of both groups who were aware of the issue identified the correct 
recommendation (FET p=0.674; Figure 3b). Overall, 11 respondents were already aware of 
the issue before the DHPC was issued (no significant difference between groups; FET 
p=0.444), either from personal experience and/or common sense (N=6), from the 
scientific literature (N=2), from colleagues (N=2) or from an electronic newsletter (N=1) 
[Table 3]. Thirty percent of all respondents were of the opinion that generally it takes too 
much time to keep up with all new safety issues. 
Attitudes 
Almost all respondents (93%) considered drug safety information important or very 
important for their work in daily practice. Most intervention group respondents (72%) 
agreed with the warning. In the control group, 50 percent of the respondents agreed with 
the issue. All but one control group respondent indicated that their own patients were not 
at risk of the issue. Twenty-five of the 28 respondents who answered this question did not 
administer or provide pegaptanib (intervention group 94%; control group 80%). 
Action Taken 
Nine respondents (six ophthalmologists, three hospital pharmacists) in the intervention 
group versus none in the control group indicated that they had taken some form of action 
in response to the issue (FET p=0.01). The issue was mainly discussed with colleagues. One 
ophthalmologist mentioned that he had discussed with colleagues that close attention 
should be paid to the volume administered with intravitreal injections in general. Two 
respondents had searched for more information (both had visited the MEB website), one 
respondent had discussed it with a patient, and two ophthalmologists indicated that they 








Figure 3  
Healthcare professionals’ knowledge A of the pegaptanib safety issue (Fisher’s exact test, p=0.046); and B the 
corresponding recommendation (Fisher’s exact test, p=0.674). The ‘recommendation’ question was not 
presented to respondents who had indicated that they did not know which safety issue had been identified for 
pegaptanib.  
 











Does it take you too much time to keep up with new drug safety issues? 
[yes(n)] 
21 6 (29) 19 6 (32) 
Can you specify which new safety issue was identified for Macugen 
(pegaptanib)? [correctly answered (n)] 
21 17 (81) 19 9 (47) 
Can you specify which recommendation was made in connection with this 
safety issue? [correctly answered (n)] 
18 13 (72) 10 7 (70) 
Were you aware of the Macugen (pegaptanib) safety issue before the DHPC 
and/or e-mail were sent? [yes (n)] 
18 6 (33) 10 5 (50) 
Attitude  
Do you think information about drug safety by means of DHPCs is important 
for your work in daily practice? [yes (n)] 
21 19 (90) 19 18 
(95) 
Do you agree with the message about this safety issue? [yes (n)] 18 13 (72) 10 5 (50) 
Are you of the opinion that one or more of your patients are at risk of the 
safety issue. [yes (n)] 
18 0 (0) 10 1 (10) 
Action taken 
Did you search for more information regarding the safety issue? [yes (n)] 18 2 (11) 10 0 (0) 
If so, did you visit the MEB website for more information regarding the safety 
issue? [yes (n)] 
16 2 (13) 10 0 (0) 
Did you discuss the safety issue with one or more of your colleagues? [yes (n)] 18 8 (44) 10 0 (0) 
Did you discuss the safety issue with (some of) your patients? [yes (n)] 18 1 (6) 10 0 (0) 
Did you change the treatment of one or more of your current patients? 
(ophthalmologists only) [yes (n)] 
10 2 (20) 9 0 (0) 
  














 n (%) N
a 
n (%) 
Did you advise one or more physicians to adjust treatment of one or more 
current patients? (hospital pharmacists only) [yes (n)] 
6 0 (0) 1 0 (0) 
Did you take any other action in response to the safety issue? [yes (n)] 18 2 (11) 10 0 (0) 
Satisfaction with DHPC/email    
Does the DHPC offer you specific support for your work in daily practice? [yes 
(n)] 
17 13 (76) 12 6 (50) 
Does the e-mail offer you specific support for your work in daily practice? [yes 
(n)] 
9 7 (78) NA NA 
How satisfied are you in general with the provision of information by letter 
(DHPC)? [on a visual analogue scale of 1-10 (mean (SD)] 
21 7.1  (1.1) 19 5.0 
(2.9) 
How satisfied are you with the provision of information by e-mail?  
[on a visual analogue scale of 1-10 (mean (SD)] 
10 7.2  (1.8) NA NA 
Do you think the link in the e-mail that provides access to the DHPC on the 
MEB website is useful? [yes (n)] 
10 6 (60) NA NA 
In future, would you like to receive e-mails with similar information in addition 
to the letter (DHPC)? [yes (n)] 
21 19 (90) 19 18 
(95) 













Would you rather receive such an e-mail from the pharmaceutical company, or 
the MEB? 














Would you rather receive the letter (DHPC) from the pharmaceutical company, 
or the MEB? 













a N represents the number of respondents that answered a particular question. The total number of respondents 
per question can differ, depending on previous answers some subsequent questions were skipped in the online 
questionnaire. For example: all questions regarding ‘action taken in response to the DHPC’ were automatically 
skipped in case a respondent indicated not to be aware of the safety issue and the recommendations that were 
given in the DHPC. Differences in percentages may exist due to rounding.  
DHPC = Direct Healthcare Professional Communication; MEB= Medicines Evaluation Board; NA= Not applicable. 
 
One hospital pharmacist had recorded the issue in a computerized physician order entry 
system. Of note, the remaining ophthalmologist had reported the issue to the marketing 







Satisfaction with Risk Communication 
The DHPC in general was rated with a mean score of 7.1 (standard deviation [SD] 1.1) out 
of 10 by the intervention group and 5.0 (SD 2.9) by the control group (Mann–Whitney U 
test p=0.024). The intervention group rated the e-mail with a score of 7.2 (SD 1.8). Fifty 
percent of the respondents in the control group and 76% of the intervention group 
thought that the traditional DHPC offered sufficient support for their work in daily practice 
(FET p=0.236). The intervention group valued the e-mail similarly to the DHPC, with 78 
percent stating that the e-mail alone offered adequate support. The link to the DHPC as 
provided in the e-mail was rated useful by 60 percent of the intervention group 
respondents. Almost all respondents in both groups stated that they would like to receive 
an e-mail with safety information. Two thirds of them preferred to receive only e-mails 
about drugs that are relevant to their daily practice. Slightly more than half of the 
respondents who stated that they would like to receive an e-mail preferred not to receive 
the DHPC, and about a third preferred both. Thirteen percent indicated that they favoured 
the traditional DHPC despite wanting to receive the e-mail. The MEB was the preferred 
source of such information for both the DHPC as well as the e-mail (60 and 72%, 
respectively).  
Discussion 
Risk communication is increasingly receiving attention in pharmacovigilance, partly due to 
an increased call for transparency. The new European pharmacovigilance legislation has 
become operational, in which risk communication plays an important role, and in 2007 an 
EU DHPC template became available.(4,5,20) Despite these improvements, much can still be 
learned and optimized by addressing multiple factors. This study offers valuable 
information, as an additional e-mail may lead to better uptake of the information than 
only the DHPC. In general, uptake of a message is improved by repetition, especially when 
the message is similar but not identical.(13) This fits with the intervention group 
respondents being more knowledgeable about the pegaptanib issue and taking action 
more often than the control group respondents. The issue was mainly discussed with 
colleagues and appears to have been a reminder that pegaptanib should be administered 
carefully. In general, people want to make informed decisions about risks.(21) Two 
respondents searched for more information about the issue, underlining that additional 
information is desired and should be provided. Most respondents stated that they would 
like to receive an additional MEB e-mail in the future. This confirms that healthcare 
professionals have more trust in an objective information source, like the MEB, than in the 
pharmaceutical industry.(8,9,11) Successful risk communication largely depends on a 







trustworthy information source and might be an important contribution to the impact of 
the intervention, as pharmaceutical companies are often distrusted.(8,22-24) When the trust 
and credibility of the source of the information are questioned, the message may not be 
heard, believed and acted upon.(22,25,26) Many factors play a role in constructing and 
deconstructing trust and, according to the so-called asymmetry principle, trust is lost more 
easily than it is rebuilt.(22)  
The DHPC was rated higher by the intervention group than the control group. Thus, 
the e-mail may have influenced the intervention group’s opinion about the DHPC. 
Repetition of a message does improve its uptake,(13) but it is unclear if satisfaction with the 
message is improved at the same time. Also, the link to the DHPC as provided in the e-mail 
may have improved its rating, as it was rated useful by 60 % of the respondents. The fact 
that they rated the DHPC similarly to the e-mail confirms that DHPCs remain an important 
communication tool.(8,10)  
The question is raised as to when a DHPC can be considered sufficiently effective. 
Although the intervention group respondents were more knowledgeable and took action 
more frequently than the control group, not everyone in the intervention group could 
identify the correct recommendation. The challenge will be to develop evidence-based 
thresholds as to what knowledge and action levels are achievable and acceptable. 
Additional measures can be demanded whenever a threshold is not reached. 
Strengths and Limitations 
To our knowledge, this is the first randomized controlled study comparing the impact of 
an additional risk communication tool with that of the DHPC. Several national authorities 
provide an e-mail service informing subscribers of safety issues concerning drugs,(27-30) but 
their impact has not yet been assessed. These results therefore offer valuable insights to 
improve current risk communication.  
This was a small study restricted to ophthalmologists and hospital pharmacists, and 
the response rate was fairly low despite two reminders, which limits its 
representativeness and generalizability. The low response rate may have caused bias, e.g. 
healthcare professionals who are unfamiliar with DHPCs or who are not specifically 
interested in drug safety issues may have been underrepresented. The control group 
consisted of slightly more ophthalmologists than the intervention group. 
Ophthalmologists could have had different opinions about the issue than the hospital 
pharmacists, but this was not the case (Mann–Whitney U test p = 0.900). Low response 
rates are not uncommon, especially in the case of online surveys.(31-33) In this case, it may 
have been attributable to the limited use of pegaptanib in the Netherlands(34) as shown by 







for that reason. Also, pegaptanib is a product with a very specific indication, and a highly 
educated group of prescribers (as was demonstrated by the 11 respondents) were already 
aware of the safety issue before the DHPC was issued. This might have been a reason for 
the non-responders to disregard the questionnaire. Yet no significant differences were 
observed between responders and non-responders. In view of its limitations, our study 
should be considered a starting point for future risk communication evaluations. Eleven 
intervention group respondents indicated that they had not received the pegaptanib e-
mail, yet those respondents did fill out the questionnaire by using the link in the invitation 
e-mail that was sent to the same e-mail address and by the same sender. Those 
respondents might have overlooked the previous e-mail. The same issue holds for the 
DHPC, with nine respondents indicating that they had not received the DHPC. Previously, 
several physicians indicated that they often mistakenly throw away the DHPC together 
with direct mail advertising from pharmaceutical companies.(9) Also, electronic messages 
may be lost. A recall bias could be another possible explanation.  
In order to minimize biased results, we did not perform an assessment before the 
DHPC was issued, nor did we provide detailed information about the study at the time of 
sending the e-mail, nor did we offer any incentives to increase response rates. Still, taking 
part in the study itself may have altered the attitude, knowledge and behaviour of the 
healthcare professionals. We are not able to verify to what extent this might have 
occurred.  
Ultimately, measuring intended behaviour is just the start of evaluating the impact of 
risk communication, which should be supported by measurement of actual behaviour 
(removing the excess volume from the pre-filled pegaptanib syringe before 
administration) and the impact on clinical outcome, i.e. occurrence of the safety event 
(increased ocular pressure).(35) 
Recommendations 
Improving the impact of future risk communication, based on these results, will benefit 
public health and, ultimately, the patient. To this end, an additional e-mail sent by a 
national authority can be considered a promising additional tool. Healthcare professionals 
could be sent e-mails only about safety issues that are relevant to their specialization in 
order to prevent ‘warning fatigue’. They should, however, still be given the opportunity to 
receive all e-mails, as was preferred by one third of the respondents in this study. Ideally, 
risk communication is a two-way process,(36,37) emphasizing the need for close 
involvement of healthcare professionals who are working in daily practice at the time 
when the DHPC is drafted. They know from experience what practising healthcare 
professionals already know about the drug and the safety issue. They are aware of the 







concerns, needs and aspects that deserve to be emphasized in the DHPC.(38,39) With their 
input, the information can be tailored, e.g. by omitting information that is considered 
common knowledge, or by providing relevant background information.  
Previous studies have shown that optimization of the format and content of DHPCs is 
possible(9,40,41) and that it can influence the impact of DHPCs.(42) A clear subject header on 
the e-mail or a notable symbol on the HPC’s mailing envelope could make it stand out and 
prevent it from being discarded.(41,43) The content should be formulated to ensure that it is 
as readable and unambiguous as possible to make sure that it will be interpreted as 
intended and to avoid any confusion.(9,44,45) The most important aspects of the warning 
and clear recommendations should be mentioned first.(21) This is emphasized by the fact 
that a total of five respondents in our study who were aware of the pegaptanib issue 
could not correctly identify the recommendation, with two respondents in the 
intervention group incorrectly indicating that treatment with pegaptanib should be 
stopped.  
Sending an additional e-mail is only one option. Other options, such as safety alerts 
in medical journals or computerized physician order entry systems, should also be 
explored, as these are also highly valued by healthcare professionals.(8) The impact of 
DHPCs may also be improved by taking the characteristics of the drug and the safety issue 
into account.(42)  
Risk communication can be evaluated in different ways, including formative 
evaluation to assess the content of a message, process evaluation to determine whether 
the audience has received the message, and outcome evaluation to determine whether 
the intended effect of the message was achieved.(38) Each method has its methodological 
challenges, and studies should be carefully designed. When evaluating impact by means of 
surveys, low response rates should be anticipated, especially when the surveys are 
conducted online. Pilot tests should be carried out to provide a basis for thorough sample 
size calculations. Several respondents in our study indicated that they had not received 
the pegaptanib DHPC and/or e-mail. This should be investigated more thoroughly, as 
reaching the target audience is a prerequisite of effective risk communication. Since risk 
perception may differ between countries and there may be cultural differences regarding 
drug use,(46,47) it is necessary to compare the impact of DHPCs, as well as the experiences 
and preferences of healthcare professionals, with regard to DHPCs in different countries.  
Conclusion 
The results of this study indicate that an additional e-mail may strengthen the uptake of a 
written DHPC, as healthcare professionals’ awareness of the safety issue was increased 







point for new strategies to improve risk communication regarding safety issues associated 
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This thesis focuses on the impact of risk communication of safety issues of drugs. 
Throughout a drugs’ post marketing lifecycle serious safety issues may emerge,(1-3) which 
can lead to hospitalization, disability, or even death of patients.(4,5) These issues need to 
be communicated to healthcare professionals. In Europe, this is mainly done with paper 
based Direct Healthcare Professional Communications (DHPCs). These warning letters are 
sent by the responsible pharmaceutical company at the instigation of national and/or the 
European Medicines Agency (EMA) and are aimed at ensuring safe and effective use of 
medicinal products.(6) However, DHPCs have not always been successful in effectively 
communicating the intended information to the healthcare professionals.(7-9) In some 
cases, drugs had to be taken off the market, because warnings were not sufficiently 
complied with. The new pharmacovigilance legislation that came into force in July 2012, 
stipulates that the outcome of risk minimization measures should be measured.(10,11) A 
reference framework regarding the effects of drug safety warnings on clinical practice is 
needed and could be obtained by identifying the effect of previous risk minimisation 
measures.(12) However, a comprehensive overview that could contribute to the debate 
about the effectiveness of DHPCs was lacking, and experiences and preferences of Dutch 
healthcare professionals with regard to DHPCs were unknown. 
 
Therefore, the main objectives of the Communicating Risk Effectively (CORE) project were: 
 To provide an overview of the impact of DHPCs and to explore different 
determinants of variation in impact. (Part 1, Chapters 2, 3, 4) 
 To explore the experiences and preferences of Dutch healthcare professionals 
with regard to the DHPC and to determine the added value of a new risk 
communication method, based on these preferences. (Part 2, Chapters 5, 6)  
 
In this chapter we discuss the main findings of the CORE project, the methodological 
considerations, and the implications of this research for current practice, as well as for 
future research. 
Main findings  
Part 1 -  The impact of safety-related regulatory action 
In chapter 2, the results are given of the systematic literature search that we conducted 
using the online literature databases Medline and Embase. We provided an overview of 
studies that assessed the impact of DHPCs, Black Box warnings, and Public Health 
Advisories. The search resulted in 52 relevant articles. We found that the evidence is 
primarily based on two drug groups, namely the third-generation oral contraceptives 







(increased risk of thrombosis) and selective serotonin reuptake inhibitors (risk of suicide in 
adolescents and children) and one drug, namely cisapride (risk of serious cardiac 
arrhythmias). The remaining articles described a broad variety of drugs and drug groups. 
Almost half of the studies had inadequate before/after designs and heterogeneity in 
analyses and outcome measures hampered the reporting of overall effect sizes. Studies 
with adequate interrupted time series design reported a more mixed impact of safety 
warnings than before/after studies. When unintended effects were assessed in case of 
selective serotonin reuptake inhibitors (suicides, spillover effects to non-targeted 
population) and third-generation oral contraceptives (conceptions, abortions), these were 
almost always present, showing the relevance of considering not only the intended but 
also the unintended effects of safety warnings. Furthermore, we concluded that safety-
related regulatory action can have some impact on clinical practice but firm conclusions 
are difficult to draw. These results showed that there is a clear need for further research 
with appropriate study designs, and statistical analyses to understand the impact of 
safety-related regulatory action. 
 
The impact of a large group of Dutch DHPCs on drug use was evaluated in chapter 3. 
Nationwide dispensing data for the period 2000–2008 for new users of drugs with one or 
more DHPCs were assessed. Fifty nine DHPCs were included for 46 drugs or drug groups. 
Impact on short-term volume of use was evaluated with regression models, and the 
presence of long-term changes in use with interrupted time series analyses incorporating 
pre-existing trends. We found that in the short term, almost half of all drugs with a DHPC 
showed a decrease in use in the year after the DHPC was issued compared with the year 
before. Long term changes in use were observed for a third of the drugs with a DHPC, 
resulting in a mean decrease in drug use of 27%, ranging from -10% to -67%. Changes in 
use were not clearly related to pre-existent trends in use.  
Based on these results we concluded that once safety issues for drugs were 
identified that warranted strong regulatory action, namely DHPCs, these resulted in short 
term reductions in use for almost half of the cases and substantial long term reductions in 
use of a third of the cases. Potential determinants for the impact on prescribing could be 
the type of adverse drug event, availability of alternative agents, the type of prescriber, 
the seriousness of the safety issue, and the medical need for the drug.  
To study this further we explored which characteristics determine impact of Dutch 
DHPCs in chapter 4. We included the same 59 DHPCs that were issued for 46 drugs 
between 2001 and 2008 for ambulatory care drugs. Using multiple linear regression we 
examined the impact on the relative change in new drug use post DHPC of: the time to 







DHPC was issued, the degree of therapeutic innovation of the drug, whether the drug was 
initially prescribed by a specialist or not, whether it was a first or a repeated DHPC, 
availability of a DHPC template when the DHPC was issued, and the type of serious safety 
issue. We observed that DHPCs had less impact on use of specialist drugs than non-
specialist drugs. DHPCs that were issued after a template was made available that 
emphasized the safety issue contributed to a lower drug use. Irreversible, potentially 
catastrophic safety issues,(13) namely with a risk of death and disability were associated 
with lower use. A marginally significant effect was found for drugs with a decreasing trend 
in use before the DHPC was issued. No significant impact was observed for the degree of 
therapeutic innovation, repeated DHPCs, and serious safety issues with a risk of 
hospitalization. These determinants together explained 39% of the overall variation in 
change of new drug use and should be considered as a first exploration of determinants 
that influence the impact of DHPCs. 
We concluded that risk communication of safety issues of drugs can be effective, 
specifically in case of well-structured information, and very serious safety issues. 
Effectiveness may be improved by tailoring DHPCs and adding other communication 
channels, for example for drugs that are increasingly being used after a DHPC is issued. 
Part 2 -  Towards optimisation of the impact of safety-related regulatory action; a focus 
on Direct Healthcare Professional Communications. 
In chapter 5, we developed and pilot tested a questionnaire to assess experiences and 
preferences of Dutch healthcare professionals with DHPCs. The questionnaire and two 
reminders were sent to a random sample of approximately 3.500 GPs, internists, 
community- and hospital pharmacists in the Netherlands. A third of the healthcare 
professionals returned the questionnaire. Although the majority of the healthcare 
professionals considered risk information of medicinal products to be important, a 
substantial group was not familiar with the DHPC as a tool for risk information. 
Pharmacists appeared to be more aware of, and more responsive to, safety issues than 
physicians. The respondents indicated mainly other channels as the source for their 
knowledge of some recent drug safety issues. Our study also showed that the healthcare 
professionals had more trust in safety information provided by the Dutch Medicines 
Evaluation Board (MEB) than by the pharmaceutical industry. The respondents preferred 
safety information to be issued by an independent source, such as the MEB, or their own 
professional associations. The preferred alternative channels of drug safety information 
were e-mail, medical journals, and computerized physician order entry systems.  
We concluded that safety information of drugs does not always reach healthcare 
professionals through DHPCs and that special effort is needed to reach general 







practitioners. We recommended that alternative and/or additional methods of risk 
communication are developed using electronic methods and medical journals. Moreover, 
(additional) risk communication coming from an independent source like the MEB should 
be considered. 
 
In chapter 6, we showed the results of a pilot study that was set up to evaluate the value 
of an e-mail which was sent to healthcare professionals in addition to a DHPC for the drug 
pegaptanib. We conducted a randomized controlled trial in which the intervention group 
received both the pegaptanib DHPC, as well as the MEB e-mail and the control group 
received the traditional paper based DHPC only. Two weeks later the study population 
received an invitation to fill out an online questionnaire. Questions were asked about the 
respondents’ knowledge and perception of the pegaptanib issue, and any action they had 
taken in response to the issue. Additional questions were asked about their satisfaction 
with the DHPC and the e-mail. Forty respondents completed the questionnaire. 
Respondents who received the additional e-mail were more knowledgeable about the 
pegaptanib safety issue and took action more often than the respondents who received 
the paper based DHPC only. The issue was discussed with colleagues by most respondents. 
The majority of both the intervention group and the control group indicated that they 
would like to receive an e-mail with safety information about drugs in the future. The MEB 
was the preferred source of information for the DHPC as well as the e-mail.  
We concluded that issuing an additional e-mail resulted in a better uptake of safety 
information than a written DHPC only, as respondent’s awareness of the safety issue was 
increased and more action taken in response to the issue.  
Methodological considerations  
New drug use as an outcome measure to assess the impact of DHPCs 
In chapter 3 and in chapter 4, we focused on new drug use as an outcome measure to 
assess the impact of DHPCs. It should be noted, that a decrease in use is not always the 
intended impact of a DHPC.(14-16) The impact of DHPCs can - and should - also be analysed 
using outcome measures that are directly attuned to the safety issue, as indicated in 
chapter 1. Such outcome measures are, for example, concomitant use of contraindicated 
drugs(17) or how often healthcare professionals order recommended laboratory tests to 
identify early potential drug toxicity.(18) The results of this study can only be used to 
anticipate the impact of DHPCs on new drug use and any additional action that is based on 
these results should be carefully considered. Nevertheless, we think that new drug use 







DHPCs, since it is an outcome measure that can reliably be assessed for a large group of 
drugs. Also, new drug use is a more sensitive measure than overall use, since changes in 
prescribing behaviour can more likely be expected in new users.(19) Incorporating a 
classification of the hoped for and expected outcome of the DHPCs in order to analyse its 
impact on a more specific outcome measure would only have been possible if it would 
have been made in a prospective setting, at the time a DHPC is issued. These studies can 
be considered a starting point for future studies that will assess more specific outcome 
measures that are attuned to the recommendations in the DHPC. 
Limited number of determinants 
In chapter 4 we included a set of seven determinants to assess which characteristics 
determine the impact of Dutch DHPCs. We limited the range of determinants due to the 
sample size and its corresponding power. Our full model explained 39% of the overall 
variation in DHPC effect size. Other factors were not included in our model that might also 
have attributed to variations in the impact of DHPCs, for example media attention, the 
incidence of safety issues, safety issues related to off-label use, and availability of 
alternative treatment. It has been suggested that media attention can play an important 
role in the impact of DHPCs as they can amplified the risks.(20-22) We performed an 
explorative lay- and professional literature search for a selection of the DHPCs in our study 
which resulted in too little information to include presence of media attention in our 
model. Likewise, the incidence of the safety issue at hand could not be included, since this 
aspect was not mentioned in the majority of the DHPCs. DHPCs concerning safety issues 
related to ‘off label’ use were too few in number, which led to insufficient variation within 
the variable for incorporation into our model. Alternative treatment was available for 
almost all drugs and was indirectly covered by the innovation variable. More innovative 
drugs did not show greater impact of a DHPC on drug use that less innovative drugs. 
Therefore, it seems unlikely that availability of an alternative treatment would be a major 
determinant. This issue could be addressed by repeating this study in a few years, when 
more DHPCs have been issued making it possible to include more determinants in a similar 
model. For now, our study should be considered as a first exploration of determinants that 
influence the impact of DHPCs that warrant further confirmation and extension. 
Generalizability 
In the studies in chapter 3 and chapter 4 a large number of DHPCs was included that were 
issued over a period of eight years. The DHPCs covered a wide variety of safety issues and 
drugs representing all main therapeutic classes prescribed in ambulatory care. Using the 







same method to assess the impact of DHPCs enables the comparison of the effects of the 
different DHPCs and increases the generalizability of the results. 
The fairly low response rates of the studies in chapter 5 and chapter 6 limit the 
generalizability of the results. Despite sending two reminders in both studies, only 34% 
and 19%, respectively, of the healthcare professionals responded. Low response rates in 
surveys amongst healthcare professionals are not uncommon due to e.g. increasing 
workloads, survey fatigue and a low priority of completing questionnaires especially 
among physicians.(23-29) Still, the low response may have biased our results in that 
healthcare professionals who are unaware of, or not interested in, DHPCs could be 
underrepresented in our samples. This could mean that, in daily practice, even fewer 
healthcare professionals are aware of DHPCs and specific safety issues than observed in 
our study, underlining the need for improvements in current risk communication. Johnson 
and Wislar stated that the response rate might not be as strongly associated with the 
quality and representativeness of a survey and stressed the importance of selecting a 
representative sample of the population.(29) In chapter 5, we were unable to analyse any 
characteristic of the non-responders due to the anonymous nature of the questionnaire. 
We could only report that our sample was representative for the Dutch setting in terms of 
sex,(30) and the percentage of GPs who work part-time.(31) We found no significant 
differences between early and late responders, except for two variables; it is possible that 
the non-responders had different preferences with regard to the pharmacists and 
pharmacotherapy meetings than the responders. Apart from these two variables, the 
results of this study were, in all likelihood, not affected by non-response bias. When 
comparing the responders to the non-responders in chapter 6 with regard to their sex, 
occupation and hospital type no significant differences were observed. The low response 
in this study could be attributed to the limited use of pegaptanib in the Netherlands.(31) 
Eleven healthcare professionals responded to our survey invitation by stating that they 
would not fill out the questionnaire because they did not administer or provide 
pegaptanib. Twenty-five respondents who did fill out the questionnaire indicated the 
same. This emphasizes the importance of a pilot study to provide a basis for thorough 
sample size calculations in case a survey is the preferred study design. 
It is not clear to what extent the results of our studies can be generalized to other 
countries. We evaluated the impact of Dutch DHPCs and the experiences of Dutch 
healthcare professionals. Often the same DHPCs, albeit translated, are issued throughout 
Europe, especially for drugs that are registered at a European level. However, healthcare 
professionals in diverse countries may respond differently to the DHPCs. Risk perception 
may differ and cultural differences regarding drug use can exist.(33,34) For example, trust in 







be expected to vary between countries as the interpretation of benefits and risks of drugs 
has shown to vary between national agencies.(35,36) A message will not be heard, believed 
and acted upon when trust and credibility of the source of the information are 
questioned.(37) This means that healthcare professionals in certain other countries might 
not prefer to receive drug safety information from their national drug regulating authority. 
This would underline that each situation needs to be assessed individually. An EU wide 
study would allow for a comparison of the (determinants of) impact of DHPCs as well as 
the experiences and preferences of healthcare professionals with regard to DHPCs in 
different countries. This will provide much needed information regarding the necessity of 
nationally tailored risk communication strategies. 
Future research  
Assessment of impact of safety-related regulatory action 
The results of our systematic review indicate a clear need for further research in order to 
fully understand the impact of safety-related regulatory action. The impact of DHPCs 
should not only be analysed by assessing drug use. Outcome measures that are directly 
attuned to the safety issue should also be assessed. Clusters of DHPCs with the same 
recommendation could be analysed to get more insight into how the impact of DHPCs on 
more specific outcomes can best be anticipated. This can be facilitated by prospectively 
classifying the recommendations that are made in the DHPCs at the time they are issued. 
Several other factors that might also attribute to variations in the impact of DHPCs 
were not included in the model in chapter 4. By repeating this study in a few years, when 
more DHPCs have been issued, and the content of the DHPCs is possibly even further 
optimized, the issue of the limited sample size could be solved and more factors could be 
included in the model. 
Both the intended and the anticipated unintended effects of safety warnings should 
be assessed. Interrupted time series would be the preferred design as it allows for greater 
reliability in assessing the impact of safety warnings in comparison to before/after 
designs. Also, all individual warnings that are issued for the drug in question should be 
assessed instead of only a selection and the impact should be reported per warning 
instead of an overall effect. This way it will be possible to gain more knowledge about the 
specific type of warning that is most effective in changing behaviour of physicians. 
Optimisation of the impact of safety-related regulatory action 
Within the field of environmental risk communication a great deal of research has already 
been performed that can be used for improving communication of drug safety issues.(38-40) 







In our studies we focused on getting empirical evidence for a few but important aspects of 
risk communication. These findings add to the practical approaches described in a specific 
US-based practical guide on how to plan, implement, and evaluate health communication 
programs.(41) With regard to surveys, low response rates should be anticipated, especially 
when the survey is conducted online. Pilot tests should be carried out to provide a basis 
for thorough sample size calculations. 
The respondents of our survey in chapter 5 indicated they would like to receive 
information of safety issues of drugs via e-mail from the MEB, which we put to the test in 
a randomized clinical trial in chapter 6. Similar randomized clinical trials could be set up to 
assess the impact of a safety warning that are communicated by other highly valued 
communication sources or channels. These channels need to be chosen based on the goal 
of risk communication, i.e. sharing new information, changing beliefs of drug benefits and 
risks, or changing healthcare professional behaviour. Particularly in the latter case more 
interventions may be needed to achieve long-term changes in behaviour. 
From the studies described in chapter 4, chapter 5, and chapter 6, we know that 
context matters. Several risk perception factors (irreversibility, high catastrophic potential 
and trust in institutions) play a role in the way safety issues of drugs and associated risk 
communication are perceived by healthcare professionals. Since not all risk perception 
factors were included in these studies, the influence of other factors, like uncertainty, 
understanding, and the ethical/moral nature is not known. Unfortunately, most risk 
perception research has been performed amongst the lay public, mostly regarding risks 
other than serious safety issues of drugs. Future research could provide more insight, for 
example by studying how physicians weigh benefits and risks when prescribing drugs for 
which a DHPC was issued. The lay public rates the benefits and risks of several drugs 
differently.(21) It is to be expected that the same holds for physicians. In general, people 
are willing to accept higher risks in case of more benefits.(21) The fact that physicians are 
making risk related decisions for their patients, instead of themselves should be taken into 
account. For it has been shown that physicians would choose riskier treatment options for 
themselves than for their patients.(42) On the other hand, one study suggests that 
regulators, physicians and patients may weigh new serious drug risks similarly, when 
presented in the context of other benefits and risks of an oral anti-diabetes drug. An 
increased, but in absolute terms still small risk of bladder cancer of a hypothetical oral 
anti-diabetes drug did not affect drug choice of all three stakeholder groups.(43) Risk 
communication tools, e.g. decision aids to facilitate shared decision making, may be 
explored when differences in benefit/risk perceptions are anticipated. 
Better understanding of the role risk perception factors play could provide guidance for 







communication methods, anticipate unintended effects, and develop new risk 
management strategies.(45) The impact of DHPCs issued for safety issues other than 
administration issues and for drugs that are more widely used should also be assessed. 
Specific attention should be paid to DHPCs communicating newly identified safety issues, 
as this new information might conflict with the views that healthcare professionals have of 
these drugs. According to the theory of cognitive dissonance, this could cause them to 
disregard the new information.(45,46)  
Implications for regulatory policy and practice 
Risk communication is receiving more and more attention within the field of 
pharmacovigilance, partly due to an increased call for transparency. In 2007 a DHPC 
template became available and in 2012 the new pharmacovigilance legislation became 
operational in which risk communication plays an important role.(6,10,11) Despite these 
improvements, still a lot can be learned and optimized. Based on this thesis, the following 
recommendations can be given (Table 1). Risk communication of safety issues of drugs 
should be improved by addressing multiple factors. 
 
Table 1. Main recommendations  
1. Improve communication methods 
 Communicate safety issues of drugs through an independent, trustworthy source. 
 Use new channels, e.g. e-mail, to communicate safety issues. 
 Make the DHPC stand out to healthcare professionals, e.g. with a picture of a yellow hand on 
the envelope. 
2. Increase  involvement of healthcare professionals 
 Involve healthcare professionals in the DHPC drafting process. 
 Improve healthcare professionals’ awareness of authorities. 
 Educate healthcare professionals about risk communication of safety issues of drugs. 
3. Improve evaluation of impact 
 Define and classify the intended effects of DHPCs prospectively. 
 Determine appropriate outcome measures to assess the impact of DHPCs. 
 Determine thresholds for when DHPC can be considered effective. 
 Anticipate unintended effects of DHPCs. 
 
1. Improve communication methods 
Trust plays an important role in the risk communication process and 
pharmaceutical companies are often distrusted.(47,48) A complex set of factors 
plays a role in the construction and deconstruction of trust and unfortunately, it 
is easier to loose than to generate or rebuild trust which was outlined by the so-







called ‘asymmetry principle’.(35) Hence, we recommend that drug safety issues 
should be communicated by a trustworthy source like the MEB.(49,50)  
New channels like e-mail could be used to communicate safety issues of 
drugs. Healthcare professionals should be able to indicate if they want to receive 
such an e-mail about all drugs or a selection only. This will prevent occurrence of 
a so-called ‘warning fatigue’ due to an overload of information. 
In this thesis, we did not study if, and in what way the content of the DHPC 
could be improved. Even though the impact of the DHPC on drug use was 
increased after the DHPC template became available, further optimization of the 
format and content of the DHPC is possible. Use of symbols is essential to make 
the DHPC stand out to healthcare professionals.(49,50) It is recommended that the 
letter should be sent with an extra symbol such as a picture of an orange hand 
printed on the envelope as is currently done in the Netherlands in cases that 
require immediate action from the healthcare professional. A different colour, 
e.g. yellow, could be used to distinguish DHPCs to merely alert healthcare 
professionals of a drug safety issue from cases where immediate action is 
required. On the envelope of the DHPC and in the header of an email the drug 
and the safety issue should ideally be mentioned. 
The most important information is not always presented adequately in the 
DHPC and readability and clarity can be insufficient.(50) The way the numbers are 
presented and risks are framed has a major influence, as for example the ‘Pill 
scare’ has shown.(21,41,51,52) Framing of risks (e.g. indicating how many patients 
have died versus how many patients survived the adverse drug event) seems to 
influence lay people and healthcare professionals similarly.(21) To establish the 
optimal presentation of risks in DHPCs previous research among lay people can 
be studied. However, healthcare professionals do not always have the same 
needs regarding risk information as lay people.(41) When communicating to 
healthcare professionals, more sophisticated language can be used, and 
references can be given to scientific background information.(53) Nevertheless, a 
so-called polysemic message, which is a message that can be interpreted in 
several ways should be avoided as it could create confusion amongst the target 
audience. The content of the DHPC, especially the recommendations, should be 
formulated as unambiguous as possible.(51,54,55) The most important aspects of 
the safety issue, including the recommendations, should be mentioned first.(53) To 
avoid unintended effects that could be caused by a polysemic message, the 








2.  Increase involvement of healthcare professionals 
Successful risk communication does not only depend on optimal communication 
methods, but also on engagement of the receiver. Ideally, risk communication is a 
two way process emphasizing the need for close involvement in the DHPC 
drafting process of healthcare professionals who are working in daily 
practice.(38,39,45,52,56,57) Also, professional associations could be involved in drafting 
and informing their members of DHPCs, since they are highly valued and 
considered to be credible information sources.(52,54) It is known how difficult it is 
to predict what risks are relevant to others.(41) Provided the correct specific 
healthcare professional is involved one may assume that they know from 
experience what is already known about the drug and the safety issue and what 
not. They are aware of what the concerns and needs are and which aspects 
deserve to be emphasized in the DHPC.(41,52) This approach could potentially avoid 
unintended effects that occurred with the SSRIs and situations like the pill scare 
could possibly be contained.(51) 
A possible approach could be the Mental Models method.(52) By 
interviewing healthcare professionals as well as regulators, their opinions can be 
identified and any differences can be addressed. This approach is quite time 
consuming however, and might be more useful as a preparation to improve the 
format and content of DHPCs in general.(53) It would be less suitable during a crisis 
situation for valuable time might be lost. Furthermore, validated tests are 
available that can be used to test the readability of DHPCs in terms of sentence 
construction, length and type of words used.(41) 
Healthcare professionals see a distinct role for regulatory authorities in 
communicating safety issues and their visibility amongst healthcare professionals 
should be improved. To assist healthcare professionals in their responsibility to 
keep abreast of newly identified safety issues of drugs, they should be educated 
that at some points in their career they will be subject to risk communication, for 
example during their training. This could be integrated with education on how to 
report safety issues. 
 
3.  Improve evaluation of impact 
Risk communication can be evaluated in different ways. With formative 
evaluation the content of the message can be assessed, process evaluation can 
for instance be used to determine whether the audience has received the 
message and with outcome evaluation it can be determined whether the 
intended effect of the message was achieved.(41) 







The intended effects of DHPCs should be defined and classified prospectively in 
order to be able to assess their effectiveness using the most appropriate 
outcome measure. These outcome measures should preferably be attuned to the 
safety issue, for example, concomitant use of contraindicated drugs(17) or how 
often health-care professionals order recommended laboratory tests to identify 
early potential drug toxicity.(18) Subsequently, it is important to determine at 
which point a DHPC can be considered sufficiently effective. Stating that the 
impact of risk minimization measures should be evaluated is useful only when 
thresholds are set and additional action is demanded whenever such a threshold 
has not been reached.(58-60) This will not be easy in view of the current lack of 
information about the effectiveness of these measures. For example it is not 
known whether a ‘ceiling effect’ could occur that will hinder a DHPC and 
additional risk communication methods to be any more effective. Moreover, 
there are no ‘universally acceptable risks’, as it depends on the context whether 
the achieved risk reduction is sufficient.(61) In the case of the DHPCs it means that 
not all adverse drug events can be prevented, despite taking into account all 
precautions.(62) Also, the ease with which thresholds can be set depends on the 
type of outcome measure. They can be determined fairly easy for the number of 
drug prescriptions, or laboratory tests. But how many adverse events can be 
accepted, would be more difficult keeping in mind underreporting and their 
possible similarity with a symptom of the disease in question. The challenge in 
the near future will be to generate evidence that can be used to establish what is 
achievable and what is not. For each DHPC the potential unintended effects 
should be verified and monitored. By anticipating the unintended effects, for 
example by giving additional information, problems that have occurred with 
selective serotonin reuptake inhibitors (decreased use by non-targeted 
population) and the third generation contraceptives (increased number of 
abortions)l can be avoided in the future. 
Final conclusion 
This thesis gives an overview of the impact of DHPCs and its determinants. Although long 
term decreases in use were observed after only a third of the DHPCs, the decrease was 
substantial. DHPCs were specifically effective in case of well-structured information, and 
very serious safety issues. Dutch healthcare professionals preferred to receive safety 
information through electronic methods and from an independent source. An additional 
e-mail that was sent by the Dutch Medicines Evaluation Board strengthened the effect of a 







and more action was taken in response to the issue. Currently, the DHPC has a clear added 
value. Any future developments will have to be monitored. From an unimpeded, research 
point of view, recommendations were given that can be used to improve current risk 
communication of safety issues of drugs. Regulatory decisions are affected by governance 
of the health sector, which may complicate implementation. A flexible attitude is required 
of all stakeholders to improve safe use of drugs which will benefit public health and, 
ultimately, the patient.  
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Dit proefschrift richt zich op risicocommunicatie over veiligheidproblemen van 
geneesmiddelen. Gedurende de levenscyclus van een geneesmiddel dat op de markt is 
toegelaten kunnen zich ernstige veiligheidsproblemen voordoen.(1-3) Deze problemen 
kunnen leiden tot ziekenhuisopnamen, handicaps, of zelfs overlijden van patiënten.(4,5) 
Zorgverleners dienen van deze kwesties op de hoogte te worden gebracht. In Europa 
wordt dit voornamelijk gedaan door middel van papieren brieven; zogenaamde Direct 
Healthcare Professional Communications (DHPC’s). Deze waarschuwingsbrieven worden 
verstuurd door het farmaceutische bedrijf op instigatie van de nationale autoriteiten en/of 
het Europees Geneesmiddelenbureau (EMA). De brieven zijn gericht op het waarborgen 
van veilig en doelmatig gebruik van geneesmiddelen.(6) DHPC’s zijn echter niet altijd 
succesvol geweest in het effectief communiceren van veiligheidsinformatie aan 
zorgverleners.(7-9) De nieuwe farmacovigilantie wetgeving die van kracht werd in juli 2012, 
bepaalt dat het effect van risico beperkende maatregelen moet worden gemeten.(10,11) Een 
referentiekader met betrekking tot de effecten van DHPC’s op de klinische praktijk is 
noodzakelijk. Dit referentiekader kan worden verkregen door het effect van voorgaande 
risico beperkende maatregelen te bepalen.(12) Een dergelijk overzicht ontbrak in het debat 
over de effectiviteit van DHPC’s. Ook waren de ervaringen en voorkeuren van Nederlandse 
zorgverleners met betrekking tot de DHPC onbekend. 
 
Daarom zijn de belangrijkste doelstellingen van het ‘Communicating Risk Effectively’ 
(CORE) project: 
• Een overzicht bieden van de impact van DHPC’s en exploreren welke 
determinanten bepalend zijn voor deze impact. (Deel 1, hoofdstukken 2, 3, 4)  
• De ervaringen en voorkeuren verkennen van Nederlandse zorgverleners met 
betrekking tot de DHPC en de toegevoegde waarde bepalen van een nieuwe 
risico communicatiemethode, gebaseerd op deze voorkeuren. (Deel 2, 
hoofdstukken 5, 6) 
 
In dit hoofdstuk bespreken we de belangrijkste bevindingen van het CORE project, de 
methodologische overwegingen, en de implicaties van het onderzoek voor de huidige 
praktijk en voor toekomstig onderzoek. 
Belangrijkste bevindingen 
Deel 1 -  De impact van veiligheidswaarschuwingen 
In hoofdstuk 2 worden de resultaten gegeven van het systematische literatuuronderzoek 







We gaven een overzicht van studies die de impact van de DHPC, Black Box 
waarschuwingen en ‘Public Health Advisories’ hebben onderzocht. De zoekactie 
resulteerde in 52 relevante artikelen. De studies waren voornamelijk gebaseerd op twee 
geneesmiddelengroepen, namelijk de derde generatie orale anticonceptiva (verhoogd 
risico op trombose) en selectieve serotonine heropname remmers (risico op zelfmoord bij 
adolescenten en kinderen) en één geneesmiddel, namelijk cisapride (risico op ernstige 
hartritmestoornissen). De overige artikelen beschreven een breed scala aan 
geneesmiddelen en geneesmiddelgroepen. Van bijna de helft van de studies was de 
onderzoeksopzet inadequaat (voor/na studies) en heterogeniteit in de analyses 
belemmerde de rapportage van algehele effecten. In studies waarin gebruik werd 
gemaakt van tijdsreeksanalyses werd melding gemaakt van een meer gemengde impact 
van veiligheidswaarschuwingen dan in voor/na-studies. Ongewenste effecten werden 
onderzocht in studies betreffende selectieve serotonine heropname remmers (zelfmoord, 
afname in gebruik door volwassenen) en de derde generatie orale anticonceptiva 
(conceptie, abortus). Deze ongewenste effecten waren bijna altijd aanwezig, waarmee het 
belang van anticiperen op niet alleen de gewenste, maar ook de ongewenste effecten van 
veiligheidswaarschuwingen is aangetoond. We concludeerden dat 
veiligheidswaarschuwingen invloed op de klinische praktijk kunnen hebben. Harde 
conclusies zijn echter moeilijk te trekken. De resultaten toonden aan dat aanvullend 
onderzoek nodig is waarin gebruik gemaakt wordt van passende onderzoeksopzetten en 
statistische analyses om de impact van veiligheidswaarschuwingen volledig te begrijpen. 
 
De impact van een grote groep Nederlandse DHPC’s op geneesmiddelgebruik werd 
geëvalueerd in hoofdstuk 3. Landelijke gegevens van verstrekte geneesmiddelen werden 
beoordeeld voor de periode 2000-2008 voor nieuwe gebruikers van geneesmiddelen 
waarvoor één of meer DHPC’s zijn verstuurd. Negenenvijftig DHPC’s werden geïncludeerd, 
verstuurd voor 46 geneesmiddelen of geneesmiddelgroepen. Effecten op korte termijn 
gebruik werden geëvalueerd met regressiemodellen en de aanwezigheid van 
veranderingen in gebruik op lange termijn met tijdreeksanalyses waarin bestaande trends 
werden ingecalculeerd. Op de korte termijn (in het jaar na de DHPC werd verzonden) 
zagen we voor bijna de helft van de geneesmiddelen een daling van het gebruik 
vergeleken met het jaar ervoor. Langdurige veranderingen in gebruik werden 
geobserveerd voor een derde van de geneesmiddelen, wat resulteerde in een gemiddelde 
afname in gebruik van 27%, variërend van -10% tot -67%. Veranderingen in het gebruik 
waren niet duidelijk gerelateerd aan reeds bestaande trends. 
Op basis van deze resultaten concludeerden we dat veiligheidswaarschuwingen een 







één derde van de gevallen op de lange termijn. Mogelijke factoren van invloed op de 
impact op het gebruik zouden kunnen zijn: het type en de ernst van de bijwerking, 
beschikbaarheid van alternatieve geneesmiddelen, het type voorschrijver en de medische 
noodzaak van het geneesmiddel. 
Om de invloed van deze determinanten vast te stellen hebben we in hoofdstuk 4 
nader onderzocht welke kenmerken de invloed van de DHPC bepalen. We includeerden 
dezelfde 59 DHPC die voor 46 geneesmiddelen werden verzonden tussen 2001 en 2008. 
Met behulp van meervoudige lineaire regressie hebben we de impact onderzocht van de 
volgende determinanten op de relatieve verandering van geneesmiddelgebruik: de tijd tot 
de DHPC vanaf de datum van registratie van het geneesmiddel, de trend in het gebruik in 
de 12 maanden voorafgaand aan de DHPC, de mate van therapeutische innovatie van het 
geneesmiddel, of het geneesmiddel aanvankelijk werd voorgeschreven door een specialist 
of niet, of het een eerste of een herhaalde DHPC betrof, de beschikbaarheid van een 
standaard DHPC sjabloon op het moment dat de DHPC is afgegeven en het type 
bijwerking. We zagen dat DHPC’s minder invloed hadden op het gebruik van 
specialistische geneesmiddelen dan op het gebruik van niet-specialistische 
geneesmiddelen. DHPC’s die werden verstuurd nadat de standaard sjabloon was 
gepubliceerd waarin het veiligheidsprobleem werd benadrukt droegen bij aan een lager 
gebruik. DHPC’s verstuurd in verband met onomkeerbare, potentieel fatale 
veiligheidsproblemen(13) (risico op overlijden en invaliditeit) waren geassocieerd met een 
lager gebruik. Een marginaal significant effect werd gevonden voor geneesmiddelen met 
een afnemende trend in gebruik voordat de DHPC werd verzonden. Er werd geen 
significant effect waargenomen voor de mate van de therapeutische innovatie, herhaalde 
DHPC’s, en veiligheidsproblemen met een risico op ziekenhuisopname. Deze 
determinanten verklaren gezamenlijk 39% van de totale variantie in de verandering van 
geneesmiddelgebruik. De studie vormt een eerste verkenning van determinanten die de 
impact van DHPC’s beïnvloeden. 
We concludeerden dat risicocommunicatie over veiligheidsproblemen van 
geneesmiddelen effectief kan zijn, met name in het geval van goed gestructureerde 
informatie en zeer ernstige veiligheidsproblemen. De effectiviteit van DHPC’s kan worden 
geoptimaliseerd door DHPC’s hierop af te stemmen en door andere communicatiekanalen 
toe te voegen, bijvoorbeeld voor geneesmiddelen die vaker worden voorgeschreven nadat 







Deel 2 -  Op weg naar optimalisatie van het effect van veiligheidswaarschuwingen; een 
focus op Direct Healthcare Professional Communications. 
In hoofdstuk 5 hebben we een vragenlijst ontwikkeld en getest om ervaringen met DHPC’s 
en voorkeuren van Nederlandse zorgverleners te bepalen. De vragenlijst en twee 
herinneringen werden vervolgens verstuurd naar een aselecte steekproef van ongeveer 
3.500 Nederlandse huisartsen, internisten, openbare- en ziekenhuisapothekers. Een derde 
van hen stuurde de vragenlijst ingevuld terug. Hoewel de meerderheid van de 
zorgverleners risico-informatie over geneesmiddelen als belangrijk beschouwde, was een 
substantiële groep niet bekend met de DHPC als methode van informatieverstrekking. 
Apothekers bleken meer bewust van veiligheidsproblemen en ondernamen meer actie 
dan artsen. De respondenten identificeerden voornamelijk andere kanalen dan de DHPC 
als bron voor hun kennis over een aantal recente veiligheidsproblemen. De studie toonde 
ook aan dat de zorgverleners meer vertrouwen hadden in veiligheidsinformatie afkomstig 
van het College ter Beoordeling van Geneesmiddelen (CBG) dan van de farmaceutische 
industrie. De respondenten waren van mening dat de veiligheidsinformatie bij voorkeur 
dient te worden verstrekt door een onafhankelijke bron, zoals het CBG, of de eigen 
beroepsvereniging. De verkozen alternatieve kanalen van veiligheidsinformatie waren e-
mail, medische tijdschriften, en geautomatiseerde voorschrijfsystemen. 
We concludeerden dat veiligheidsinformatie over geneesmiddelen de zorgverlener 
niet altijd bereikt via DHPC’s en dat additionele inspanningen nodig zijn, voornamelijk om 
huisartsen te bereiken. Alternatieve en/of aanvullende risicocommunicatie methoden 
dienen op elektronische wijze of via medische tijdschriften plaats te vinden. Bovendien 
dient (additionele) risicocommunicatie door een onafhankelijke bron, zoals het CBG, te 
worden overwogen. 
 
In hoofdstuk 6 rapporteren we de resultaten van een pilotstudie die werd verricht om de 
additionele waarde te bepalen van een e-mail die door het CBG is verzonden voor het 
geneesmiddel pegaptanib. We voerden een gerandomiseerde gecontroleerde studie uit 
waarin de interventiegroep zowel de pegaptanib DHPC, als een e-mail gestuurd werd. De 
controlegroep kreeg enkel de traditionele papieren DHPC. Na twee weken ontvingen 
beide groepen een uitnodiging voor deelname aan een online vragenlijstonderzoek. 
Vragen werden gesteld over de kennis en de perceptie van de respondenten over de 
pegaptanib kwestie en actie die zij naar aanleiding daarvan hadden genomen. Extra 
vragen werden gesteld over hun tevredenheid met de DHPC en de e-mail. Veertig 
respondenten vulden de vragenlijst in. Respondenten die de extra e-mail ontvingen waren 
beter geïnformeerd over het pegaptanib veiligheidsprobleem en zij namen vaker 







werd door de meeste respondenten besproken met collega's. De meerderheid van de 
respondenten in zowel de interventiegroep als de controlegroep gaf aan dat ze in de 
toekomst graag een e-mail zouden ontvangen met veiligheidsinformatie over 
geneesmiddelen. De respondenten ontvangen zowel de DHPC als de e-mail bij voorkeur 
van het CBG. We concludeerden dat het versturen van een additionele e-mail effectiever 
is gebleken dan het versturen van enkel een papieren DHPC. Respondenten waren beter 
op de hoogte van het veiligheidsprobleem en ondernamen meer actie naar aanleiding van 
de kwestie. 
Methodologische overwegingen 
Nieuw geneesmiddelgebruik als uitkomstmaat om de impact van DHPC’s te beoordelen 
In hoofdstuk 3 en hoofdstuk 4 hebben we ons gericht op nieuw geneesmiddelgebruik als 
uitkomstmaat om de impact van DHPC’s te beoordelen. Opgemerkt dient te worden dat 
een afname in gebruik niet altijd het beoogde effect van een DHPC behoeft te zijn.(14-16) 
Het effect van DHPC’s dient tevens te worden geanalyseerd met behulp van 
uitkomstmaten die direct zijn gerelateerd aan het veiligheidsprobleem, zoals aangegeven 
in hoofdstuk 1. Dergelijke uitkomstmaten zijn bijvoorbeeld; gelijktijdig gebruik van 
gecontra-indiceerde geneesmiddelen(17) of hoe vaak zorgverleners laboratoriumtests 
aanvragen om vroegtijdig mogelijke toxiciteit van een geneesmiddel te identificeren.(18) De 
resultaten van dit onderzoek kunnen slechts worden gebruikt om te anticiperen op de 
impact van DHPC’s op nieuwe geneesmiddelgebruik. Alle andere maatregelen die 
gebaseerd worden op deze resultaten moeten zorgvuldig worden overwogen. Desondanks 
zijn wij van mening dat nieuw geneesmiddelgebruik een geschikte uitkomstmaat is om de 
rol van determinanten van effecten van DHPC verkennen. Het is een uitkomstmaat die 
betrouwbaar kan worden beoordeeld voor een grote groep van geneesmiddelen. Nieuw 
geneesmiddelgebruik is tevens een meer gevoelige maat dan het totale gebruik, 
aangezien veranderingen in het voorschrijfgedrag sneller verwacht kunnen worden bij 
nieuwe gebruikers.(19) Classificatie van de gewenste en verwachte effecten had een 
analyse van de impact van DHPC’s op meer specifieke uitkomstmaten kunnen faciliteren. 
Een dergelijke classificatie zou echter alleen mogelijk zijn geweest indien vastgesteld in 
een prospectieve setting, voorafgaand aan de verzending van de DHPC. De studies 
beschreven in hoofdstuk 3 en 4 kunnen worden beschouwd als uitgangspunt voor 
toekomstige studies. Deze studies kunnen meer specifieke uitkomstmaten evalueren 







Beperkt aantal determinanten 
In hoofdstuk 4 hebben we een reeks van zeven determinanten geïncludeerd om te 
beoordelen welke kenmerken de invloed van Nederlandse DHPC’s bepalen. We hebben 
het aantal determinanten moeten beperken als gevolg van de steekproefgrootte. Ons 
volledige model verklaart 39% van de totale variantie in de verandering van 
geneesmiddelgebruik. Andere factoren die niet zijn opgenomen in ons model dragen hier 
wellicht ook aan bij, zoals bijvoorbeeld media-aandacht, de incidentie van de 
veiligheidsproblemen, veiligheidsproblemen gerelateerd aan off-label gebruik en de 
beschikbaarheid van alternatieve geneesmiddelen. Er is gesuggereerd dat media aandacht 
een belangrijke rol zou kunnen spelen bij de impact van de DHPC.(20-22) Eerder voerden wij 
een exploratieve zoekactie uit onder leken- en vakliteratuur voor een selectie van de 
DHPC’s in ons onderzoek. Dit leverde te weinig informatie op om de aanwezigheid van 
media-aandacht te includeren in ons model. De incidentie van veiligheidsproblemen kon 
eveneens niet worden geïncludeerd, omdat het in de meerderheid van de DHPC’s niet 
werd genoemd. DHPC’s verzonden in verband met veiligheidsproblemen gerelateerd aan 
‘off-label' gebruik waren te gering in aantal, wat zorgde voor onvoldoende variatie binnen 
de variabele voor inclusie in ons model. Alternatieve geneesmiddelen waren beschikbaar 
voor bijna alle geneesmiddelen en dit aspect werd indirect geïncludeerd in de innovatie 
variabele. DHPC’s verzonden voor meer innovatieve geneesmiddelen hadden geen grotere 
impact op het gebruik dan minder innovatieve geneesmiddelen. Daarom lijkt het 
onwaarschijnlijk dat de beschikbaarheid van een alternatieve behandeling een belangrijke 
determinant zou zijn. Het probleem van het beperkte aantal determinanten kan worden 
aangepakt door deze studie te herhalen op een moment dat er meer DHPC’s zijn 
verzonden waardoor het mogelijk wordt meer determinanten in een vergelijkbaar model 
te includeren. Op dit moment kan onze studie worden beschouwd als een eerste 
verkenning van determinanten die de impact van DHPC beïnvloeden. Verdere bevestiging 
en uitbreiding van deze studies is gerechtvaardigd. 
Generaliseerbaarheid 
In de studies beschreven in hoofdstuk 3 en hoofdstuk 4 is een groot aantal DHPC 
opgenomen welke zijn verzonden gedurende een periode van acht jaar. De DHPC’s 
besloegen een breed scala van veiligheidsproblemen en geneesmiddelen die alle grote 
therapeutische klassen vertegenwoordigden die worden voorgeschreven in de ambulante 
zorg. Uniformiteit van de methode om impact van DHPC beoordelen maakte de 
vergelijking van de effecten van de verschillende DHPC’s mogelijk en verhoogde de 







De vrij lage respons van de studies beschreven in hoofdstuk 5 en hoofdstuk 6 beperkt de 
generaliseerbaarheid van de resultaten. Ondanks het verzenden van twee herinneringen 
in beide studies, reageerde slechts 34% en 19% (respectievelijk) van de zorgverleners. 
Lage respons bij enquêtes onder zorgverleners is niet ongewoon als gevolg van 
bijvoorbeeld toenemende werkdruk, ‘vragenlijst vermoeidheid’ en een lage prioriteit van 
het invullen van vragenlijsten, voornamelijk onder artsen.(23-29) Desondanks kan de lage 
respons onze resultaten hebben vertekend in de zin dat zorgverleners die zich niet bewust 
zijn van, of niet geïnteresseerd zijn in DHPC’s, ondervertegenwoordigd zijn in onze 
steekproeven. Dit zou kunnen betekenen dat in de dagelijkse praktijk nog minder 
beroepsbeoefenaren in de gezondheidszorg zich bewust zijn van DHPC en specifieke 
veiligheidsproblemen dan waargenomen in onze studie, wat de noodzaak van 
verbeteringen in de huidige risicocommunicatie onderstreept. Johnson en Wislar 
verklaarden dat de respons wellicht niet zo sterk geassocieerd is met de kwaliteit en de 
representativiteit van een enquête en benadrukten het belang van het selecteren van een 
representatieve steekproef van de bevolking.(29) In hoofdstuk 5 konden we geen 
kenmerken van non-respondenten analyseren wegens het anonieme karakter van de 
vragenlijst. We konden slechts melden dat onze steekproef representatief was voor de 
Nederlandse setting op het gebied van sekse,(30) en het percentage van de huisartsen die 
in deeltijd werken.(31) We vonden geen significante verschillen tussen vroege en late 
respondenten, op twee variabelen na. Het is mogelijk dat non-respondenten andere 
voorkeuren hebben dan respondenten betreffende de apothekers en de farmacotherapie 
vergaderingen als bron van veiligheidsinformatie. Buiten deze twee variabelen zijn de 
resultaten van deze studie naar alle waarschijnlijkheid niet beïnvloed door non-response 
bias. In hoofdstuk 6 werden bij vergelijking van de respondenten met de non-
respondenten met betrekking tot geslacht, beroep en type ziekenhuis geen significante 
verschillen waargenomen. De lage respons in deze studie kan worden toegeschreven aan 
het beperkte gebruik van pegaptanib in Nederland.(32) Elf zorgverleners reageerden op de 
uitnodiging voor deelname aan onze enquête door te stellen dat zij de vragenlijst niet 
zouden invullen, omdat ze pegaptanib niet toedienen of verstrekken. Vijfentwintig 
respondenten die de vragenlijst invulden gaven hetzelfde aan. Dit benadrukt het belang 
van een pilotstudie die als basis kan dienen voor gedegen steekproefgrootte berekeningen 
in het geval een vragenlijstonderzoek de voorkeur geniet om de impact van 
veiligheidswaarschuwingen te evalueren. 
Het is niet duidelijk in welke mate de resultaten van onze studies gegeneraliseerd 
kunnen worden naar andere landen. We evalueerden de invloed van de Nederlandse 
DHPC en de ervaringen van Nederlandse zorgverleners. In de meeste gevallen is dezelfde 







geneesmiddelen die zijn geregistreerd op Europees niveau. Echter, zorgverleners in de 
diverse Europese landen kunnen verschillend reageren op de DHPC. Risicoperceptie kan 
uiteenlopen en culturele verschillen met betrekking tot geneesmiddelgebruik kunnen 
bestaan.(33,34) Vertrouwen in instituties bijvoorbeeld, één van de factoren die bepalen hoe 
een risico wordt ervaren kan variëren van land tot land, zoals de interpretatie van 
voordelen en risico's van geneesmiddelen bleek te verschillen tussen diverse nationale 
geneesmiddelautoriteiten.(35,36) Een bericht wordt niet gehoord, geloofd en opgevolgd als 
het vertrouwen in en de geloofwaardigheid van de bron van de informatie ter discussie 
wordt gesteld.(37) Dit kan betekenen dat zorgverleners in bepaalde andere landen er de 
voorkeur aan geven om de veiligheidsinformatie over geneesmiddelen niet te ontvangen 
van de nationale geneesmiddelenautoriteit. Dit zou benadrukken dat elke situatie apart 
moet worden beoordeeld. Een EU-breed onderzoek zou een vergelijking van de 
(determinanten van) impact van DHPC’s in verschillende landen mogelijk maken evenals 
een vergelijking van de ervaringen en voorkeuren van zorgverleners met betrekking tot de 
DHPC. Hiermee kan informatie verkregen worden over de noodzaak van specifieke 
nationale risicocommunicatie strategieën. 
Toekomstig onderzoek 
Beoordeling van de impact van veiligheidsmaatregelen 
Uit de resultaten van onze systematische review blijkt een duidelijke behoefte aan nader 
onderzoek om de impact van veiligheidsmaatregelen volledig te kunnen begrijpen. De 
impact van DHPC’s kan niet alleen worden bepaald door het geneesmiddelgebruik te 
analyseren. Uitkomstmaten die meer specifiek zijn afgestemd op de veiligheidskwestie 
moeten ook worden geanalyseerd. Clusters van DHPC’s met dezelfde aanbeveling kunnen 
meer inzicht geven in de te verwachten gevolgen van DHPC’s voor meer specifieke 
uitkomstmaten. Dergelijke analyses kunnen worden gefaciliteerd door de aanbevelingen 
die in de DHPC worden gegeven prospectief te classificeren. 
Verschillende andere factoren die ook van invloed zouden kunnen zijn op de impact 
van de DHPC werden niet geïncludeerd in het model dat werd beschreven in hoofdstuk 4. 
Over een aantal jaar, wanneer er meer DHPC zijn verzonden, en de inhoud van de DHPC zo 
mogelijk nog verder is geoptimaliseerd, kan dit onderzoek worden herhaald. Andere 
factoren kunnen dan ook worden opgenomen in een model en het probleem van de 
beperkte steekproefomvang kan hiermee worden opgelost. 
Zowel de gewenste als de verwachte ongewenste effecten van 
veiligheidswaarschuwingen moeten worden beoordeeld. Tijdreeksanalyse is hiervoor het 







de impact van veiligheidswaarschuwingen in vergelijking met een voor/na 
onderzoeksopzet. Tevens dienen alle waarschuwingen die worden afgegeven voor een 
geneesmiddel individueel beoordeeld te worden in plaats van slechts een selectie van 
waarschuwingen en rapportage van een algeheel effect. Op deze wijze wordt het mogelijk 
om kennis te vergaren over het type waarschuwing dat de gewenste gedragsverandering 
van zorgverleners het meest effectief kan faciliteren. 
Optimalisatie van de impact van veiligheidswaarschuwingen 
Voornamelijk naar communicatie over milieu gerelateerde risico’s is reeds veel onderzoek 
uitgevoerd, waarvan de resultaten kunnen worden gebruikt bij het verbeteren van de 
communicatie over veiligheidsproblemen van geneesmiddelen.(38-40) Onze studies waren 
gericht op het verkrijgen van empirisch bewijs voor een aantal belangrijke aspecten van 
het risico communicatie. Deze bevindingen dragen bij aan de praktische benadering die 
staat beschreven in een praktische handleiding over de wijze waarop 
gezondheidscommunicatieprogramma’s gepland, geïmplementeerd en geëvalueerd 
dienen te worden.(41) Met betrekking tot enquêtes, dient een lage respons te worden 
verwacht; vooral in geval van online enquêtes. Pilotonderzoeken moeten worden 
uitgevoerd om een basis te bieden voor grondige berekeningen van de steekproefgrootte. 
De respondenten van de studie beschreven in hoofdstuk 5 gaven aan dat ze graag 
informatie over veiligheidsproblemen van geneesmiddelen ontvangen via e-mail en van 
het CBG. Deze voorkeur hebben we op de proef gesteld in een gerandomiseerde klinische 
studie in hoofdstuk 6. Vergelijkbare gerandomiseerde klinische studies kunnen worden 
opgezet om de impact van een veiligheidswaarschuwing te beoordelen die wordt 
gecommuniceerd via andere zeer gewaardeerde communicatiebronnen of -kanalen. Deze 
methoden moeten worden gekozen op basis van het doel van risicocommunicatie, dat wil 
zeggen nieuwe informatie delen, opvattingen over voordelen en risico’s van 
geneesmiddelen veranderend, of gedrag van zorgverleners veranderen. Vooral in het 
laatste geval zijn wellicht meer interventies nodig om op lange termijn veranderingen in 
het gedrag te bereiken. 
Van de in hoofdstuk 4, hoofdstuk 5 en hoofdstuk 6 beschreven studies, weten we 
dat context er toe doet. Diverse risicoperceptie factoren (onomkeerbaarheid, hoog fataal 
risico en vertrouwen in instituties) spelen een rol in de manier waarop veiligheid van 
geneesmiddelen en de bijbehorende risico communicatie worden gepercipieerd door 
zorgverleners. Aangezien niet alle risicoperceptie factoren werden opgenomen in deze 
studies, is de invloed van andere factoren, zoals onzekerheid, begrip, en de 
ethische/morele aard niet bekend. Helaas is de meerderheid van het huidige onderzoek 







veiligheidsproblemen van geneesmiddelen. Toekomstig onderzoek kan meer inzicht 
bieden, bijvoorbeeld door te bestuderen hoe artsen de voordelen en risico's afwegen bij 
het voorschrijven van geneesmiddelen waarvoor een DHPC is afgegeven. Leken 
beoordelen voordelen en risico's van diverse geneesmiddelen verschillend.(21) Hetzelfde 
valt te verwachten voor artsen. In het algemeen zijn mensen bereid om hogere risico’s te 
nemen wanneer de voordelen groter zijn.(21) Met het feit dat artsen risico gerelateerde 
beslissingen maken voor hun patiënten, in plaats van voor zichzelf moet ook rekening 
worden gehouden. Het is aangetoond dat artsen risicovollere behandelingsopties voor 
zichzelf zouden kiezen dan voor hun patiënten.(42) Een andere studie suggereert dat 
toezichthouders, artsen en patiënten nieuwe ernstige risico’s van een geneesmiddel op 
vergelijkbare wijze kunnen afwegen, wanneer deze worden gepresenteerd in de context 
van andere voordelen en risico's van een oraal anti-diabetes geneesmiddel. Een verhoogd, 
maar in absolute termen klein risico op blaaskanker van een hypothetisch oraal anti-
diabetes medicijn had geen invloed op de keuze voor een geneesmiddel door alle drie de 
groepen.(43) Inzet van risicocommunicatie middelen als ‘keuzehulpen’ die gedeelde 
besluitvorming kunnen vergemakkelijken kan worden onderzocht wanneer verschillen in 
percepties over voordelen en risico’s kunnen worden verwacht. 
Beter begrip van de rol die risicoperceptie factoren spelen kan een leidraad vormen 
voor de optimalisering van het effect van toekomstige DHPC’s.(44) Dit zal het beleid om 
risico communicatiemethoden te verbeteren, anticipatie op ongewenste effecten en 
ontwikkeling van nieuwe strategieën voor risicomanagement ondersteunen.(45) De impact 
van DHPC’s die zijn verstuurd wegens andere dan administratieve kwesties en voor 
geneesmiddelen die op grotere schaal worden gebruikt, moeten ook worden beoordeeld. 
Specifieke aandacht moet worden besteed aan DHPC’s waarmee nieuw geïdentificeerde 
veiligheidsproblemen worden gecommuniceerd, omdat deze nieuwe informatie zou 
kunnen botsen met de opvattingen die zorgverleners hebben over deze geneesmiddelen. 
Volgens de theorie van cognitieve dissonantie, kan dit ervoor zorgen dat zorgverleners 
deze nieuwe informatie buiten beschouwing laten.(45,46) 
Implicaties voor regelgeving en praktijk 
Risicocommunicatie krijgt meer en meer aandacht binnen het gebied van de 
geneesmiddelenbewaking, mede als gevolg van verhoogde aandacht voor transparantie. 
In 2007 kwam er een DHPC sjabloon beschikbaar en in 2012 werd de nieuwe 
farmacovigilantie wetgeving van kracht, waarin communicatie over risico's een belangrijke 
rol speelt.(6,10,11) Ondanks deze verbeteringen, kan er nog veel worden geleerd en 








 Tabel 1. Belangrijkste aanbevelingen  
1. Verbeter communicatie methoden 
 Communiceer veiligheidsproblemen via een onafhankelijke, betrouwbare bron. 
 Gebruik nieuwe communicatiekanalen, bijvoorbeeld e-mail om veiligheidsproblemen te 
communiceren. 
 Zorg dat de DHPC opvalt voor zorgverleners, bijvoorbeeld door middel van een afbeelding van 
een gele hand op de envelop. 
2. Vergroot betrokkenheid van zorgverleners 
 Betrek zorgverleners bij het opstellen van de DHPC’s. 
 Vergroot het bewustzijn onder zorgverleners over geneesmiddelautoriteiten. 
 Licht zorgverleners voor over risicocommunicatie over veiligheidsproblemen. 
3. Verbeter evaluatie van impact 
 Definieer en classificeer de beoogde effecten van DHPC’s prospectief. 
 Stel passende uitkomstmaten vast om de impact van DHPC’s te beoordelen. 
 Stel vast wanneer DHPC’s als doeltreffend beschouwd kunnen worden. 
 Anticipeer op ongewenste effecten van DHPC’s. 
 
gegeven (Tabel 1). Risicocommunicatie over veiligheidsproblemen van geneesmiddelen 
moet worden verbeterd door meerdere factoren aan te pakken. 
1. Verbeter communicatie methoden 
Vertrouwen speelt een belangrijke rol in het risicocommunicatieproces en 
farmaceutische bedrijven worden vaak gewantrouwd.(47,48) Een complex geheel 
van factoren speelt een rol in de opbouw en afbraak van vertrouwen en helaas 
is het makkelijker om vertrouwen te verliezen dan het te genereren of opnieuw 
op te bouwen zoals geschetst door het zogenaamde 'asymmetrie principe'.(35) 
Daarom raden wij aan veiligheidsproblemen van geneesmiddelen te 
communiceren via een betrouwbare bron, zoals het CBG.(49,50) 
Nieuwe kanalen zoals e-mail kunnen worden gebruikt om veiligheid van 
geneesmiddelen te communiceren. Zorgverleners moeten kunnen aangeven of 
ze een dergelijke e-mail willen ontvangen voor alle geneesmiddelen of een 
selectie geneesmiddelen. Hiermee wordt het optreden van een zogenaamde 
'waarschuwingsmoeheid' als gevolg van een overvloed aan informatie 
voorkomen. 
In dit proefschrift hebben we niet bestudeerd of, en op welke wijze de 
inhoud van de DHPC kan worden verbeterd. Hoewel het effect van de DHPC 
over geneesmiddelgebruik al werd verhoogd na de beschikbaarheid van de 
standaard DHPC sjabloon, blijft verdere optimalisatie van de vorm en inhoud 







zorgen dat de DHPC opvalt bij zorgverleners.(49,50) Het is aanbevelenswaardig de 
brief te versturen met een extra symbool, zoals een foto van een oranje hand 
afgedrukt op de envelop. Dit gebeurt momenteel in Nederland in gevallen die 
onmiddellijk optreden van de zorgverlener vergen. Een andere kleur, 
bijvoorbeeld geel, kan worden gebruikt om de ‘standaard DHPC’ te 
onderscheiden van oranje hand gevallen waarin onmiddellijke actie door 
zorgverleners is vereist. Op de envelop van de DHPC en in de header van een 
eventuele e-mail dient het geneesmiddel en het veiligheidsprobleem in kwestie 
duidelijk te worden vermeld. 
De belangrijkste informatie is niet altijd adequaat gepresenteerd in de 
DHPC en de leesbaarheid en duidelijkheid kunnen onvoldoende zijn.(50) De 
manier waarop aantallen worden gepresenteerd en risico's worden 
weergegeven heeft een grote invloed, zoals bijvoorbeeld de 'pil scare' heeft 
laten zien.(21,41,51,52) Dit zogenaamde ‘framen’ van risico's (bijvoorbeeld 
aangeven hoeveel patiënten zijn overleden versus hoeveel patiënten de 
bijwerkingen van het geneesmiddel hebben overleefd) lijkt leken en 
zorgverleners op vergelijkbare wijze te beïnvloeden.(21) Om de optimale 
weergave van risico’s in DHPC te bereiken kan bestaand onderzoek onder leken 
worden bestudeerd. Zorgverleners hebben echter niet altijd dezelfde behoeften 
inzake risico-informatie als leken.(41) Bij het informeren van zorgverleners kan 
meer geavanceerde taal worden gebruikt, en referenties kunnen worden 
gegeven naar wetenschappelijke achtergrondinformatie.(53) Niettemin moet een 
zogenaamde polysemische boodschap (een boodschap die kan worden 
geïnterpreteerd op verschillende manieren) worden vermeden omdat het 
verwarring bij de doelgroep zou kunnen veroorzaken. De inhoud van de DHPC, 
met name de aanbevelingen, moet zo eenduidig mogelijk worden 
geformuleerd.(51,54,55) De belangrijkste aspecten van het veiligheidsprobleem, 
met inbegrip van de aanbevelingen, moeten eerst worden vermeld.(53) Om 
ongewenste effecten te voorkomen die kunnen worden veroorzaakt door een 
polysemisch bericht moet de inhoud van de DHPC vooraf getest worden door 
de doelgroep.(53) 
2. Vergroot betrokkenheid van zorgverleners 
Succesvolle risicocommunicatie is niet alleen afhankelijk van optimale 
communicatie methoden, maar ook van de betrokkenheid van de ontvanger. 
Idealiter vormt risicocommunicatie een tweerichtingsproces wat de noodzaak 







zorgverleners die in de dagelijkse praktijk werken met het geneesmiddel in 
kwestie.(38,39,45,52,56,57) Ook beroepsverenigingen kunnen betrokken worden bij 
het opstellen van DHPC's en het informeren van hun leden, omdat ze hoog in 
het vaandel staan bij zorgverleners en worden beschouwd als geloofwaardige 
informatiebronnen.(52,54) Het is bekend hoe moeilijk het is om te voorspellen 
welke risico's voor andere personen relevant zijn.(41) Mits de juiste specifieke 
zorgverlener is betrokken men mag aannemen dat deze uit ervaring weet wat 
er al bekend is over het geneesmiddel en het veiligheidsprobleem en wat niet. 
Zij zijn zich bewust van de zorgen en behoeften en welke aspecten in de DHPC 
benadrukt dienen te worden.(41,52) Deze benadering kan mogelijk ongewenste 
effecten die optraden in het geval van de SSRI’s voorkomen en situaties zoals de 
‘pill scare’ zouden kunnen worden ingedamd.(51) 
Een mogelijke aanpak is de ‘Mental Models’ methode.(52) Door 
zorgverleners en toezichthouders te interviewen kunnen hun meningen worden 
geïnventariseerd en eventuele verschillen kunnen gericht worden aangepakt. 
Deze aanpak is echter nogal tijdrovend, en wellicht meer bruikbaar als 
voorbereiding op de vorm en inhoud van DHPC's in het algemeen.(53) De 
methode is minder geschikt tijdens een crisissituatie waarin kostbare tijd 
verloren zou gaan. Verder zijn er diverse gevalideerde tests beschikbaar welke 
gebruikt kunnen worden om de leesbaarheid van DHPC testen op het gebied 
van zinsbouw, lengte van en het type gebruikte woorden.(41) 
Zorgverleners zien een duidelijke rol voor toezichthoudende instanties in 
de communicatie van veiligheidsproblemen en de herkenbaarheid van deze 
instanties dient te worden verbeterd onder zorgverleners. Om zorgverleners te 
assisteren bij hun verantwoordelijkheid om op de hoogte te blijven van nieuwe 
geïdentificeerde veiligheidsproblemen van geneesmiddelen, moeten ze worden 
geïnformeerd over risicocommunicatie die zij gedurende hun carrière zullen 
ontvangen. Dit kan bijvoorbeeld tijdens de opleiding plaatsvinden, geïntegreerd 
met het onderwijs over de wijze waarop de veiligheidsproblemen 
gerapporteerd dienen te worden. 
3. Verbeter evaluatie van impact 
Risicocommunicatie kan op verschillende manieren worden geëvalueerd. Met 
behulp van zogenaamde formatieve evaluatie kan de inhoud van een bericht 
worden beoordeeld, procesevaluatie kan bijvoorbeeld worden gebruikt om te 
bepalen of het publiek een bericht heeft ontvangen en met uitkomst evaluatie 







De beoogde effecten van DHPC's moeten worden gedefinieerd en prospectief 
wordem geclassificeerd om na te kunnen gaan wat de meest geschikte 
uitkomstmaat is om de effectiviteit van de DHPC’s te kunnen evalueren. Deze 
uitkomstmaten moeten bij voorkeur worden afgestemd op het 
veiligheidsprobleem, bijvoorbeeld gelijktijdig gebruik van gecontra-indiceerde 
geneesmiddelen,(17) of hoe vaak zorgverleners laboratoriumtests hebben 
aangevraagd om mogelijke toxiciteit van geneesmiddelen te identificeren.(18) 
Vervolgens is het belangrijk om te bepalen op welk punt een DHPC voldoende 
effectief kan worden beschouwd. Aangeven dat de invloed van risico 
beperkende maatregelen moeten worden geëvalueerd is alleen dan nuttig 
wanneer drempels worden gesteld en aanvullende maatregelen wordt 
gevraagd wanneer een dergelijke drempel niet is bereikt.(58-60) Dit zal niet 
gemakkelijk zijn, gezien het huidige gebrek aan informatie over de effectiviteit 
van deze maatregelen. Zo is het niet bekend of er een 'plafond effect' zou 
kunnen ontstaan wat een DHPC en alle additionele risicocommunicatie 
methoden zal belemmeren om nog meer impact te sorteren. Bovendien zijn er 
geen ‘algemeen aanvaardbare risico’s’ vast te stellen, omdat het afhankelijk is 
van de context of het bereikte risicoreductie voldoende is.(61) Bij de DHPC 
betekent dit dat niet alle bijwerkingen voorkomen kunnen worden ondanks 
inachtneming van alle voorzorgsmaatregelen.(62) Het gemak waarmee 
drempelwaarden kunnen worden ingesteld is ook afhankelijk van het type 
uitkomstmaat. Deze kunnen vrij gemakkelijk worden bepaald voor het aantal 
geneesmiddelvoorschriften, of laboratoriumtesten. Maar het aantal 
bijwerkingen dat kan worden aanvaard, zou moeilijker zijn, rekening houdend 
met onderrapportage en mogelijke gelijkenis met symptomen van de ziekte in 
kwestie. De uitdaging in de nabije toekomst zal zijn om bewijzen te genereren 
die kunnen worden gebruikt om vast te stellen wat haalbaar is en wat niet. Voor 
elke DHPC moeten de mogelijke ongewenste effecten worden geverifieerd en 
gemonitord. Door te anticiperen op de ongewenste effecten, bijvoorbeeld door 
het geven van aanvullende informatie, kunnen problemen die zich hebben 
voorgedaan met selectieve serotonine heropname remmers (verminderd 
gebruik door volwassenen) en de derde generatie anticonceptiva (verhoogd 
aantal abortussen) wellicht worden vermeden in de toekomst. 
Eindconclusie 
Dit proefschrift geeft een overzicht van de impact van DHPC’s en haar determinanten. 







van de DHPC’s was deze daling aanzienlijk. De DHPC’s bleken voornamelijk effectief in 
geval van goed gestructureerde informatie en zeer ernstige veiligheidsproblemen. 
Nederlandse zorgverleners gaven er de voorkeur aan om informatie over 
veiligheidsproblemen te ontvangen via elektronische kanalen en van een onafhankelijke 
bron. Een extra e-mail die werd verzonden door het College ter Beoordeling van 
Geneesmiddelen versterkte het effect van een schriftelijke DHPC door zorgverleners meer 
bewust te maken van het veiligheidsprobleem en meer actie te laten ondernemen naar 
aanleiding van de kwestie. Momenteel heeft de DHPC een duidelijke toegevoegde waarde. 
Eventuele toekomstige ontwikkelingen zullen moeten worden gemonitord. Vanuit een 
onbelemmerd onderzoeks-oogpunt, zijn aanbevelingen gedaan die kunnen worden 
gebruikt om de huidige communicatie over veiligheidsrisico's van geneesmiddelen te 
verbeteren. Beslissingen van toezichthouders worden beïnvloed door het bestuur van de 
gehele gezondheidszorgsector, wat de uitvoering van deze aanbevelingen kan 
bemoeilijken. Een flexibele houding van alle betrokkenen is vereist om veilig gebruik van 
geneesmiddelen te verbeteren die de volksgezondheid en uiteindelijk de patiënt ten 
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